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III SUMMARY 
 
The work prestented in this thesis discusses molecularly imprinted polymer (MIP) based 
scavengers for the purification of active pharmaceutical ingredients (APIs). The manufacturing 
of APIs often involves the use of highly reactive reagents, which could remain as undesired 
residues in the final product. Genotoxic impurities (GTIs) represent a class of compounds of 
special concern, which can participate in alteration of DNA and subsequently cause cancer. 
Regulatory agencies have recently issued new guidelines on the control of GTIs. In general, 
product risk assessment can be influenced by the presence of GTIs, therefore the control and 
removal of GTIs are of great interest to the pharmaceutical industry. 
 
Novel molecularly imprinted polymers have been designed and synthesized that can recognize 
pharmaceutical impurities such as acetamide, thioacteamide and aminopyrimidine. Thorough 
evaluation and characterization have demonstrated the feasibility to use MIPs as selective 
sorbents for purification of APIs. Rebinding tests indicate that high affinity interactions are 
present between the binding sites of the MIP and the target impurities, resulting in a highly 
efficient purification. Different MIP formats were successfully synthesized for the purpose to 
increase the binding capacity. The new MIPs developed offer a new and inventive purification 
technique for the pharmaceutical industry as an efficient and selective sorbent.  
 
The successfully developed acetamide MIPs were tested in combination with organic solvent 
nanofiltration (OSN). This case study investigated the hybrid approach of MIPs and OSN for 
application in the pharmaceutical industry. Upon comparing the effectiveness of MIPs and 
OSN, it was concluded that the MIP based scavengers function better at low GTI 
concentrations, whilst OSN functions better at high GTI concentrations. Hence OSN can be 
used as a rough cleaning phase and the MIPs as a polishing phase, indicating that a hybrid 
approach can be beneficial for removal of impurities in the pharmaceutical industry. 
 
Furthermore, a novel and more effective HTS screening method based on grafting of PES 
membranes for MIP libraries was developed in this work. It was shown that successful grafting 
of both membrane filter plates and loose membrane discs is supported by calculations of the 
grafting amount and permeability. Furthermore TGA, SEM and EDX analysis also strongly 
indicate that polymer is successfully grafted on the membrane surface. The rebinding tests 
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performed on both the grafted membranes filter plates and grafted loose membrane discs 
display that a difference in binding between the MIP and NIP can be observed. 
 
MIPs intended for the use as catalysts promoting cyclisation of end-products in peptide 
synthesis were synthesized and investigated. The first preliminary tests showed that by using 
reduction and oxidation protocols for peptides, somatostatin and desmopressin could be opened 
and re-closed and simultaneously followed by LC-MS analysis. By studying the linear to cyclic 
peptide ratios obtained by LC-MS, it can be observed that the ratio of linear to cyclic peptide 
decreases, meaning that the cyclic form possibly increases and thus indicating that the presence 
of polymer promotes the cyclisation of somatostatin. Furthermore, the preliminary results 
suggest that the imprinted polymer promotes the cyclisation better than the corresponding NIP 
and the promotion also exhibits selectivity for the imprinted somatostatin since desmopressin 
does not display any significant change in ratio compared to the free solution control sample. 
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ZUSAMMENFASSUNG 
 
Die vorliegende Doktorarbeit präsentiert die Arbeit an molekular geprägten Polymeren (MIPs) 
zur Aufreinigung von arzneilich wirksamen Bestandteilen (APIs).  
 
In der Herstellung von APIs werden häufig hochreaktive Reagenzien benötigt, die als 
unerwünschte Überreste in dem Endprodukt verbleiben können. Genotoxische 
Verunreinigungen (GTIs) stellen eine Verbindungsklasse von besonderer Bedeutung dar, da sie 
eine Rolle bei der Veränderung von DNA spielen und, darauf basierend, Krebs hervorrufen 
können.  
 
Regulierende Stellen haben letztlich neue Richtlinien zur Kontrolle von GTIs herausgegeben. 
Generell kann die Risikoeinstufung eines Produktes vom Vorhandensein von GTIs beeinflusst 
werden. Aus diesem Grund ist die Kontrolle und die Entfernung von GTIs von großem Interesse 
für die pharmazeutische Industrie.  
 
Neue molekular geprägte Polymere, die pharmazeutische Verunreinigungen wie Acetamid, 
Thioacetamid und Aminopyrimidin erkennen können, wurden entwickelt und synthetisiert.  
Durch die umfassende Untersuchung und Charakterisierung wurde die Möglichkeit, MIPs als 
selektive Bindungsphase für die Aufreinigung von APIs zu verwenden, gezeigt. Bindungstests 
weisen darauf hin, daß zwischen den Bindungsstellen des MIPs und der Ziel-Verunreinigung 
Wechselwirkungen mit hoher Affinität bestehen. Dies führt zu hocheffizienter Aufreinigung.  
Um die Bindungskapazität zu erhöhen, wurden verschiedene MIP-Formate erfolgreich 
synthetisiert. Die neuentwickelten MIPs stellen in ihrer Nutzung als effiziente und selektive  
Bindungsphasen eine neue und innovative Aufreinigungstechnik für die pharmazeutische 
Industrie dar.  
 
Die erfolgreich entwickelten Acetamid-MIPs wurden in Kombination mit lösemittelstabiler 
Nanofiltration (OSN) getestet. Die Fallstudie untersuchte den Hybrid-Ansatz von MIPs und 
OSN für die Anwendung in der pharmazeutischen Industrie.  
 
Bei dem Vergleich der Effektivität von MIPs und OSN wurde beobachtet, daß die MIP-
basierten Fänger bei niedrigen GTI Konzentrationen besser arbeiten, wohingegen OSN besser 
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bei hohen GTI Konzentrationen funktioniert. Ein Hybrid-Ansatz kann gewinnbringend für die 
Entfernung von Verunreinigungen in der pharmazeutischen Industrie sein, indem OSN als 
Grobreinigung und die MIPs als Feinreinigung dienen.  
 
Darüber hinaus wurde in dieser Arbeit eine neue und effektivere HTS-Methode basierend auf 
der Polymerisation von PES-Membranen für MIP-Bibliotheken entwickelt. Es wurde gezeigt, 
daß  sowohl die Polymerisation von Membran-Filterplatten als auch losen Membran-Plättchen 
von Berechnungen der Polymerisationsmenge und Durchlässigkeit gestützt wird. Darüber 
hinaus weisen die Ergebnisse von TGA, SEM und EDX-Analysen stark darauf hin, daß 
Polymer erfolgreich auf die Membranoberfläche aufpolymerisiert wurde. Die Bindungstests, 
die sowohl mit den Membran-Filterplatten als auch den losen Membranplättchen durchgeführt 
wurden zeigen, daß ein Unterschied zwischen MIP und NIP in der Bindung besteht.  
 
MIPs zur Verwendung als Katalysator für die Zyklisierung von Endprodukten in der 
Peptidsynthese wurden synthetisiert und untersucht. Die ersten, vorläufigen Tests zeigten, daß 
bei der Verwendung von Reduktions- und Oxidations-Protokollen für Peptide sowohl 
Somatostatin als auch Desmopressin geöffnet und wiederholt geschlossen werden konnten. 
Dies wurde mit LC-MS Analysen verfolgt.  
 
Die Annahme, daß durch das Polymer die Zyklisierung von Somatostatin begünstigt wird, wird  
gestützt von den LC-MS Ergebnissen. Das Verhältnis verschiebt sich von linearem zu 
zyklischem Peptid. Darüber hinaus weisen die vorläufigen Ergebnisse darauf hin, daß das 
geprägte Polymer die Zyklisierung besser als das NIP unterstützt. Dieses Verhalten scheint  
außerdem selektiv für das geprägte Somatostatin zu sein, da Desmopression im Vergleich zu 
der Kontrollprobe in Lösung keine signifikante Änderung in den Verhältnissen zeigt. 
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1. INTRODUCTION 
 
 “…98.5% purity doesn’t mean very much when we are talking about biologically active 
contaminants that, in varying minuscule amounts, can create powerful effects...” 
   P. Raphals1 
 
This quote effectively summarizes the significance of the work described in this thesis. Carrying 
this in mind the first chapter will describe the development of active pharmaceutical ingredients 
(APIs), as well as the components of importance used for the development of new improved 
purification techniques with a beneficial impact on the pharmaceutical industry. 
 
 
1.1 IMPURITIES IN ACTIVE PHARMACEUTICAL INGREDIENTS 
 
The presence of even small concentrations of impurities can disrupt the production and sales of 
drugs. Therefore the ability to monitor and control these impurities at very low concentrations 
is of great importance. Screening for impurities throughout the entire API synthesis process, 
and not only in the finished product, is hence necessary since impurities can be eliminated 
during the process itself, e.g. degradation, or new impurities can form by side-reactions. 
Generally a finished synthesized API is assessed for toxicity by first using in vitro screening 
and if acceptable concentrations of harmful substances are established animal testing will 
performed before permission for Phase 1 human trials can be given by the regulatory agencies. 
To obtain this permission a thorough summary for the new API, containing the actual and 
potential impurities with the highest likelihood to form during synthesis, purification and 
storage should be completed according to the ICH Guidance Q3A (R2)2. Depending on the 
level of toxicity of the impurities and the dosage of the drug the limits of the impurities present 
are determined. For common impurities, e.g. residual solvents, general limits based on 
toxicology data have been decided. The permissible daily exposure (PDE) is calculated using 
Equation 1 below. 
Equation 1  PDE = (NOEL x weight adjustment) / (F1 x F2 x F3 x F4 x F5) 
Where NOEL is the so called no observed effect limit, F1 is the extrapolation between species 
(e.g. 12 for mice to humans), F2 is the individual variation, F3 is the length of the toxicology 
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study, F4 is the severe toxicity factor, and F5 is the factor used only when the LOEL (lowest 
observed effect limit) is accessible. Residual metals also need to be kept within the existing 
specifications.14  
 
The acronym ACE, short for Avoid, Control, and Expel beautifully sum up the methods used 
to control impurities. When the cause of the impurity formation is e.g. the use of a specific 
solvent, it can be avoided by changing the solvent3. Another way to control impurities is to spot 
them in the early phases of synthesis, as this offers more opportunities to expel them by taking 
preventive measurements in the workup process4. 
 
One well-known case of impurity contamination of drugs on the market is Viracept produced 
by Hoffmann- La Roche. In June 2007 the drug was withdrawn from the market after patient 
complaints of unusual smell and after analysis Roche found high concentrations of the impurity 
ethyl mesylate.5 This was reason for concern as ethyl mesylates have proven to be carcinogenic, 
genotoxic, as well as teratogenic. Roche found the source of the impurity and managed to 
remove it down to the specification levels, allowing the drug to be reinstituted to the market. 
However, this example clearly illustrate the importance to remember that the superior method 
to control GTIs is to really understand the mutagenicity by evaluate actual data and not only 
theory. 
 
The development of drugs comes with great responsibilities. Hence, with the potential risk of 
exposing patients to impurities it is of great importance to understand the toxicity of all 
compounds involved. Predicting the toxicity of the drug substance and related impurities can 
however prove difficult. This was the case with the eosinophilia myalgia syndrome caused by 
impurities in L-tryptophan nutritional complements, which was the example the opening quote 
of this thesis was referring to.1 The impurity that is believed to have caused the syndrome is the 
derivative of bis-tryptophan as illustrated in Figure 16,7. The thalidomide drug case is another 
well-known unfortunate incident caused by impurities. The drug thalidomide was given to 
pregnant women to treat nausea, however the (S)- enantiomer lead to adverse limb deformation 
in the fetus they carried. After ingestion of the drug the (R)- enantiomer is transformed into the 
toxic (S)- enantiomer via racemization. When synthesizing the drug meperidine isostere the 
impurity 1-methyl-4-phenyl-tetrahydropyridine (MPTP) was formed by accident. This impurity 
can cross the brain barrier after which it most likely forms the cation MPP+, which causes 
permanent Parkinson like symptoms in people that used the meperidine isostere drug 
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recreationally8. During the Vietnam war the defoliant Agent Orange, a 1:1 combination of 2,4-
D and 2,4,5-T, was dropped on the landscape. The main components were quickly metabolized 
but the impurities present, particularly 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), turned out 
to be both carcinogenic and teratogenic also in very low concentrations.14 These examples 
demonstrate the importance of understanding the possible impurities present in drugs we 
produce. Hence improved techniques to detect and remove these impurities to stringent low 
levels are of great importance. 
 
 
Figure 1 Illustrates a number of example of toxic impurities present in some chemicals.14  
 
1.2 PURIFICATION OF ACTIVE PHARMACEUTICAL INGREDIENTS 
 
Various regulatory authorities are responsible for setting the purity standards for APIs that reach 
the market. Hence, before pharmaceutical and biotechnology companies are allowed to 
introduce a drug to be sold to patients they need to receive approval from these different 
agencies. The purity standards set relate to the potencies, identity and levels of impurities, as 
well as physicochemical properties. One of the main regulatory agencies is the Food and Drug 
Administration (FDA) which is responsible for approving new drug applications (NDAs). 
These NDAs have to fulfill requirements based on the testing methodology developed by the 
U.S. Pharmacopeia (USP), a non- profit, government organization, which the FDA is enforcing. 
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Drug specifications and standards for environmental impact etc. may however differ for the 
regulatory authorities in other countries e.g. the European Medical Agency (EMA) for the 
European Union. In an effort to make these guidelines globally analogous, the International 
Conference on Harmonization (ICH) continuously works on standardizing regulations. 
 
In order to reach the standards set and make sure a pure API with tolerable concentrations of 
impurities are obtained, a variety of purification processes are used. The processes applied 
depend on the specific product formed with some examples including crystallization, drying 
for removal of volatiles, washing cycles, resolution separation, preparative column 
chromatography, fractional distillation, membrane processes, and application of resins and 
scavengers. Generally the higher the selectivity towards an impurity is, the lower the API losses 
are and the more efficiently the impurity is removed. In addition to the removal of impurities 
directly as they form, it can be beneficial to have an additional purification step after the workup 
to obtain a higher purity9,10,11. The conventional purification techniques used in API are 
summarized in Figure 2 together with the two new emerging techniques investigated in this 
thesis. 
 
 
Figure 2 Examples of conventional techniques (blue) used for purification together with the techniques 
investigated in this thesis; MIPs and to a smaller extent OSN (green).  
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To make certain that the drugs that reach the markets are safe and efficient, are the most 
important assignments of the different regulatory agencies. Even a slight variation in the drug 
substance concentration can make the drug, not only unproductive, but also toxic depending on 
the safety margin of the API. Therefore reproducibility in all stages, from compound synthesis 
all the way to the production of different batches is of great importance. The aim of process 
development is to decrease heterogeneity by overcoming the problems the conversion of solids 
and liquids into homogeneous mixtures can present. Also therapeutically inactive compounds, 
i.e. excipients, influence the formulating process and because of the variety of different 
operations involved in the process, for example blending, milling, drying, compression and film 
coating, a broad range of material science is crucial for a successful API formulation12. The 
control of the physical characteristics; hygroscopicity, particle size and distribution, is hence 
highly important in order to obtain reproducibility in produced batches and can be obtained by 
choosing the excipients and processes with the appropriate characteristics. Formulation has a 
substantial impact on the total cost of bringing drugs to the market and could even cancel 
ongoing clinical trials or discontinuing the sales if specifications are not met13. In general the 
preferred design for small molecule APIs is solids with the ability to crystallize and re-
crystallize, because they are convenient tools for both drug substance and product quality 
control. Furthermore, crystalline drugs generally offer a satisfactory shelf life because of their 
good stability compared to amorphous solids14. Roughly 70-90 % of the substances under 
development exhibit poor solubility, nevertheless they do reach the market, meaning that the 
window of potential active pharmaceutical ingredients broadens15. Crystallization is also an 
effective technique for impurity removal and is hence commonly used for this purpose. In order 
to reach the specified impurity level sometimes numerous repeating re-crystallization cycles 
are necessary. This opens up for process optimization and the development of new purification 
techniques. 
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1.3 GENOTOXIC IMPURITIES IN ACTIVE PHARMACEUTICAL INGREDINTS  
 
The definition of impurities in pharmaceutical products is any substances that is not the active 
ingredient thus not presenting any therapeutic benefit for the patient, an impurity may or may 
not cause undesirable effects.16 A sub-category of impurities present in APIs with strictly 
controlled allowed limits is compounds with potential genotoxic effects. One of these unwanted 
effects of genotoxic materials is cancer; with cancer being a leading cause of death worldwide. 
According to the World Health Organization the numbers of deaths from cancer are predicted 
to almost double from 7.6 million in 2008 to 13.1 million by 2030. Hence great efforts are made 
to understand and control genotoxic impurities during the development process.  
 
Genotoxins, also called mutagens, are potentially carcinogenic by causing damage or 
modifications to the DNA which can lead to transcription and protein translation problems.14,17 
Over the last decade the concern about genotoxic impurities has increased significantly in the 
pharmaceutical industry, which is reflected in the number of hits in literature on “genotoxicity” 
and “genotoxic impurity”.18 The strict allowed amounts are due to the fact that genotoxins 
belong to a class of extraordinary toxic impurities as classified by the ICH Q3 A2. As a result 
genotoxic impurities must be controlled down to ppm or even ppb levels, which is difficult to 
analyze and control and can cause delays in the development of APIs.19 The mechanism by 
which genotoxins cause damage to DNA entail an electrophilic attack on the nucleophilic parts 
of the DNA, more precisely the nitrogen and oxygen in pyrimidine and purine bases. Genotoxic 
compounds that are bidentate have the capability to react with two nucleophilic sites 
simultaneously and form either: (1) a bicyclic or tricyclic system from one molecule; (2) two 
different molecules in the same or opposite DNA strands resulting in inter- or intrastrand 
coupling; or (3) a DNA-protein adduct20. A number of functional groups considered to be so 
called structural alerts for genotoxicity are summarized in Figure 3. 
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Figure 3 Structural alerts of functional groups that may be potential genotoxins. Where R= aryl, alkyl, H; 
EWG= electron-withdrawing group; X= leaving group, e.g. Br.14 
 
As a result of the many possible structural variations and that the structures do not necessarily 
need to be related, genotoxic impurity control is very complex. Some of these structural alerts 
are described in more detail hereafter. Aldehydes belong to another group of compounds that 
are potentially genotoxic, via reaction with the deoxyguanosine residues at the N1 and the 
exocyclic amine sites. Metabolic epoxidation of aromatic hydrocarbons may result in 
genotoxicity, one example being the particularly potent mutagen aflatoxin B1. Aryl boronic 
acids and boronic esters have demonstrated mutagenicity in bacteria, at this point no animal 
testing data is existing. 14,21,22,23,24     
 
Tools, such as software programs and databases, for prediction of a compound’s genotoxicity 
are available and approved by regulatory authorities. However, it should be noted that these 
software are operated by people, and the quality of the results are therefore strongly dependent 
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on the data inputted. To improve the prediction of a compounds genotoxicity it is standard to 
include (1) computational screening; (2) microbial screening, e.g. the Ames test; and (3) animal 
testing, commonly on mice and rats. The aim of this screening and testing is to establish an 
upper limit dosage, at which there is limited risk of causing cancer. Potential genotoxic 
impurities (PGIs) can be complicated to isolate, identify, and prepare at an early stage in the 
development, and are thus often not tested in animals. Therefore PGIs are per definition 
impurities with inadequate toxicological data to determine the tolerable exposure limit. If PGI 
formation cannot be avoided best practise state that the limit should be reduced to the lowest 
possible value25. In clinical trials PGIs are subject to the so called threshold of toxicological 
concern (TTC), where the standard limit is 1.5 mg day-1 for clinical trials exceeding 12 months 
(higher exposure doses are allowed for shorter clinical trials) 26. The TTC values are based on 
the tolerable risk of 1 in 100.000 developing cancer by exposure at the given doses.  
 
A number of repair mechanisms for handling foreign compounds are available in biological 
systems. Compounds can, for example, be removed unchanged via capture by present 
nucleophiles, or be metabolized. Genetic materials can also be repaired by enzymes, or affected 
cells can be programmed to die. Additionally, when the damage is not too widespread the 
organism can also survive and the modified genes will then be incorporated in the following 
generations. This means that PGIs can be active in vitro tests but in animal tests no activity is 
detected27. 
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1.4 GENOTOXIC IMPURITIES OF INTEREST 
 
In this section a number of genotoxins of interest for this thesis is described in greater detail, 
including mode of toxicity. 
 
1.4.1 ACETAMIDE 
 
Acetamide is a derivate from acetic acid and ammonia, and is a white, odorless, hygroscopic 
solid which is often used in electrochemistry and organic synthesis (Figure 4). Acetamide 
dissolves easily in water, displays amphoteric properties and hydrolizes slowly except for when 
an acid or base is present. In combination with acids, e.g. HBr, HCl, HNO3, acetamide forms 
solid complexes. 
 
Figure 4 Schemetic structural drawing of acetamide. 
 
Acetamide is generally produced via dehydration of ammonium acetate according to the 
reaction below. 
NH4OOCCH3 → H2O + CH3CONH2 
For industrial production the above method is transformed into a continuous process. 
Acetamide can also be synthesized via hydrolysis of acetonitrile under evaluated temperatures 
in acidic or basic environments. 
CH3CN +H2O → CH3CONH2 
Acetamide can be used for a large variety of applications. Amongst other, suppressing acid 
formation in explosives, inks, lacquers and perfumes. It can also be used as a mild moisturizer 
or as a softener for leather, paper, plastics and textiles. Other applications are in pharmaceutical, 
pesticide and antioxidant synthesis.28  
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Acetamide is a recognized carcinogen to humans, hence its presence in API manufacturing is 
monitored and strictly controlled.29,30,31,32 It is generally formed from as a side-product in the 
synthesis route rather than from degradation33 and although it is normally only used indirectly 
as building blocks in API synthesis, such as the derivates 2- and N-bromoacetamide or 
trifluoroacetamide, acetamide itself is a potential impurity in the formed API compounds. 
Another potential contamination source of acetamide in APIs is the hydrolysis of acetonitrile. 
Acetonitrile is not only a commonly used solvent for synthesis in the pharmaceutical industry, 
but it can also be used directly as a reagent in the actual API synthesis34. 
 
Based on evaluation of the data published it is concluded that the carcinogenic effects of 
acetamide are most likely not caused by a genotoxic mechanism, but can be assigned to 
inhibition of gap-junction intercellular communications (GJICs).29,35 Gap junctions are proteins 
responsible for the exchange of small molecules and ions between the plasma membrane 
channels and neighboring cells. This communication between cells is crucial for the control of 
cell differentiation, growth and death, and the subsequent maintenance of homeostasis36. 
 
1.4.2 THIOACETAMIDE 
 
Thioacetamide (TAA) is a compound containing a thio-sulfur group and has been used for a 
variety of different purposes, including as an organic solvent, fungicide, stabilizer of motor oil 
and as an accelerator in the vulcanization of rubber (Figure 5).37 In 1948 Fitzhugh and Nelson 
were the first to report TAA as a hepatotoxic agent after investigating its toxic effects after 
contamination of orange juice, originating from its use as a fungicide in orange groves.38 It has 
been found that single doses, ranging between 1-2 mmol/kg, of TAA in animal models can 
generate centrolobular, middle part of an organ, necrosis followed by regenerative response.37,38 
When the toxin is administrated chronically hepatocellular carcinoma is induced and recent in 
vivo studies in rodents demonstrated very selective liver damages such as cirrhosis, fibrosis and 
hepatic necrosis and apoptosis.39,40,41 
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Figure 5 Structure of thioacetamide. 
 
The toxicity of TAA is initiated by metabolic activity via a mixed-function oxidase system42,43. 
Two oxidations are the first steps in the metabolism of TAA (Figure 6), forming the reactive 
metabolites thioacetamide sulfoxide (TASO) and thioacetamide-S,Sdioxide by S-oxidation. 
These metabolites eventually modify amine-lipids and proteins with following function 
impairment and cytotoxicity. Together with reactive oxygen species (ROS) these intermediates 
form free radicals responsible for liver damages. Studies have shown that rodents developed 
cell death by apoptosis and necrosis concurrently when given TAA44. The mechanism behind 
the liver damages caused by TAA has been thoroughly investigated. The results show that the 
formed reactive metabolites cannot only bind covalently to cellular macromolecules but also 
stimulate oxidative stress42. It has been observed that lipid peroxidation, gluthion depletion and 
reduction of thiol groups follow ROS formation after thioacetamide exposure42,43. Another 
effect observed is that intracellular storages of calcium has been mobilized, both this and ROS 
have been shown to activate a number of processes responsible for cell damage and 
proliferation45. In the cells mitochondria are well-known as the suppliers of energy; however, 
they also work as hubs where important signals carrying information for initiation of cell death 
come together. Thus mitochondria compose a target for the toxic effects of TAA. The 
subsequent elevated formation of ROS species and interference of calcium homeostasis have 
the possibility to enhance the permeability of the inner membrane of the mitochondria, as well 
as disrupt the membranes and inhibit mitochondrial respiration41,46.  
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Figure 6 Describes the metabolism of TAA in rat hepatocytes. The first step (1) is a reversible S-oxidation to 
TASO (2). More oxidation follows creating the highly reactive species TASO2 (3 and 4). TASO2 can directly 
imidoylate amine groups on cellular proteins or PE phospholipids (7). Other possible fates are the formation of 
acetamide (6) or the reactive derivative acetyl sulfinic acid (5) after reaction with water. (5) reacts with protein 
amine groups to form amide derivatives (8).41  
 
1.4.3 AMINOPYRIDINES AND RELATED COMPOUNDS 
 
Some commonly used starting materials and catalysts in API synthesis are aminopyridine 
derivatives. The derivative 4-dimethylaminopyridine (DMAP) is for example used as the 
catalyst for synthesis of glucocorticoids, acylations, amino-group protection, esterifications, 
and sylilations47,48,49,50,51,52. DMAP is regarded as a potentially genotoxic impurity because it 
contains alerting genotoxic structures53. Other closely related compounds are aminopyrimidines 
and because of their structural similarity they are also considered as compounds of concern. 
Aminopyrimidines have for examples been used as nucleic acid base mimics, a base for 
anticancer drugs e.g. as inhibitors of a subfamily of receptor protein kinases, and in medicinal 
chemistry as an aniline replacements 54,55,56. One biologically active pyrimidine containing 
compound is Wy-14,643 (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid), which has 
been reported as a non-genotoxic carcinogenic. Non-genotoxic carcinogens stimulate tumor 
formation via mechanisms other than direct DNA interactions, for example by interfering with 
signal transduction mechanisms and gene expression regulating cell growth and death.57,58  
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Although most aminopyrimidines do not exhibit direct toxic effects its corresponding 
derivatives can show signs of toxicity. However, the mechanism of the oxidative metabolism 
of 2-aminopyrimidine derivatives is not well-known except for sulfadiazine, a sulfamide with 
high liver toxicity.59  
 
1.5 MOLECULARLY IMPRINTED POLYMERS - FUNDAMENTALS OF IMPRINTING 
 
Molecular interaction in nature, for example hydrogen bonding, ion pairing, and hydrophobic 
interactions, are essential for the function of a variety of systems that we all depend upon. Two 
examples illustrating such interactions are enzymes and antibodies with their remarkable 
capacity to distinguish and bind specific substrates with high accuracy. Self-organization and 
self-assembly are distinct chemical and physical interactions which form the basis of the 
characteristics displayed by enzymes and antibodies. This realization has lead to an increased 
interest in nanostructured materials and their possible application in mimicking biological 
materials. By studying the design and synthesis of complex biological molecular structures and 
configurations a new generation of separation, sensing, catalysis, and diagnostic materials can 
potentially be identified. The common theme linking these systems is molecular recognition 
with a high degree of affinity and selectivity for a specific molecule. Based on this a number of 
methods exploiting template mediated and self-assembly synthesis have been generated. 60,61,62 
An example of such a material is Molecularly Imprinted Polymers (MIPs), which are known 
for their robustness and antibody resembling capability to specifically bind and discriminate 
different molecules.63 The technique molecular imprinting developed while striving to mimic 
nature’s remarkable capacity to distinguish and bind specific substrate with high accuracy with 
man-made synthetic materials.64 It is an interdisciplinary technique linking together elements 
from a number of disciplines in chemistry e.g. polymer, organic, analytical, physical and 
biochemistry.65 Today one can choose from a number of formats when synthesizing MIPs.60,62 
,66,67,68 
 
The majority of imprinting is prepared by the synthesis of a polymer network around a template 
of interest (Figure 7) spanning from small molecules, biological macromolecules or 
microorganism, to crystal particles and even individual ions63. During the imprinting various 
interactions including covalent, electrostatic, hyrdrophobic, van der Waals bonds and metal 
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coordination form between the functional monomers and the template. In the presence of a 
cross-linker such interactions hold the template in place during the polymerization process. As 
a result the formed highly cross-linked polymer material contains binding sites complementary 
in shape, size and functional groups for binding of the template after template removal. The 
functionality of MIPs is hence based on acting like a template memory with selective and strong 
binding capacity of the template or related structures; mimicking antibodies. MIPs exhibit some 
additional advantageous characteristics to naturally occurring recognition systems, such as high 
tolerance for mechanical stress, high pressures, high temperatures, wide pH ranges, a variety of 
solvents and strong radiation. Furthermore, the relatively simple synthesis process in 
combination with the possibility to store the MIPs under harsh conditions and their capability 
to repeatedly bind templates, have resulted in an significant interest of these materials and their 
possible applications.  
 
Figure 7 Schematic drawing of MIP concept. 
 
A large variety of MIP applications has already been demonstrated in solid phase extraction, 
affinity separation, biosensors, immunoassays and controlled drug release systems.60,69 
Literature has also been published demonstrating possible applications of MIPs as a separation 
media in the pharmaceutical industry and in bio- and pharmaceutical analysis70,71. However, 
the use of MIPs for removal of genotoxins from APIs is a novel application area and the first 
publications on the topic have only recently been published indicating a current and growing 
interest10,72,73,74.  
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The simplicity of the required materials, equipment and processes all contribute to the growing 
interest in MIPs and the molecular imprinting technique. Additionally, in most published papers 
MIPs are produced using free radical polymerization indicating that they can easily be produced 
with readily available equipment in most laboratories. This facile production method has led to 
a broad application range for MIPs, nevertheless the challenge remains to overcome the 
shortcoming that no general imprinting protocol exist and a comprehensive procedure is still 
necessary to target a wide range of molecules.  
 
Depending on the chemistry and morphology design for the desired MIP, the imprinting process 
can be divided into three steps, binding site design, scaffold design, and morphology design 
(Figure 8). The first step of imprinting is to consider the template of interest and create a binding 
site with functional groups corresponding to the template molecule. By studying the functional 
and structural characteristics of the imprinting target, and simultaneously having the operating 
conditions of the MIP in mind, possible polymerization mixtures are chosen. The interaction 
between template and functional monomer can be either covalent or non-covalent. This is then 
reflected in the type of binding occurring in the resulting binding site in the polymer matrix. 
One approach taking advantage of both covalent and non-covalent imprinting is the so called 
hybrid approach. However, for this approach the actual recognition interactions are still non-
covalent. 75 An additional significant imprinting technique of interest for research groups is 
metal ion imprinting and metals can also be used for creating coordination sites for 
templates.76,77 Non-covalent imprinting remains the most generally used technique, where the 
template of choice is mixed in a pre-polymerization mixture of one or more functional 
monomers and then polymerized after addition of a surplus of cross-linker. 78,79 After removal 
of the template by extraction the resulting polymers are generally employed in separation 
processes, for example as stationary phases in chromatography.  
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Figure 8 Overview of the steps involved in MIP design. Adapted from reference 63.   
 
The structure of the polymer network influences the formed binding sites and hence determines 
the capability of the MIP to bind the imprinted molecule. The majority of MIPs reported are 
synthesized using free radical polymerization, where the template and functional monomer 
complex are mixed with an excess of a cross-linker and a solvent named porogen.80 This 
kinetically controlled polymerization fixates the polymer chains in an asymmetrical glass-like 
structure by the cross-linker. In turn the solvent does not only serve as monomer and template 
solubilizer, but it is also involved in the important phase separation process to create pores in 
the polymer network. The formation of such pores is further necessary to enable transport, 
template removal and binding to the binding sites generated. A number of factors including the 
solvent, which affects the pore size, and surface area, which affects the amount of cross-linker, 
determine the resulting highly heterogeneous amorphous structures of MIPs which are 
illustrated in Figure 9. 
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Figure 9 Schematic drawing showing possible binding sites present in a MIP.63 
 
The heterogenic amorphous MIP structure exhibits some drawbacks such as template bleeding, 
slow mass-transfer and non-specific binding, and other MIP formats are therefore being 
investigated in an attempt to improve the overall performance. Suggested formats include, but 
are not limited to, beads, nanoparticles, membranes, films, fibers, and tubes.81,82,83 This shows 
the complex mixture of different chemical and materials sciences involved in the MIP synthesis. 
The most important factors influencing the final MIP will be discussed in more detail in the 
sections below. 
 
1.5.1. FREE RADICAL POLYMERIZATION 
 
For large industrial scale free radical polymerization offers a straightforward technique for 
preparation of polymers. Because this technique displays a high flexibility in purity of the 
reagent and experimental conditions, the majority of vinyl polymers are for example 
synthesized via free radical polymerization.84 Furthermore, free radical polymerization is 
compatible with a large variety of functional monomers and has a high tolerance towards 
additional chemicals, such as an imprinting template, making it an attractive technique for MIP 
formation. Not surprisingly this is reflected in the number of reported MIPs adopting free 
radical polymerization as the main mechanism for formation.60 
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Free radical polymerization can be divided into either a homogenous or heterogeneous reaction. 
A homogeneous polymerization is a so called one-phase reaction, which is independent of the 
number of compounds in the polymerization mixture. A well-known example of homogeneous 
polymerization is for example bulk. Conversely, a polymerization with more than one phase is 
termed a heterogeneous reaction, with important examples including emulsion- and suspension 
polymerizations. The three main steps involved in the chain reaction of free radical 
polymerization are shown in Figure 10 and will be explained in further detail in section 
1.5.1.1 - 3.85  
 
 
I 
 
→ 
 
2R* 
Initiation 
R* + M 
 
→ 
 
M1* 
M1* + M 
 
→ 
 
M2* Propagation 
Mn* + M → Mn+1* 
   Termination 
Mn* + MZ* 
 
→ 
 
Mn-MZ combination 
Mn* + MZ* 
 
→ 
 
MnH + MZ= disproportionation 
 
Figure 10 Simple schematics of the main steps responsible for the chain reaction in free radical polymerization. 
 
1.5.1.1. INITIATION 
 
The generation of free radicals by an initiator starts the polymerization. An initiator is a 
compound that decays after exposure to either thermal or UV irradiation. The formed free 
radical then attacks the double bond of the monomer present, thus forming a free radical on the 
monomer i.e. intermediate radical. The rate of this initiator decay (υi) is described by; 
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Equation 2 υi = d[RM*]/dt = 2kd f [I]   
 
Where [I] is the concentration of initiator, [RM*] the propagation species concentration with 
respect to time, kd the rate or decay constant, f the efficiency of the initiator to propagate chains, 
and the 2 represents the two radicals formed per initiator compound.  
 
1.5.1.2 PROPAGATION 
 
The reaction of a free radical and a monomer forms a chain carrier. By addition of new 
monomers propagation rapidly occur causing mainly linear polymer chains to be formed. The 
propagation reaction can be described by the following equation. 
 
Equation 3 RMn* +M→RMn+1*   
 
Where RMn* is the chain carrier, M free monomer and RMn+1* the formed chain carrier with 
an additional monomer. 
 
The rate of propagation can be described as; 
 
Equation 4 υp = kp [M][M*]   
 
Where vp is the rate of propagation, kp the propagation constant, [M] is the free monomer 
concentration, and [M*] is the concentration of free monomer radicals. The concentration of 
growing reactive chains is described by [M*]. By observing the decrease of monomer 
concentration the progress of the reaction can hence be tracked. 
 
1.5.1.3 TERMINATION 
 
Until the free radicals react to form covalent bonds, the propagation process runs continuously. 
This can normally be observed when the concentration of free radicals is high or in the case 
when chain transfer agents are present. The two types of termination processes include the 
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formation of a macro-chain by the recombination of two macro-radicals, and the 
disproportionation that results in a double bond and a C-H bond terminates the chain. When 
considering these two processes a number of possible termination reactions can take place 
during the polymerization including: 
 
a) The combination of two active chain-ends 
b) An active chain terminus and an initiator radical can react 
c) The radical can be transferred from one molecule to another, such as initiator, monomer, 
solvent or template 
d) Termination by reaction of an active compound with impurities present, e.g. free oxygen or 
inhibitors 
 
The termination rate (υt) can be described as: 
 
Equation 5 υt =2kt[M*][M*]   
 
Where kt is the termination rate constant and [M*] the concentration of free monomer radicals.  
 
When equilibrium between the production and the utilization of free radicals occur a so called 
steady-state has been reached which can be described as:  
 
Equation 6 2kt [M*]2 = 2kd f [I]   
 
Where kt is the termination rate constant, [M*] the concentration of free monomer radicals, kd 
the rate or decay constant, f the efficiency of the initiator to propagate chains, [I] is the initiator 
concentration, and the 2 represents the two radicals formed per initiator compound.  
 
When combining Equation 6 with Equation 4 the polymerization rate (υp) can be described 
as: 
 
Equation 7 υp = kp [M](f kd [I]/kt)1/2   
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1.5.2 IMPRINTING CONCEPTS  
 
Multiple concept on how to establish the specific binding functionality in the cavities in the 
polymers have been developed. Depending on the pre-arrangement of the monomers, and the 
template in the pre-polymerization mixture, the imprinting is categorized as covalent, non-
covalent or semi-covalent.  
 
1.5.2.1 COVALENT IMPRINTING  
 
Covalent imprinting was first reported in the early 1970s by Wulff et al..86 As the name suggests 
during covalent imprinting the template is bound covalently to the functional monomer before 
polymerization (Figure 11). After the formation of the polymer the covalent bonds are cleaved 
to release the template. This forms binding sites that are able to rebind the template via the same 
covalent bonds that were initially used in the imprinting step. The main advantage of covalent 
imprinting is that every polymerizable template results in one imprinted binding site containing 
functional monomers arranged in the best possible geometrical arrangement. In theory 
covalently imprinted polymers should therefore offer binding sites with high binding capacity 
and strong affinity. Furthermore, the highly stable complexes formed in the binding sites make 
it possible to use polar solvents without damaging the formed structure. However, the downside 
to the stability is the inherent slow template binding and subsequent release87. In spite of the 
advantageous attribute of covalent imprinting some disadvantages are present. One of the more 
serious limitations being the restricted number of chemical functional groups that can easily 
form the required reversible covalent bonds, with examples of suitable groups including 
disulfides88, ketals89, imines90 and boronate esters91. Needless to say the number of accessible 
template with fitting functional groups is yet another limitation to the covalent imprinting 
approach. The process of removing and rebinding the template, i.e. creating and breaking the 
covalent bonds, should be quick under general process conditions, thus further limiting the 
application of covalent imprinting.63 Finally important to note is that though examples of 
covalent imprinting can be found in literature92,93, it has not become the first method of choice. 
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Figure 11 Imprinted 4-nitrophenyl-α-D-mannopyranoside-2,3:4,6-di-O-(4-vinylphenylboronate) MIP (2). (a) the 
covalent template monomer, is synthesized via condensation of 4-vinylbenzeneboronic acid with 4-nitrophenyl-α-
D-mannopyranoside. (b) After copolymerization with cross-linker (divinylbenzene or ethyleneglycol 
dimethacrylate) the polymer is formed. (c) The template is removed by hydrolysis of the boronate ester groups and 
addition of 4 equivalents of water to reveal the imprinted binding site.93 
 
1.5.2.2 NON-COVALENT IMPRINTING 
 
The non-covalent technique was first introduced in the early 80s by Mosbach et al (1981).94,95 
In the non-covalent imprinting interactions such as hydrogen bonds, electrostatic interactions 
and coordination-bond formation are used as the fundamental basis, and the stability of these 
interactions determines the imprinting success. Because hydrogen bonds depend on both 
distance and direction between the template and the functional monomer, thus creating highly 
defined binding sites, they tend to be the primary choice of use87. It is fairly straight-forward to 
imprint lipophilic, low-molecular weight templates that contain basic or acidic functionalities 
when using non-covalent imprinting60. Because of its simplicity non-covalent imprinting has 
further become the preferred method of choice for synthesis of MIPs currently reported in the 
literature. 
 
During non-covalent imprinting a self-assembled complex is formed between the template and 
the functional monomer when these are dissolved in an appropriately selected solvent. After 
addition of an excess of cross-linker the mixture is then polymerized resulting in an insoluble 
porous polymer material, containing binding sites according to the pre-formed self-assembled 
complex. After polymerization the template can be removed easily by using a relative mild 
solvent for extraction and the formed binding site is able to rebind the imprinted template, or 
analogues, via the same non-covalent interactions. 
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A variety of commodity monomers able to form non-covalent interactions can be used as 
functional monomers, and systems based on acrylic and methacrylic monomers, such as 
methacrylic acid and ethyleneglycol dimethacrylate as cross-linker, have repeatedly been 
demonstrated as suitable systems for MIPs. As a result numerous reports on different templates 
containing hydrogen bond- or proton-accepting functionalities that are imprinted with 
methacrylic acid have been reported in literature with one example included in Figure 12.96  
 
 
Figure 12  Non-covalent imprinting of 9-ethyladenine (9EA) with functional monomer MAA and cross-linker 
EDMA.63  
 
The widespread usage of methacrylic acid as a functional monomer in non-covalent imprinting 
can be explained by the fact that it can easily form corresponding interactions, such as hydrogen 
bonds or hydrogen-bonded ion pairs, with the template. Furthermore, for many single systems 
specific binding constants are formed between methacrylic acid and the template, with values 
of the constant ranging from single figures up to several hundred for weak hydrogen bonds, 
cyclic hydrogen bonds or hydrogen interactions formed in non-polar aprotic solvents 
respectively.63 In the self-assembly phase between the functional monomer and the template, 
methacrylic acid acts as either an hydrogen bonding donor or acceptor, hence creating ionic 
interactions to amines and hydrogen bonds to amides, carboxyls and carbamates. Sellergen et 
al.(1993)97 were the first to report successful enantiomeric separations using this approach and 
by using enantiomeric derivates of amino acids and a number of highly selective chiral 
stationary phases were demonstrated.95,97,98  
 
Non-covalent imprinting has been thoroughly studied using L-phenyl alanine as imprinting 
template in a model system. Phenomena such as band broadening by chromatography, the 
influence of the solvent on the ion exchange retention, protonation state effect on imprinting 
and photo- versus thermal polymerization, have been studied in detail and have provided a 
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better fundamental understanding of the non-covalent imprinting approach.79,97,99,100,101,102 
Additionally, the association constants between specific templates and methacrylic acid can 
easily be determined by NMR spectroscopic and chromatographic studies of the self-assembled 
complex in the pre-polymerization mixture. In order to improve the capacity of MIPs 
synthesized via non-covalent imprinting aspects of supra-molecular chemistry is considered, 
and has resulted in novel functional monomers that are designed to form stronger interactions 
with a specific template than the commodity acrylic monomers. 
 
Despite the versatility of non-covalent imprinting, the technique displays some drawbacks like 
highly heterogeneous binding site distribution, low binding capacities and also, rather 
frequently, poor target specificity when using polar solvents like for example water. This can 
be explained by the fact that the interaction between templates and functional monomers are 
relatively weak. Subsequently one has to add an excess of functional monomer in respect to the 
amount of template and use low polar solvents that the maximum number of binding complexes 
are formed in relation to the template.60 This leads to materials with binding sites that are not 
clearly defined and with an inhomogeneous distribution, because a large quantity of the 
functional monomer is randomly distributed in the polymer thus creating non-specific binding 
sites. Optimized reaction conditions that present favorable and stable pre-polymerization 
complexes, are therefore required to enable successful non-covalent imprinting.  
 
1.5.2.3 SEMI-COVALENT IMPRINTING 
 
A third imprinting approach is the semi-covalent approach which is a hybrid between covalent 
and non-covalent imprinting. The semi-covalent approach demonstrates similarities to covalent 
imprinting in the first step of imprinting, where the functional monomer is covalently bound to 
the template. However, the binding step displays non-covalent binding properties that are 
activated after the template is removed following the polymerization. The semi-covalent 
method can thus be considered as a mixture of both covalent and non-covalent imprinting as 
indicated by the name. 
 
Semi-covalent imprinting can be divided into two types where in the first the template is 
connected directly to the monomer, and in the second a spacer group connects the template and 
monomer62. The first report on semi-covalent imprinting using the first approach was published 
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in the early 1990s by Sellergren and Andersson.103 In this work a structural analogue of p-
aminophenylalanine was imprinted and two polymerizable groups were attached to the 
monomer via ester bonds. Following the template removal carboxylic acid groups were then 
exposed in the binding site, and rebinding of the target analyte occurred via a mixture of 
hydrogen bonds and electrostatic interactions.103 The second kind of semi-covalent imprinting 
is also known as the sacrificial spacer approach and was first established by Whitcombe et al. 
(1995)104, who used a spacer group in the imprinting process to circumvent crowding in the 
binding site and promotes unrestricted rebinding of the analyte.104 Another example of semi-
covalent imprinting using a sacrificial spacer group for imprinting of cholesterol is illustrated 
in Figure 13.  
 
 
Figure 13 Imprinting of cholesterol by the sacrificial spacer (semi-covalent) method. (a) is the template monomer, 
cholesteryl (4-vinyl)phenyl carbonate and (b) the formed polymer. (c) template is removed by alkaline hydrolysis 
and (d) template rebound in the binding site. 93 
 
Finally, MIPs can also be prepared by additional combined techniques, including metal-ion 
mediated imprinting62. Recent advancement of such techniques has been reported by Takeuchi 
et al. (2009)88, where covalent imprinting was initially used for the polymerization, after which 
the template is removed and the free functional groups in the binding sites are modified post 
polymerization. Analysis of the materials showed that only the post modified polymers 
containing the cofactor bind the target analyte to a high degree – just like enzymes are 
dependent on cofactors for catalytic activity.88  
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1.5.3 TEMPLATES - FROM SMALL MOLECULES TO BIOMOLECULES 
 
The molecularly imprinting technique offers the possibility to imprint molecules ranging from 
small size, like acetamide, to large biomolecules, such as peptides and proteins. Furthermore, 
the template used for imprinting dictates the entire polymerization process; from the choice of 
functional monomer to the solvent system used. Hence, it is of immense importance to gather 
knowledge of the characteristics of the template or analyte intended for imprinting and 
rebinding prior to designing the imprinting process.  
 
Synthesized MIPs that can bind not only the imprinted templates but also other target analytes 
or structurally similar analytes, are fundamental in the continuous development of new MIPs. 
One of the advantages of such MIPs is that in addition to the compound intended for rebinding 
in the imprinting process, other target analogues can also be used as a template for the 
imprinting step. Depending on the nature of the end-use template, an analogue can be a better 
option for imprinting for example if the template is toxic and/or very costly, can possibly cause 
interference or reactivity problems, or if it promotes extreme template bleeding. A suitable 
analogue for imprinting should fulfill a series of criteria including:  
 
 Be accessible in large quantities to a reasonably low cost 
 Be soluble in the pre-polymerization mixture 
 Exhibit good cross-reactivity in the resulting binding sites 
 
Due to these specific criteria it is easy to realize that the choice and/or the design of templates 
is a complicated assignment, which may include numerous repetitions and synthesis of 
different possible template candidates that exhibit appropriate properties. However, depending 
on the specificity intended for the MIP, where high specific binding of a single molecule and 
exclusion of templates similar in structure are necessary, it might not be possible to use 
analogue replacement.  
 
One favorable approach for template design may be to synthesize libraries based on the specific 
functionalities of the targets. A simpler target with some, or all, functionalities may then be 
used for complex natural compounds that contain a limited number of functional groups. 
Nemoto et al. (2007)105 used this method to synthesis domoic acid, a fish poison, imprinted 
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polymers by employing commercial available di- and triacids such as triacid pentane-1,3,5-
tricarboxylic acid as templates (Figure 14)105. 
 
 
Figure 14 Left: Structure of the fish posion domoic acid; Right: Structure of the template used for imprinting, 
pentane-1,3,5-tricarboxylic acid 
 
However, if the desired targets are too complex, exhibit poor solubility, are not commercially 
available or difficult to synthesis in large quantities the established imprinting methods are not 
effective. This is especially true for biomolecules, such as proteins, nucleic acids and 
polysaccharides. In order to imprint these compounds an aqueous environment might be 
necessary to dissolve and/or stabilize the target so that it is close to its natively preferred 
configuration. The obvious disadvantage of using an aqueous medium is that stable electrostatic 
interactions, the foundations of molecular imprinting, can be interrupted by water’s polar 
influence and predisposition to hydrogen bonding. In addition, these compounds are hard to 
encounter in large enough quantities to enable the imprinting process. One approach to 
circumvent this is to use fragments corresponding to sub-structures of the target as templates 
for imprinting106,107,108. However, the obvious risk of using only parts of the target, or similar 
compounds, is the potential formation of less specific binding sites rather than binding sites 
with considerable affinity for the large biomolecule target. The first reports demonstrating this 
approach was the imprinting of peptides106 and vitamins107. This so called epitope imprinting 
has further been combined with surface imprinting approaches to develop MIPs demonstrating 
cross-reactivity with peptides109 and proteins108 by using just short peptide sequences i.e. 
epitopes.  
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1.5.4 FUNCTIONAL MONOMERS  
 
One of the most widely used monomers in MIP formation is methacrylic acid (MAA). Although 
MAA is an incredibly resourceful functional monomer in forming fine imprints, a number of 
other commercially available monomers may be used to form optimal interactions with 
different functional groups, e.g. monomers with amine groups for acidic functionalities on the 
template. Vinyl pyridine (VP) and meth acrylamide (MAAM) are examples of other commonly 
used functional monomers in non-covalent imprinting (Figure 15). In order to find the most 
favorable functional monomer for the template of choice, theoretical predictions based on 
structural observations of the intermolecular interactions can be used. A number of different 
techniques can be used to gain information of the self-assembled complexes formed in the pre-
polymerization solution, e.g data modeling NMR, UV-vis, or IR 79,110,111,112. However, trial and 
error is still commonly used and has proven to be effective in the design of MIPs with 
noteworthy imprinting effect, especially in combination with high-throughput techniques.63,91  
 
Figure 15 Examples of commercially available functional monomers used in non-covalent imprinting.63 
 
As mentioned earlier non-covalent imprinting comes with some limitations, including the 
heterogeneous binding site distribution, poor binding capacities and reduced performance in 
polar solutions. One contributing factor to the limitations observed is that the commodity 
monomers used for imprinting do not always provide an optimal fit for the templates. The 
development of new functional monomers for use is hence of great interest for the imprinting 
community. One approach to improve the recognition properties of MIPs could be to mimic 
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techniques used in nature, in the sense that recognition is achieved by a number of different 
functional monomers, and not only by one single functional monomer. In Figure 16 an example 
of a MIP synthesized using a mixture of functional monomers is illustrated. Despite the 
theoretical simplicity of this approach, it is associated with some drawbacks due to the fact that 
the fundamentals of non-covalent imprinting are the self-assembly principle. When adding 
more than one monomer to the pre-polymerization mixture the number of possible interactions 
also increases. Therefore the self-assembly equilibria present in the pre-polymerization solution 
do not only consist of template- monomer complexations, but also  direct monomer-monomer 
interactions.63 
 
 
Figure 16 A schematic drawing of an amino acid analogue monomer imprinted MIP.63  
 
Even if a limited number of commodity monomers have been used for most of the successfully 
synthesized MIPs, a stoichiometric non-covalent imprinting could offer improved MIPs with 
either higher selectivity or better binding capacity. This can be obtained by using host-guest or 
supramolecular chemistries inspired by Nature.66 MIPs synthesized with stoichiometric non-
covalent imprinting exhibit relatively clear-cut binding sites with the functional groups mainly 
placed within them. Takeuchi et al. (1995) were one of the first to report MIPs synthesized 
using this technique, using a designed bis(acrylamido)pyridine monomer to imprint a barbital 
(Figure 17)113. For this MIP the designed monomer has an hydrogen bonding donor-acceptor-
donor element that corresponds well to the acceptor-donor-acceptor element in the template. 
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Figure 17 Imprinted barbital and the proposed formed binding sites.63 
 
1.5.5 CROSS-LINKER SYSTEMS 
 
Another critical part in the imprinting process is the type and amount of cross-linker used, as 
this can have a variety of effects on the performance on the synthesized MIP. Cross-linkers are 
responsible for the three-dimensional structure of the MIP by “freezing” the self-assembled 
complex formed in the pre-polymerization mixture. Hence, a high level of cross-linking 
produces rigid binding sites, as well as satisfactory porosity, in the polymer and thus influence 
the selectivity of the resulting MIP.60 Depending on the ratio of cross-linker to monomer 
different polymer morphologies can be obtained, ranging from gel-like polymers to stable 
macro-porous materials when using low and high amount of cross-linker respectively. MIPs 
also obtain their characteristic mechanical stability from the cross-linker systems, making them 
insoluble in organic solvents, which is a prerequisite for many applications. 
 
In addition to the template the solvent system also influences the choice of cross-linker, with 
organic solvent and aqueous solutions requiring different cross-linkers. Examples of cross-
linkers for imprinting in aqueous solutions are acrylamide, N,N’-methylenebisacrylamide 
(MBA), N-isopropylacrylamide (NIPAm) (Figure 18), whereas ethylene glycol dimethacrylate 
(EGDMA) and divinyl benzene (DVB) are commonly used cross-linkers for imprinting in 
organic solvent (Figure 19). 
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Figure 18 Structure of some cross-linkers commonly used for imprinting in aqueous solutions. From left to 
right; N,N’-methylenebisacrylamide, NIPAm,acrylamide 
   
 
Figure 19 Structures of EDMA and DVB commonly used cross-linkers in organic solvents. 
 
A number of factors influence the choice of (co-)monomer – cross-linker systems. Firstly, one 
has to consider the reactivity of the double-bonds in the monomers, which for homogeneous 
polymerization to occur should be related. Secondly, depending on the polarity of the pre-
polymerization complex a suitable co-monomer – cross-linker system has to be selected. For a 
rather weak pre-polymerization complex a less polar environment is required compared to when 
a stronger complex is used. For non-covalent imprinting in organic solvents the most frequently 
used monomer systems include: 
 
 Hydroxyethylmethacrylate (HEMA)/EGDMA 
 Methacrylic acid (MAA)/EGDMA 
 Styrene/DVB 
 
The HEMA/EGDMA system exhibit polar characteristics and is therefore a suitable choice for 
pre-polymerization complexes with strong affinity between template and monomer. However, 
because of the OH-group present in HEMA, polymers synthesized with this system have a 
tendency to swell in contact with aqueous solutions. A less polar alternative is the 
MAA/EGDMA system. Since EGDMA is a di-ester of MAA and ethylene glycol the double 
bond reactivity of EGDMA and MAA is comparable. This in addition to the mechanical and 
thermal stability of the MAA/EGDMA complex, has made it the most frequently used monomer 
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system to date. Additionally, MAA/EGDMA also shows further advantages in offering an 
overall good wettability and fast mass transfer. For template/functional monomer complexes 
with weaker interaction characteristics, the styrene/DVB cross-linker system is more 
appropriate because of its less polar characteristics compared to MAA/EGDMA. Thus, the 
crosslinker system does not interfere with the self-assembly of the template and functional 
monomer. 
 
1.5.6 INITIATORS 
 
The polymerization technique is selected according to the characteristics of the chemicals used. 
In theory this means a variety of techniques can be used, but free radical polymerization as 
previously discussed, is by far the most frequently used method. Initiation of free radical 
polymerizations can be done by a large variety of initiators. The class of azo-initiators, which 
cleave bonds homolytically, is frequently used in molecularly imprinting with two of the more 
common examples of azo-initiators shown in Figure 20. There are two ways in which 
decomposition can occur, either by thermal or photochemical initiation, depending on the 
initiator used in the synthesis. 
 
Figure 20 The two frequently used azo-initiators AIBN (Azobisisobutyronitrile) and ABDV 
(Azobisdimethylvaleronitrile). Decomposition temperature AIBN: 60 °C, ABDV: 45 °C) or photochemically.  
 
1.5.7 SOLVENTS 
 
The terms solvents and porogens are both used during discussions about molecular imprinting, 
but one should differentiate between the two. The purpose of a solvent is to solubilize all the 
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reactants in the polymerization mixture, as well as to disperse the produced reaction heat. The 
solvents used should also promote a homogeneous cross-linking in the polymer. It is more 
complicated to choose the optimal solvent in precipitation polymerizations compared to bulk 
polymerization, as in the first step the solvent should exhibit good solubilization for the reagents 
but the synthesized polymer should be insoluble to promote precipitation.    
 
A porogen on the other hand, is a solvent that promotes pore formation in the polymer matrix 
during the polymerization. In molecular imprinting pore formation is a crucial part of the 
synthesis, because pores are necessary to enable the template to access the cavities. Even if the 
porogen used for synthesis influences the pore size, the formed polymer matrix generally has a 
broad pore size distribution, and the pore size of MIPs may vary from micro- to meso- to macro-
sized pores. To better understand the influence on the final MIPs various commonly used 
solvents in molecular imprinting have been carefully studied. Table 1 summarizes the properties 
of a number of solvents. 
 
Table 1 A summary of the properties of a number of solvents. 
 Disperion Polar Hydrogen bonding 
Hydrogen 
bonding 
capacity 
  δ D δ P δ H   
MeCN 15.3 18.0 6.1 Poor 
Benzene 18.4 0 2.0 Poor 
CHCl3 17.8 3.1 5.7 Poor 
CH2Cl2 18.2 6.3 6.1 Poor 
Cyclo-hexane 16.8 0 0.2 Poor 
Ethy acetate 15.8 5.3 7.2 Poor 
DMF 17.4 13.7 11.3 Moderate 
H2O 15.5 16.0 42.4 Strong 
HOAc 14.5 8.0 13.5 Strong 
Isopropanol 15.8 6.1 16.4 Strong 
MeOH 15.1 12.3 29.3 Strong 
THF 16.8 5.7 8.0 Moderate 
Toluene 18.0 1.4 2.0 Poor 
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One very important aspect to consider when choosing a solvent for imprinting, is that it should 
not interfere with the self-assembled complex in the pre-polymerization mixture. With the 
complex in mind the solvent should be chosen by, not only considering solubility properties but 
also the properties summarized in Table 1. When studying the H-bond and polar terms and the 
H-bond capacity of the solvents listed it is evident why imprinting in e.g. water or MeOH is 
generally avoided. Although MeCN and DMF exhibit high polar terms compared to water and 
MeOH their H-bond capacity is less pronounced. It is hence of great importance to know what 
type of interactions are present in the selected system. Electrostatic interactions may be 
disrupted by polar solvents, whereas solvent with a high dielectric constant could have an 
influence on the forces between a positively and a negatively charged compound. Conversely, 
hydrogen bonds are susceptible to protic solvents and even though it is acknowledged that the 
structure of the MIP is significantly influenced by the porogen used, its effect on the actually 
imprinting step is more disputed.  
  
1.6 DIFFERENT FORMATS AND FORMATION OF MOLECULARLY IMPRINTED 
POLYMERS 
 
MIPs exhibit a number of advantages over biological receptors, including their good 
mechanical and chemical stability, low preparation cost and broad possible operating 
conditions. However, as mentioned earlier MIPs also display some limitations e.g. 
heterogeneous binding site distribution, poor selectivity, binding capacity and accessibility of 
binding sites, and further improvements are highly desirable.102 Overcoming current MIP 
limitations provides an interesting possibility for developing new applications, and the 
development of new formats and synthesis techniques aimed at improving the homogeneity of 
the binding sites, the binding capacity, the mass transfer and the accessibility, is constantly 
ongoing in the MIP community. There are a variety of different types of MIPs that can be 
synthesized depending on the intended end purpose. Commonly used formats include 
monolithic bulk polymers, polymeric membranes or polymeric beads. 
 
 
47 
 
1.6.1 PARTICLES 
 
Monolithic MIPs are synthesized via free radical bulk polymerization. When using a high cross-
linking level solid polymer materials are formed displaying good mechanical and thermal 
stability. Bulk polymerization is an uncomplicated technique where all the components are 
mixed and polymerized in one pot. During synthesis the template, functional monomer, co-
monomer (if used) and cross-linker are dissolved in the chosen solvent, and with either thermal 
or photochemical initiation the polymerization is started. After polymerization and incubation 
the resulting material is isolated from the polymerization tube. The formed polymer is crushed 
and sieved into the desired particle size and the template and unreacted compounds are removed 
by soxhlet-extraction. The common particle size for chromatographic applications is between 
26 and 36 µm, whereas a larger particles (36-63 µm) are used for solid-phase extraction (SPE). 
 
Because of its simplicity, bulk polymerization is an attractive method for preparing MIPs but 
as mentioned before it also exhibit some limitations. Apart from the heterogenous binding sites 
formed because of the nature of the polymerization, the work-up of the monolith polymer also 
contributes to limitations of the method. When crushing the monolith into the desired particle 
size, irregularly shaped and sized particles are formed (Figure 21). This may cause problems 
when using the MIPs in a number of end-applications, for example through the creation of back-
pressure in HPLC column when the particles are used as stationary phases or the generation of 
light-scatter in optical applications. Another crucial weakness of bulk polymerization is that a 
large part of the polymer is lost during the crushing and sieving process. Additionally, the 
heterogeneously distributed binding sites, make complete template removal very challenging. 
This is due to the highly cross-linked polymer matrix that partly or completely captures the 
template, leading to template bleeding hence causing false positives in the analysis or to an 
irreversible blocking of the binding sites respectively. 
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Figure 21 Microscopy (left) and scanning electron microscopy (SEM) (right) pictures of acetamide imprinted bulk 
polymers. 
 
To overcome the limitation of bulk MIPs there is growing interest in developing MIPs with 
spherical shapes and narrow size distrubutions. Taking inspiration from conventional polymer 
chemistry, suspension and emulsion polymerization techniques have hence been tried for MIP 
production.81,114 Another early approach tested for synthesizing uniform and spherical particles 
is to use a silica mold and graft a layer of MIP on the surface. This technique has further been 
developed and  for more current application it is more common that the initiator or the template 
is immobilized on the surface of porous silica, and the polymerization is taking place in the 
pores. Following the polymerization the silica mold is removed by etching, leaving mirrored 
porous polymer beads as illustrated in Figure 22.109,115,116,117  
 
 
Figure 22 SEM pictures of acetamide imprinted porous silica particles after etching of the silica.  
 
In the attempt to develop spherical MIPs other techniques have also emerged, such as mini-
emulsion where polymer beads are synthesized by a two-phase polymerization and inverse 
micro-emulsion technique that Shea et. al. (2010) used to synthesize nanoparticles imprinted 
with a hydrophilic peptide.63,118 Precipitation polymerization is one technique which has proven 
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useful for molecular imprinting and the synthesis of spherical particles, and because of its 
simplicity become a commonly used technique. This technique can also be used to prepare 
nanoparticles, submicron particles, micro-gels as well as particles within the micron range. 
However, to circumvent agglomeration a high dilution is necessary, resulting in a potentially 
lower yield of the process.119,120,121,122  
 
1.6.2 IMPRINTED POLYMERIC MEMBRANES 
 
By customizing the characteristics of membranes a number of possible applications are 
anticipated in e.g. industrial separations and purifications. Depending on the mode of 
transportation the imprinted membranes can be divided into different categorizes namely 
adsorption and active transport (Figure 23). The mechanism of transport can be either retention 
of template transport by adsorption, or active transport where the template more easily travel 
trough the membrane compared to other compounds. The first technique used to synthesize 
molecularly imprinted anisotropic microporous membranes, was a combination of a phase 
inversion technique in combination with the imprinting procedure in one step. By using this 
method membranes with affinity for templates ranging from small molecules to proteins have 
been produced. However, in an attempt to overcome robustness limitations often observed in 
one-pot synthesized membranes, composite membranes have gradually gained importance and 
are becoming the more common alternative for manufacture of imprinted membranes. Rather 
than one-step synthesis the imprinting step for composite membranes is separated from the 
phase inversion, or the synthesis method used for membrane formation. Most commonly the 
imprinting is carried out by either grafting the MIP onto the membrane surface or by 
incorporating pre-synthesized particles into the membrane.63,123      
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Figure 23 Summary of separation mechanisms for molecularly imprinted membranes: (a) a concentration gradient 
drives the transport of A , whereas the nonspecific transport of B is hindered, (b) MIP binding sites at the surface 
bind A and hinder the transport through the membrane, while the transport of B is driven by diffusion, (c) increase 
of the membrane permeability, caused by e.g. increased membrane swelling, (d) decrease of the membrane 
permeability, for example, caused by e.g. decreased membrane swelling as a result of A binding to MIP sites.123 
 
1.7 APPLICATIONS 
 
One area where MIPs have proven to make an impact is in SPE and trace analysis. Molecularly 
imprinted solid phase extraction (MISPE) offers a reproducible and effective solution 
opportunity to improve sample extraction techniques, capable of enriching as well as cleaning 
up samples for analysis, a step that often prolong the sample preparation procedure.124 A variety 
of examples of MISPE applications have been published to date,125,126,127,128 and the range of 
successful application demonstrate that MISPEs can in fact compete with, and in some cases 
even outdo, the performance of some generic techniques such as enrichment based on metal 
mediated chelation, Lewis acidic metal oxides (e.g. TiO2), and strong cation-exchange 
chromatography. The successful applications of MIPs in MISPEs can clearly be observed in 
the large number of published papers coming up to almost 200 publications during 201063. 
Examples include the analysis of the tobacco-specific biomarker NNAL in urine samples and 
the selective enrichment of sulfopeptides in a strong pH-dependent manner.125,128 The factors 
contributing to the success of MISPEs are the clear-cut procedure in how affinity for specific 
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compounds or group of compounds can be synthesized, as well as the relative inexpensive 
production and the robustness of the materials.  
 
Another area in constant need of improved and economically viable affinity-based separations 
is large-scale processes in many chemical industries. Some examples include water purification 
from toxic organic pollutants and purification of raw material or unwanted compounds, such as 
flavors, in food processing. This is especially true for API purification in the pharmaceutical 
and biopharmaceutical industries, where delays caused by purification problems may lead to 
increased production costs and, more importantly, longer time for the drug to reach the 
market.63 MIPs could also possibly be a tool for second generation development of a drug 
production process optimization. 
 
Reports on successful examples of MIP applications in a variety of industries have already been 
published to date. One such example addressed the challenge faced by governmental water 
purification of removing trace amounts of endocrine disrupters from water. These chemicals 
affect the hormonal, i.e. endocrine, system in mammals and can create adverse developmental, 
immune, neurological and reproductive effects.129,130 In an effort to use MIPs for removing 
trace amounts of endocrine disruptors that slip through the current purification system, MIPs 
targeting chemicals mimicking the natural female hormone 17-β-estradiol have also been 
synthesized and evaluated. Mattiasson with colleagues (2007) demonstrated that effective 
purification of wastewater down to trace levels of 17-β-estradiol was possible with the help of 
MIPs.129 Another application where MIPs have proven useful is the removal of riboflavin, 
vitamin B2, from beverages.131 A general occurring problem in the beverages industry is 
chemical processes that influence the quality of the product. Flavor in for example beer, milk 
and wine can be compromised by photo-oxidizing reactions driven by riboflavin, and these 
products are hence normally placed in light-protected containers. For the removal of riboflavin 
a very selective purification process is needed so that no other substances are removed 
unintentionally. Riboflavin template water-compatible MIPs was synthesized and demonstrated 
to effectively remove roughly 90% of the riboflavin present in beer.131,132 Cobalt imprinted 
MIPs with excellent selectivity for iron-containing ions could possibly be applied in reactors in 
nuclear power plants to improve the decontamination processes. Metal oxides are formed when 
structural materials in e.g. water cooling systems, come in contact with coolant agents, causing 
these oxides to entrap the radioactive ions. MIPs could offer a competitive alternative to current 
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techniques which often require time-consuming and expensive cleaning procedures for removal 
of radioactive ions.91  
 
Due to the high binding selectivity MIPs could potentially be used as chemical sensors and 
assays. As a result a large number of publications on MIP-based sensors have been published 
over recent years for intended use in areas including electrochemical, mass-sensitive, optical 
and surface Plasmon resonance analysis133,134,135,136,137. The examples mentioned combine 
different MIP materials, ranging from meth- acrylates, styrene based, polyurethanes to 
inorganic sol-gel materials, with quartz crystal microbalance (QCM). QCM devises combined 
with MIPs were first developed by Dickert et al. (2000) with the application for observing 
engine oil degradation and the polyaromatic hydrocarbon concentration in water.138 Other 
examples of sensor applications are MIPs with fluorescence characteristics. This can be 
achieved by either imprinting of a molecule that is fluorescent or by using a fluorescent 
component, e.g. a functional momoner, in the MIP itself.139,140,141 Furthermore, MIPs could 
potentially replace expensive antibodies in immunoassays by offering advantages like 
improved stability, as well as functionality in both aqueous and organic media. However, the 
inherited disadvantages, like the necessity for template molecules for MIP production and the 
cross-reactivity often correlated with MIPs, limit the applications to date.142,143 Although a large 
number of successful MIP-based sensors have been published to date, further studies 
investigating the binding mechanisms between the MIP and the analyte, as well as the 
selectivity and evaluation of roughness, should be conducted. Furthermore, in order to achieve 
real implementations in industry of MIP-sensors, the gap between fundamental research and 
application needs to be eliminated, such as scale-up and reproducibility. With this in mind, 
pharmaceutical industry with its strict quality controls conditions and high purity requirements 
could benefit from MIP-based sensors to detect trace amounts of unwanted compounds.144     
 
MIPs applied in therapeutic applications have also been investigated, for example for drug 
delivery using hydro-gels and in a more recent approach where the MIP itself acts as an API 
capable to inhibit the enzyme trypsin.122,121,145,146 As demonstrated in this section the possible 
applications for MIPs range over a large number of possible applications. However, work 
presented in this thesis focuses primarily on MIP applications in the pharmaceutical industry. 
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1.7.1 MIPS AS CATALYSTS 
 
MIPs share some similarities with enzymes in the sense that they are capable of binding specific 
molecules. This in turn could present the opportunity to use MIPs in organic synthesis and in 
catalysis. Because of the flexibility in the design of MIPs and their robustness, industrial process 
applications in synthesis and catalysis are further appealing. One part of this work will hence 
focus on examining the possibility to use MIPs as catalysis for peptide synthesis in the 
pharmaceutical industry.  
 
Development of innovative catalysis with improved performance in the chemical industry is of 
high interest, as the quality of catalysts influences the advancement of both research and 
production synthetic work. Synthesized catalytic materials may exhibit a high catalytic activity 
combined with substrate, reaction, and stereoselectivity equivalent to that of enzymes. In 
addition, synthetic catalysts can be superior in availability, stability, and in the number of 
different reactions catalyzed. The development of synthetic catalysts has shown great progress 
in recent years and a large variety of compositions have been used to synthesize new catalytic 
materials, such as crown ethers, cyclodextrins, or large ring systems. Synthetic polymer 
materials offer an exciting opportunity to prepare new synthetic catalysts because they generally 
exhibit high chemical, heat, and solvent resistance, and are because of their widespread use in 
industrial applications suitable for scale-up processing. Compared to other host materials 
polymers are inherently more complex systems because of their three-dimensional structure. 
However, the same characteristics also give them a clear advantage as some of the distinctive 
capabilities of enzymes are directly linked to their polymeric nature. A successful synthetic 
catalyst should exhibit well-defined cavities according to the substrate or transition state 
structure, with stereochemically directed functional groups. Additionally, the interactions 
binding the template can be rather complicated and it should therefore be possible to incorporate 
a mixture of binding types such as, electrostatic, hydrogen bonding or hydrophobic interactions, 
in the cavities. MIPs fit these criteria and are therefore an interesting option for producing 
synthetic catalyst materials.63,66  
 
The first applications of MIPs as a synthetic catalysts in chemical synthesis were the so called 
micro-reactors147,148,149. Micro-reactors function as catalysts in the sense that they provide 
orientation for selective reaction, e.g. enantiomeric product excess. In order to achieve this, the 
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MIP is imprinted with the reaction product and when the precursor is inserted in the formed 
cavity the formation of the imprinted structure is favored over other possible reaction products. 
Successful examples of stereoselective cyclo-addition reactions were performed using MIPs to 
form cyclopropanedicarboxylic and cyclobutanedicarboxylic acids 147,148. Other examples 
using MIP micro-reactors have been published with chiral cavities for asymmetric synthesis, 
and the first enantioselective synthesis of an amino acid, L-DOPA149,149. Another interesting 
approach for using MIPs as catalysts is called anti-idiotypic, which has been used in assisting 
drug-screening. Yu et al. (2002) demonstrated this approach by imprinting a proteinase 
kallikrein inhibitor, and using the synthesized MIPs as reactors for the production of new 
enzyme inhibitors.150  
 
MIPs applied as catalysts can be divided into two main types. One is the imprinting of low-
molecular-weight templates, which exhibit good catalytic activity when used in solutions. The 
templates can be the reaction template or, if information is available, a transition-state analogue, 
and the end product. These MIPs can in some ways be considered to be synthetic 
metalloenzymes.63 Examples of application of such MIP-based catalysts include catalysis of 
hydrogenation reactions and Suzuki coupling reactions151,152. The second main type of MIP-
based catalysts is bio-inspired and aim to mimic enzymes. The goal for such catalysts is to 
produce a MIP with a binding cavity having enzymatic features which promotes stabilization 
of the transition state and stereoselectivity. A number of attempts have been published with 
MIPs mimicking the actions of for example chymotrypsin and more recently carboxypeptidase 
A, with the latter showing equivalent and even better catalysis compared to the corresponding 
enzyme153,154,155. However, although MIPs have been demonstrated to exhibit comparable 
catalytic activities to enzymes, further improvements are needed before MIPs will be superior 
to enzymes in respect of reaction variety, increased reaction rates, stereochemical selectivity, 
and yield.63,66 
 
1.8 HIGH-THROUGHPUT SYNTHESIS AND SCREENING TECHNIQUES 
 
In order to produce customized MIPs for specific targets a rapid polymer development and 
optimization is required. The normally used bulk polymerization procedure is rather time-
consuming and is hence not effective for screening of possible polymer compositions when 
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short time-lines are required. Improved performance of MIPs can be accomplished by combined 
screening techniques, using scale-down mini-MIPs based on the monolithic bulk 
approach156,157. Mini-MIPs enables an opportunity to do a thorough and methodical screening 
of possible polymer compositions within a reasonable time-frame.91,158 To facilitate the analysis 
the smaller material quantities, MIPs are normally synthesized and tested for imprinting effect 
by equilibrium batch re-binding in multi-well plates. The only difference between the mini-
MIPs compared to the normal bulk polymerization material is the amount synthesized, which 
offers the opportunity to partially automate the polymerization process. Plate technology, in 
particular plate readers and pipetting robots, is useful for high-throughput synthesis and 
screening of mini-MIPs (Figure 24). However, one shortcoming shared with the monolithic 
approach is template removal where the extensive washing process considerably slows down 
the optimization of the MIP composition.159 
 
ExplorasepTM is a commercially available screening method based on the cross-reactivity 
exhibited by MIPs, i.e. structures other than the imprinted template also show affinity. 
ExplorasepTM are based on 96-well plates with MIP libraries consisting of different functional 
monomers, e.g. acidic, basic or neutral compounds. Re-binding tests can quickly provide results 
on suitable affinity materials for different compounds.160  
 
 
 
Figure 24 Example of a high-throughput synthesis and screening setup for MIPs.158  
   
 
 
56 
 
1.9 ORGANIC SOLVENT NANOFILTRATION 
 
Another upcoming technique showing promising performance for separation and purification 
purposes in the pharmaceutical and fine chemical industries is organic solvent nanofiltration 
(OSN). The removal of genotoxic impurities and the development of sustainable, green 
processes are hence areas of great interest in these industries.161,162 Strict regulations for 
genotoxins in APIs and general high costs for down-stream separation processes further calls 
for new innovative techniques to solve these challenges, with OSN and MIPs potentially 
suitable techniques for use.163,164,165,166   
 
Nanofiltration has already been successfully applied in a range of aqueous application including 
water softening and waste-water treatment. However, polymeric membranes developed for 
aqueous applications can display some disadvantages when exposed to organic solvents and 
some chemical compounds, in degradation and chemical instability, aging, and plasticization.167 
A new generation of polymeric OSN membranes has been developed specifically for use in 
organic solvents and they demonstrate improved chemical stability as well as pH resistance.168 
Depending on the separation requirements the molecular weight cut-off of the membranes can 
be modified accordingly by altering the ratio of the solvents used in the membrane synthesis.169 
Furthermore, separations using OSN membranes can be performed at room temperature, 
allowing OSN to be used in separations with thermally sensitive compounds.170 A number of 
examples where OSN membranes have been tested for use can be found in literature, including 
examples in API purification, catalyst recycling, peptide and oligonucleotide synthesis, and 
solvent recovery.9,171,172,173  
 
Similar to MIPs, membrane separations is an interdisciplinary field, involving materials 
science, chemical synthesis and characterization, and process engineering. The separation range 
for currently commercially available OSN membranes range between 100-2000 g mol-1, 
However, to date the mechanism of how the separation in fact works is not entirely understood. 
The association between the size of the compound and the related rejection is rather strong, 
resulting in better rejection of larger compounds than smaller ones174. However, other factors 
such as the charge of the compound and interactions occurring between the compound, the 
solvent and the membrane have also been proven to influence the performance of the 
membranes.175,176,177 Membrane performance is generally described with regards to two main 
57 
 
factors the membrane selectivity and the flow. In membrane terms the flow is measured in flux, 
or permeation rate, where the flux is defined as the volume of solvent passing through the 
membrane per unit area and unit time (L m-2 h-1), and the permeability is defined as the flux 
including the dependency on  operating pressure (L m-2 h-1 bar)-1). The membrane selectivity is 
defined as the rejection, which is expressed as a percentage, of a compound that is unable to 
pass the membrane. More specifically the rejection is determined as ((Cf – Cp)/Cp)*100), where 
Cf is the concentration of compound in the feed and Cp being the concentration of compound in 
the sample which passed the membrane also known as permeate. Another well-recognized term 
used for expressing a given membrane’s separation performance is the molecular weight cut-
off (MWCO). The MWCO value can be determined from rejection of compounds with 
increasing molecular weights plotted versus rejection in a so called MWCO-curve. 
 
OSN membrane filtration can be performed as either dead-end or cross-flow operation (Figure 
25). In dead-end filtration, pressure pushes the feed over the membrane perpendicular to the 
surface, and in cross-flow the solvent is passed in a loop enabling the feed to be added in a flow 
pattern that is parallel to the membrane surface. However, the permeate still passes through the 
membrane in a perpendicular fashion. This enables better stirring and minimizes the build-up 
of a concentration gradient on the surface and means that the operation is less prone to fouling.  
 
 
 
Figure 25 Schematic drawings of dead-end (a) and cross-flow (b) filtration.170   
 
Fouling is phenomena often seen in aqueous membrane filtration and is described as the 
decrease in performance of the membrane because of the accumulation of suspended or 
dissolved compounds on the surface, and in the pores of the membrane.178 One process 
potentially contributing to fouling is concentration polarization, which is the gathering of 
retained compounds as a layer at the interface between the membrane and the feed solution. 
This leads to a higher concentration of the compound at the surface compared to the rest of the 
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feed solution which in turn can have a negative effect on both the flux and the rejection 
performance.170 
 
For membrane preparation a number of different characteristics are taken into consideration for 
the choice of materials, chemical and thermal stability, commercial availability and price, and 
film forming properties. Consistent purity to enable FDA approval is further important factors 
for applications in the food and pharmaceutical industries. One of the most flexible, cost 
efficient and reproducible methods for preparation of polymeric asymmetric membranes is 
phase inversion. Asymmetric membranes consist of a porous layer with a skin-layer on top. The 
permeability and selectivity are influence by the thin skin-layer depending on the composition, 
thus affecting the overall performance. Thin film composite (TFC) membranes represent 
another central class of polymeric membranes. In TFCs an ultra-thin layer functions as a 
separation barrier on top of a porous support, the ultra-thin layer can have the same or different 
chemical composition or structure. Structural differences between asymmetric membranes and 
TFCs are illustrated in Figure 26. For the synthesis of the separating ultra-thin layer of TFC 
membranes dip-coating or interfacial polymerization is used, whereas the support-layer is 
synthesized via conventional phase inversion. The inherent layered design of TFC membranes 
offers the possibility to vary the chemistry and performance, as the two layers can potentially 
be optimized independently to obtain optimal membrane performance.170,179  
 
 
Figure 26 Schematic drawing of the main polymeric membrane types in OSN, (a) integrally skinned asymmetric 
membrane, (b) thin film composite (TFC) membrane.170  
 
1.10 THERAPEUTIC PEPTIDES IN THE PHARMACEUTICAL INDUSTRY 
 
The field of peptide therapeutics has gained increasing interest in the last years from the 
development expansion in the late 1990s, with a number of successful peptide therapeutics, 
including glucagon-like peptide 1 receptor (GLP-1R) agonists, having reached the market. 180 
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Peptide therapeutics are generally administered intravenously, but can also be either injected, 
inhaled, or orally delivered. In the early clinical development phases, metabolic disease and 
oncology are the main peptide therapeutic applications, whereas in the later clinical 
development phases infectious disease replaces metabolic disease. Peptide therapeutics come 
in a number of different formats such as linked to small molecules, biopolymers, carbohydrates, 
lipids, polyethylene glycol (PEG) or proteins. Additionally, peptide therapeutics can exhibit 
different modes of action including cell-targeting or cell-penetrating. Because of the general 
short half-lives of peptides in the body, sometimes just minutes, the therapeutic applications of 
peptide therapeutics are limited. However, by attaching the peptides to molecules such as PEG 
or immunoglobulin the half-life can be considerably prolonged to days or even weeks. 
 
The development of intracellular targeted peptides is currently limited due to the cellular 
membrane hindering many drugs and peptides to cross over the membrane. Peptides that are 
specially designed to penetrate the cell membrane and target intracellular processes are hence 
of great interest to the pharmaceutical industry. The peptides that have overcome this hindrance 
are in general cationic or amphipathic molecules, for example peptides integrating sequences 
called cell-penetrating peptides. The progress in this area is reflected in the number of peptides 
integrating other compounds entering Phase I studies in recent years.180  
 
As mentioned earlier peptide therapeutics can act on a wide range of targets. Analysis of the 
peptide therapeutics pipeline shows that roughly 10% of the targets are bacterial, fungal or viral 
organisms. The mode of action of the therapeutic peptides vary from ion channels, intracellular 
targets, non-enzymatic transmembrane proteins, non-transducing receptors, pumps and 
transporters, and receptor enzymes with each group compromising less than 10% of the 
development compounds. The by far most common targets are cell surface molecules, 
especially the G-protein-coupled receptors taking up 39% of the peptides in the clinical 
pipeline. This observation can be explained by the fact that the easy access position and wide 
range of functions associated with the G-protein-coupled receptors, thus making them attractive 
drug targets.180,181  
 
Because of the powerful potential drug applications, peptide therapeutics also exhibit great 
commercial value as seen in the increase in global sales between 2009 and 2011180. The 
development of new peptide therapeutics further offers a considerable commercial value for the 
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pharmaceutical industry in a variety of applications in markets such as diabetes and oncology 
drugs. 
 
New peptides with innovative structures and mode of actions, for example peptide-drug 
conjugates and controlled peptides, are also developed as the next generation of peptide 
therapeutics. Such developments could possible expand the number of targets and applications 
for peptide therapeutics in the future. One interesting design is to freeze the peptides in specific 
conformations, leading to high-affinity compounds that are stable, less subjected to degradation 
and with improved pharmacological characteristics. By controlling the structure of the peptides 
the cell membrane permeation can also be improved, enabling intracellular processes to be 
successfully targeted. Although the potential of structurally designed peptides have been 
recognized, the lack of fundamental understanding of cell permeability processes makes it 
difficult to develop these peptides.180,182 
 
1.10.1 SOMATOSTATIN AND SOMATOSTATIN ANALOGUES 
 
Somatostatin is a cyclic tetradecapeptide with the sequence H-Ala-ly-Cys-Lys-Asn-Phe-Phe-
Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Figure 27). There are two forms of somatostatin produced 
by tissue-specific protelytic cleavage of a widespread pro-hormone precursor present in 
mammals. One is somatostatin-14 and the second somatostatin-28, containing 14 and 28 aminos 
acids respectively. The bioactivity of somatostatin is limited by its fast proteolytic degradation 
in the blood, where the half-life in plasma is approximately 1 minute.183 The broad spectrum of 
biological activity of somatostatin can be divided into four processes at a cellular level, 
including neurotransmission, grandular secretion, smooth muscle contractility, and cell 
proliferation.187 Hence, the synthesis of somatostatin analogues exhibiting increased half-life is 
of great importance for drug applications. Somatostatin is generally synthesized using solid 
phase techniques for peptides, however, the yields are somewhat limited and the product 
contains relatively large amounts of impurities. This is not uncommon when using solid phase 
technique, and in the case of somatostatin synthesis dimerization is also observed.184 
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Figure 27 Structure of somatostatin. 
 
Depending on the chemical type of the active ingredient or the mode of action for treatment of 
a specific condition, an API can be categorized in one or more drug classes. Somatostatin is a 
hormone which is synthesized by the hypothalamus, pancreas and gastrointestinal tract and was 
first discovered as in inhibitor of growth hormone release, but is now recognized to be involved 
in a number of gastrointestinal processes. The gastrointestinal processes are mediated via high-
affinity membrane receptors present in different density in the tissue. A schematic drawing of 
the mode of action for Somatostatin is illustrated in Figure 28. For example somatostatin acts 
by inhibiting the growth hormone release from the anterior pituitary, and insulin and glucagon 
from the pancreas. Furthermore, somatostatin decreases the release of most gastrointestinal 
hormones as well as lowering the gastric acid and pancreatic secretion. Somatostatin has also 
been used to lower bleeding from esophageal varcies using its capability to decrease abdominal 
blood flow. Somatostatin is also present in a number of locations in the nervous system and 
displays neural control over a large number of physiological functions. With this broad 
spectrum of effects in mind it is not unexpected that somatostatin has been the focus of many 
pharmaceutical research studies. Additionally, analogues of somatostatin have also been used 
for treatment of vasoactive and intestinal peptide secreting tumors, carcinoid tumors, 
gucagonomas tumors in the pancreas, and various pituitary adenomas, non-cancerous tumors 
in the pituitary gland. Somatostatin analogues have also been proven effective for treatment of 
conditions where growth hormone is over-secreted.185,186,187 Somatostatin analogues are also 
leading the way in demonstrating the growing potential for the development of peptides for rare 
diseases including the unique somatostatin receptor agonist pasireotide, which is the first FDA 
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approved drug for Cushing’s syndrome (currently in Phase III for acromegaly, a syndrome 
cause by excess production of growth hormone).180 
 
 
Figure 28 Gastrointestinal actions of somatostatin. 188  
 
1.11 CHARACTERIZATION TECHNIQUES 
 
There are a number of different polymerization techniques that can be used to make MIPs. 
These polymerization techniques also offer a possibility to accumulate useful information about 
the properties of the materials according to the different modes of preparation. This is especially 
important as the chemical and morphological traits of MIPs are challenging to characterize in 
detail because the imprinting takes place at molecular level. Some of the main characterization 
techniques used for MIP characterization are discussed in details in the sub-sections below. 
 
1.11.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY AND MASS 
SPECTROMERTY 
 
High performance liquid chromatography (HPLC) is an analytical separation technique that 
provides an efficient peak-resolution in a relatively short amount of time. The general setup of 
an HPLC consists of a continuous or discontinuous pump, a sample injector, a column filled 
with stationary phase, and a detector. The pump pushes the mobile phase against high pressure 
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creating a constant flow of the mobile phase, transporting the injected sample over the column 
where it is separated. The detector transforms the measured characteristics, commonly mass or 
volume based concentration, into an electronic signal. A commonly used concentration-based 
detector is the diode-array detector (DAD) where the measured absorption signal is converted 
by a diode array. The difference between a DAD- and a normal spectrometer-detector is that 
the entire UV/VIS spectrum is scanned rather than just one single wavelength, thus different 
wavelengths are measured in parallel. This provides the possibility to demonstrate the results 
acquired in a three-dimensional chromatogram presenting information about the sample’s 
absorption, retention time, and wavelength. By alternating the polarity of the stationary and 
mobile phases separation of the analyte can be achieved. There are two common stationary 
phases used for HPLC analysis called normal- and reversed- phased. Normal-phase consists of 
a polar stationary phase in combination with a non-polar mobile phase, whereas reverse phased 
is a non-polar stationary phase combined with a polar mobile phase.  
 
In the MIP field HPLCs are used for evaluating the performance of the imprinting. However, 
the performance of MIPs are not evaluated by using HPLC in the conventional way to separate 
components in a mixture but rather by using the MIP as the stationary phase to investigate 
binding capacity. During testing empty HPLC columns are slurry-packed with the MIP 
materials and then applied as the stationary phase in the analysis. A void-marker that is not 
retained on the column, e.g. acetone, is initially injected to determine the dead volume. The 
imprinted template, or a structurally related compound, are then injected and the retention times 
for the void-marker and the template are compared. In case of a well-functioning imprinting the 
template compound will be retained longer in the column than other control compounds, 
because the specific binding will outperform the non-specific binding resulting in longer 
retention times87. HPLC analysis is limited in that extensive peak broadening and tailing are 
commonly observed features when analyzing MIPs, due to the heterogeneous distribution of 
binding sites189. Additionally, to make sure that the retention observed is a result of the 
imprinting effect, the same analysis is implemented using a control NIP. Based on the 
information attained from HPLC important characteristics of the MIP can be calculated, 
including the capacity factor k, imprinting factor IF, and separation factor α as defined in 
Equation 8,Equation 9,and Equation 10 below.  
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The capacity factor is calculated according to Equation 8 below. 
 
Equation 8  k = (tR – t0)/t0   
 
Where tR is the retention time of the template and t0 the retention time of the void marker. When 
the capacity factor for both MIP and NIP is calculated, kMIP and kNIP respectively, the imprinting 
factor of the MIP can be defined according to Equation 9. 
 
Equation 9  IF = kMIP/kNIP  
 
The separation factor can be calculated from the capacity factors from two different compounds 
k1 and k2, when a mixture of compounds is injected on the MIP packed column and the two 
resulting peaks show sufficient resolution (Equation 10). 
 
Equation 10  α =k2/k1 
 
The resolution and retention times are strongly affected by the mobile phase used for HPLC 
analysis. This is because the stationary phase is less flexible than the mobile phase, therefore 
the selection of mobile phase is essential for a satisfactory analysis. Generally organic solvents 
are considered to be the most suitable for low to moderately polar templates, however, the 
retention times may be improved by using aqueous solution. The drawback when using aqueous 
mobile phases is that the retention time of polar templates decreases.60 
 
1.11.2 SCANNING ELECTRON MICROSCOPY  
 
A scanning electron microscope (SEM) forms an image by scanning a probe (a focused electron 
beam) across a sample. By interacting with a thin surface layer, a couple of micrometers 
maximum, a signal is detected from low energy secondary electrons emitted from the sample 
surface. From this procedure compositional and topographic information about the sample can 
be obtained. The main components of a SEM are normally gathered in one unit formed of the 
electron optical column with an electron gun and three condenser lenses, which forms the 
electron beam, and the general source for display and electron beam scanning. A raster, placed 
above the sample, scans the electron beam. The SEM has higher resolution and a larger depth 
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of field in comparison to reflected light optical microscopy. The specimen chamber, where the 
sample is mounted, is large enabling samples of a large size to be analyzed and furthermore the 
sample preparation is uncomplicated, as long as the sample can handle high vacuum and drying. 
Because of their non-conductivity most polymer samples need conducting coatings, or low 
accelerating voltages, in order to avoid them from getting charged by the beam. The qualitative 
interpretation of the resulting SEM pictures is straightforward as they produce a picture of the 
sample in the same direction as the electron beam. The interaction with the beam, the detector 
and signal processing used, all have an influence on the formed SEM pictures. 
 
A number of phenomena arise when a sample is hit with the electron beam, namely; secondary 
electrons are emitted, emission of backscattered electrons, absorption of electrons, X-ray 
formation, and occasional photon emission. The mentioned events are all correlated and to some 
degree affected by the sample’s topography, atomic number and chemical characteristics. 
However, topography is the largest influence on the formed backscattered, secondary and 
absorbed electrons, therefore these are the main phenomena used for studying the surface of a 
sample. Beam electrons that are elastically scattered by the nuclei and leave the surface are 
called backscattered electrons. These backscattered electrons hold a large amount of energy and 
can therefore origin from depths more than 1µm. Because the electrons leave the surface over 
a broad area, a good resolution can be achieved depending on the beam voltage and the 
characteristics of the sample. Interaction of the primary electron beam with the sample further 
generates secondary electrons. These are emitted from the top layer, a few nanometers, of the 
sample and are therefore released with low energy. The electronic circuit scanning the electron 
beam over the sample is hence the factor that determines the magnification and resolution of 
the SEM pictures. The maximum magnification achieved using SEMs is ×300 000 and the 
diameter of the electron beam hitting the sample gives the theoretical resolution. The practical 
resolution on the other hand is influenced by a number of other factors, including the sample 
preparation and a variety of instrumental settings, and realistically a resolution of 1 nm can be 
achieved under the correct circumstances.190,191            
 
1.11.3 ENERGY DISPERSIVE X-RAY ANALYSIS  
 
By studying x-rays emitted from SEM analysis information about the elemental composition of 
the sample can be obtained. This technique is called energy dispersive x-ray (EDX) analysis. 
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X-ray photons are created when a high energy electron beam hits a sample. Analytical details 
about the sample can then be gained from the subsequent x-ray energy spectrum, where the 
photons are recorded as sharp peaks. When the sample is hit by the high energy electron beam 
an inner shell electron is removed from its position, and when these excited electrons return to 
their ground state x-rays are released from the atoms. The produced x-rays can be divided into 
the two types called characteristic and continuum x-rays. The characteristics x-rays have, as the 
name implies, well identified energies corresponding to the atoms in the sample. Conversely, 
the continuum x-rays display a broad spectra of energies and represent the background in the 
x-ray energy spectra. The continuum x-rays are formed when the incoming high energy 
electrons are disrupted by scattering from the nucleus, resulting in x-rays with valuable 
information. 
 
The EDX spectrometer gathers the emitted x-rays and produces an energy spectrum. Each x-
ray that hits the detector creates an electron pair hole, which subsequently produces a current 
pulse. The number of electron pairs created is further proportional to the energy of the detected 
x-ray photon. After amplification of the pulses and separation according to size by a 
multichannel analyzer, an energy spectrum is formed. One drawback with this technique is that 
some of the element peaks may overlap thus causing indistinct results.191 
 
1.11.4 THERMOGRAVIMETRIC ANALYSIS 
 
Thermogravimetric analysis (TGA) is a technique that measures the weight loss of a sample as 
a function of temperature or time. TGA hence enables transitions, or degradation processes, in 
the polymers to be followed by the mass change. TGA can also be useful for determining the 
amount of residual silica present in composite materials. During analysis the sample is burned 
in a furnace under either an inert or an oxidizing environment. The heat transfer of the sample 
is depending on the speed of the flowing gas, and the change of mass in the sample during the 
analysis is measured by an electromagnetical or photoelectrical compensating scale. Based on 
the compensation signal the mass of the sample depending on temperature or time can be 
decided. By simultaneously recording the change in mass, temperatures, and heat mass transfer 
of the sample, information about the sample’s vaporization and melting behavior, i.e. mass loss 
or no mass loss respectively, can also be determined. The mass change for polymers can be 
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demonstrated as either one-phase or as several phases. The mass loss (mL) is then calculated 
according to Equation 11. 
 
Equation 11  mL = ((ms – mf)/ms) x 100 [%]   
 
Where mS is the starting mass and mf the final mass.192  
 
1.11.5 DIFFERENTIAL SCANNING CALORIMETRY ANALYSIS 
 
A differential scanning calorimeter (DSC) analyses the heat flow (dH/dt) of a sample pan 
relative to a reference pan. The DSC instrument registers endothermic and exothermic changes 
in the sample which in turn provide information into the glass transition temperature, 
crystallization, melting and decomposition of polymers. The analysis can give quantitative and 
qualitative information about the physical and chemical changes in the polymer (Figure 29). 
 
 
Figure 29 Typical thermogram with the main transitions observed in DSC. 
 
1.11.5.1 THERMOPOROMETRY USING DSC 
 
DSC can also be used to measure the porosity of materials in a swollen state; so called 
thermoporometry.193,194 Using thermoporometry the pore diameter of porous polymer materials 
can be calculated. A small specific amount of sample is weighed into the sample pan and after 
a specific volume of acetonitrile is added, the melting point of acetonitrile is followed and 
studied. In order to calculate the pore diameter193 from the resulting DSC curves the change in 
temperature (∆T) is calculated using Equation 12 and Equation 13:  
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Equation 12  ∆T = T – T0  
 
Where in this case T0 is the melting point of the used pure acetonitrile (-46 ± 0.3 ⁰C), obtained 
from linear regression. By substituting the calculated ∆T value in Equation 13. 
 
Equation 13  Rp(Å) = (-309/∆T) + 13 
 
The constant 13 correspond to the non-freezable solvent, forming a layer at the surface of the 
internal pores with a thickness of 13 Å.  
 
In addition to the pore diameter, pore volume is an essential parameter for characterization of 
porous polymer materials. Thermoporometry can also be used to calculate the total pore 
volume, e.g. the cm3 pore per gram porous solid194. The pore volume can be calculated 
according to Equation 14 below: 
 
Equation 14  𝑽𝒑 =  
∆𝑯𝒑𝒐𝒓𝒆 𝑪𝒍𝒊𝒒
∆𝑯𝒕𝒐𝒕 𝑪𝒔𝒐𝒍𝒊𝒅 𝝆𝒍𝒊𝒒
    
 
Where Cliq represents a known mass of liquid, ρliq is the density of the solvent, which is added 
to specific amount of porous solid Csolid. The DSC melt endotherms determine ∆Hpore, the pore 
melt peak area, and ∆Htot, the combined pore and excess melt peak areas. 
 
The ratio between the two ∆H-values is related to the amount of liquid enclosed in the pores. A 
number of assumptions are made for Equation 14, including a temperature independent heat 
fusion ∆H and liquid density, and satisfactory peak separation of the pore and excess melt peaks 
for separate integration. Furthermore, assumptions that the entire volume of liquid freezes and 
melts during the initial quench cooling and heat steps, respectively, are made and thus the 
amount forming the thin liquid layer at the pore surfaces is negligible.  
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When the pore diameter and volume are known the surface area of the sample can be determined 
using the Wheeler equation as detailed in Equation 15.195  
 
Equation 15  Surface area (SA) = 4000 x Vp/Dp 
 
Where Vp is the pore volume and Dp the pore diameter. 
 
1.11.6 NITROGEN ADSORPTION 
 
By measuring the adsorption of an inert gas, typically nitrogen, on the surface of a solid material 
physical gas adsorption can provide information about the morphology of a material. 
Depending on whether the material is porous or not, the gas is adsorbed on the surface of the 
pores or the outer surface. The most common method used for analyzing nitrogen adsorption is 
the Braunauer-Emmet-Teller (BET) method. From the resulting physisorption isotherms one 
can gain characterization parameters relating to the specific surface area (SA), pore volume (Vp) 
and pore diameter (Dp)196. 
 
It is practical to divide pores according to their apparent sizes. The IUPAC classification197 
states that porous materials can be divided into the three following groups: 
 
1) Macropores which have pores with diameters larger than 500 Å 
2) Micropores which has diameters smaller than 20 Å  
3) Mesopores which are used for pores with a diameter between 20 – 500 Å 
 
By plotting isotherms based on the adsorption data obtained one can gain information of the 
surface area and porosity of the material. These plots are obtained by measuring the quantity of 
nitrogen adsorbed on a surface over a wide range of relative pressures at constant temperature. 
By measuring the amount of nitrogen eradicated from the sample as the relative pressure is 
decreased. The resulting isotherms are divided into five types as shown in Figure 30.  
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Figure 30 Adsorption isotherm types I to V, classification according to Brunauer, Emett, and Teller.198 
 
The isotherm type applicable for composite MIPs and thin-walled beads is Type IV. This type 
is correlated with mesoporosity and generally displays hysteresis loops between the adsorption 
and desorption isotherms. The hysteresis loop and the steep slope at higher relative pressures 
are attributed to capillary condensation occurring in mesopores. Monolayer-multilayer 
adsorption is responsible for the initial part of the isotherm and by using the BET method the 
surface area of the material can be calculated.199,200 Only a certain part of the isotherm, relative 
pressure (p/p0) between 0.05 – 0.30, is taken into account for the linearity entailed for the BET 
plot.  
 
The total pore volume is obtained from the assumption that the pores are filled with liquid 
adsorbate at a relative pressure close to unity, and by measuring the amount of gas adsorbed 
calculations can be made. For mesoporous materials the isotherms form a plateau at a high 
relative pressure ratio of p/p0 > 0.95, as an indication of complete filling of the mesopores with 
the adsorbate liquid. By using the normal liquid density calculation (Equation 16), the amount 
of adsorbed nitrogen is converted into the corresponding volume and subsequently the specific 
pore volume can be determined.201  
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Equation 16 Vliq = (Pa Vads Vm)/(RT) 
 
Where Pa and T are ambient pressure and temperature and Vm is the molar volume of liquid 
nitrogen (34.7 cm3/mol).  
 
Given that pores which would not adsorb nitrogen below a relative pressure of 1 have a 
negligible contribution on the overall pore volume and surface area of the material, an 
estimation of the average pore size can be obtained from the pore volume. Assuming cylindrical 
pore geometry Equation 17 can be used to determine the average pore radius (rp); 
 
Equation 17 rp=(2*Vliq)/S 
 
Where Vliq is derived from Equation 1 and S is the BET surface area. 
 
The pore size distribution is defined by the distribution of pore volume relative to the pore size. 
It is commonly acknowledged that the desorption, rather than the adsorption, isotherm is more 
fitting for the evaluation of the pore size distribution for a sample. The desorption isotherm is 
closer to the real thermodynamic stability because it displays a lower relative pressure, therefore 
resulting in a lower free energy. The Barrett, Joyner and Halenda (BJH) method is a common 
way to calculate pore size distribution from the resulting isotherms.202 The BJH method works 
under the assumption that the initial relative pressure (P/P0)1 is close to unity, and all pores are 
filled with liquid. At the surface of the largest pores a layer of nitrogen with a thickness of t1 is 
physically absorbed. As P/P0 decreases the nitrogen is evaporating from the inner capillary with 
a radius rK. The correlation between the pore volume Vp1 and the inner capillary volume VK is 
given by Equation 18: 
 
Equation 18 Vp1 = (VK1 r
2
p1)/r
2
K1 
 
When the relative pressure is lowered from (P/P0)1 to (P/P0)2 a volume V1 will desorb from the 
pore surface. This represents not only the volume in the pores decreasing but also a subsequent 
reduction in thickness of the adsorbed layer by an amount ∆t1. As the relative pressure decreases 
the average change in the thickness is ∆t1/2. The pore volume of the largest pore can therefore 
be expressed as detailed in Equation 19: 
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Equation 19  Vp1 = V1 (rp1/(rK1 +∆t1/2 )
2 
 
Where Vp1 is the pore volume, rp1 the pore radius, rK1 the capillary radius, and ∆t1 the difference 
in thickness. 
 
This process is repeated when the relative pressure is repeatedly decreased. The BJH method 
offers a way of computing the cumulatively summed up pore areas for every step in the 
desorption process. 
 
1.11.7 ELEMENTAL ANALYSIS 
 
One technique commonly used to obtain insight into a material’s qualitative and quantitative 
elemental composition is elemental analysis (EA). EA is based on the combustion of a dry 
sample in an environment containing an excess of oxygen. From the resulting combustion 
products the composition can then be determined based on calculations. EA is a useful 
technique for determination of polymerization completion, as well as chemical composition of 
MIPs. By comparing the EA results and the theoretic calculated polymer composition from the 
components in the polymerization mixture, assuming a quantitative yield of polymerization to 
obtained values from EA, the degree of inclusion of the monomers can be determined. A high 
yield of monomers included in the final polymer is indicated by an agreement of the theoretical 
and measured values.203 Unfortunately the sensitivity of the EA technique is not good enough 
to determine the residual template remaining in the MIP.87 
 
The theoretical molecular mass of the repeat unit can also be calculated from the molar ratio of 
the compounds, including monomer, co-monomer, cross-linker, and their specific molecular 
weight as detailed in Equation 20 . 
 
Equation 20   𝑴 (𝒓𝒆𝒑𝒆𝒂𝒕 𝒖𝒏𝒊𝒕) =  ∑ 𝒂𝒊 ∗ 𝑴𝒊𝒊  
 
Where a is the relative amount and M is the molecular mass of the compound i. 
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When all the sources have been considered the mass-percentage of a specific element in the 
MIP can be calculated as detailed in Equation 21. 
 
Equation 21  % (𝒆𝒍𝒆𝒎𝒆𝒏𝒕) =  
∑ 𝑵𝒊∗𝒂𝒊∗𝑴(𝒆𝒍𝒆𝒎𝒆𝒏𝒕)
𝑴(𝒓𝒆𝒑𝒆𝒂𝒕 𝒖𝒏𝒊𝒕)
 
 
Where Ni is the number of atoms in the compound and a is the relative amount and M is the 
molecular mass of the compound i. 
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2 OBJECTIVE 
 
Impurities in APIs can cause undesired and even toxic effects in humans, therefore the control 
and selective removal of these compounds are crucial. Thus in order to ensure that the APIs 
that reach the market are safe regulatory authorities issues guidelines limiting the allowed 
amount of trace impurities in APIs. Especially genotoxic impurities have gained increasing 
attention over the last decade by both regulatory agencies and the pharmaceutical industry. 
 
With the increasing concern of control and removal of genotoxic impurities in combination 
with the recent regulation and guidelines presented by regulatory agencies in the US and 
Europe, require control of potential genotoxins in drug substances to be limited to levels of 
ppm. In order to comply with the strict regulations pharmaceutical companies have employed 
a range of approaches including re-design of processes to avoid generation of genotoxins, 
alteration of process parameters to reduce impurities to acceptable levels, increased process 
understanding to prove that genotoxin cannot be formed or is effectively removed and toxicity 
studies to demonstrate that genotoxins are not harmful at the low levels envisaged. If genotoxins 
are formed despite the introduced controls the drug substance may still be viable for use after 
removal of the harmful material. However, as extremely low contamination levels are required, 
efficient impurity removal and high accuracy low level analysis is crucial. Hence with new 
guidelines the need for new innovative, selective and efficient purification techniques increases, 
and provides an opportunity for emerging technologies to fill this need. 
 
Two emerging separation techniques, indicating promising performance in lab-scale studies, 
are MIPs and OSN. MIPs can be designed to selectively bind to specific impurities hence 
enabling specific removal of a selected genotoxin. OSN separates solutes primarily based on 
steric factors and as many genotoxins are small (commonly 50-150Da) compared to drug 
substances (commonly 250-1000Da) a large separation potential is often present. Thus, these 
techniques could possibly be beneficial for API purification. 
 
This work was part of a large European project NEMOPUR, New Molecular Purification 
Technology for Pharmaceutical Production, with the aim to develop new generation of 
technologies and processes for more selevtive, sustainable and energy efficient separation for 
the pharmaceutical industry. In the project collaboration partners from academia, small to 
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medium enterprises as well as large pharmaceutical companies representing the end-users, were 
working together. The project was designed to take advantage of the academic research 
expertise in combination with the industrial experience in developing new purification 
techniques that will meet the need of the pharmaceutical industry, focusing on MIPs and OSN.  
 
For the work presented in this thesis the implementation of MIPs for different applications in 
the pharmaceutical industry was studied in detail. Within the framework of the project two 
impurities were chosen for concept testing, acetamide a small genotoxiv impurtiy and 
somatostatin a cyclic peptide. This thesis is further divided into three parts with the first section 
studying the synthesis and characterization of new MIP based scavengers for the removal of 
genotoxic impurities, the second part detailing the development of a new high-through-put 
screening method by grafting of MIPs onto polymeric membranes, and the last part 
investigating the synthesis, optimization and use of MIPs as catalysts for the synthesis of a 
cyclic peptide (Somatostatin). 
 
MIPs have previously demonstrated good imprinting of small compounds, therefore removal 
of acetamide down to stringent levels might be a suitable application. However, for 
implementation in pharmaceutical industry the MIPs have to demonstrate high selectivity and 
loading capacity in order to limit any API loss in the removal process, thus new MIPs 
demonstrating those characteristics will be developed. Furthermore, the objective is to 
demonstrate that the newly developed MIP based scavengers can be applied over a broad range 
of compounds and API solutions, so in addition to acetamide other impurities with relevance to 
the pharmaceutical industry will be investigated.  
 
One bottleneck with MIP synthesis is the screening process to obtain high selectivity. For 
implementation of MIP based scavangers in pharmaceutical industry the tedious monomer 
screening process for composition optimization should be made more efficient in order to meet 
tight timelines. Hence, a new more time-efficient HTS screening method based on grafting 
MIPs on membrane surface will be developed.  
 
Cyclic peptides display some advantages over linear peptides, including stability because of 
their resistance to proteases and efficient crossing of cell membranes.  Thus, they are of great 
interest to the pharmaceutical industriey.  Although peptide macrocycles are found in many 
natural products, current synthetic methods are inefficient, resulting in low yields, and are in 
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many cases not economically sustainable. Developeing a robust, large-scale manufacturing 
process might be challenging depending on the peptide synthesized, where a number of 
protecting groups, coupling and oxidation chemistries is needed. Many cyclic peptides are first 
synthesized as linear and then consequently folded stepwise to get the right configuration. For 
minimization of API peptides loss during synthesis and purification further work in process 
development is needed.204 Thus, new peptide imprinted MIPs will be developed for process 
optimization of cyclic peptide synthesis, where the MIP based scavengers act as catalysts 
promoting cyclisation of the peptide. 
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3. RESULTS AND DISCUSSION 
 
3.1 ACETAMIDE IMPRINTED POLYMERS 
 
For removal of acetamide from API-solutions imprinted polymers were prepared. In order to 
synthesize polymers with a high capacity for pharmaceutical applications different formats 
were compared. 
 
The first generation of polymers prepared was in the bulk format. This is the most commonly 
used format synthesizing molecularly imprinted polymers and can easily be used for 
chromatographic testing of recognition and selectivity properties of the polymer. For the work 
presented common commercially available monomers and cross-linkers for facilitating future 
scale-up processes were used.  
 
The evaluation of the bulk polymers included employing them as a stationary phase in HPLC 
analysis, batch rebinding test followed by LC-MS analysis and solid phase extraction 
experiments evaluated by LC-MS. 
 
In order to increase the loading capacity other formats where prepared and evaluated. For a 
material with increased porosity, polymers prepared via precipitation polymerization were 
synthesized and thoroughly characterized. Subsequent testing with batch rebinding experiments 
followed by LC-MS analysis was performed. Furthermore pore-filling of a solid silica support, 
which after etching procedure provided uniformly shaped porous particles was investigated. 
Also this material was characterized and tested with batch rebinding test followed by LC-MS 
analysis. 
 
3.1.1 MONOLITHIC POLYMERS VIA BULK-POLYMERIZATION 
 
Free radical solution polymerization initiated by UV-light was employed for the bulk polymer 
synthesis.  
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3.1.1.1 COMPOSITION OF THE BULK POLYMERS 
 
To meet the criteria set in the project for new effective and cost efficient purification techniques 
for the pharmaceutical industry, common commercially available monomers and cross-linkers 
were chosen.  
 
A well-described procedure for synthesizing imprinted polymers is based on a pair of these 
monomers and cross-linker, namely methacrylic acid (MAA) and ethylene glycol 
dimethacrylate (EGDMA) respectively.205,206,207,208  The polymerization is initiated by either 
heat or UV-light. The monomers used for the bulk polymers presented in this work, MAA and 
methacrylamide (MAAM), have also proved to exceptionally complement the hydrogen bond 
donor-acceptor motif in acetamide, which offers the possible binding sites formation of binary 
hydrogen bonds between the monomer and acetamide as shown in Figure 31. 209,210,211,212,213  
 
 
Figure 31  Host-guest interactions between the functional monomer MAA and the template acetamide.  
 
The porogens were selected considering the solubility of acetamide as well as the polarity of 
the porogen in its role as a solvent. Toluene was selected for its low polarity index 2.4 in order 
to facilitate the host-guest interactions but because of some limitations in solubility of 
acetamide, acetonitrile (polarity index 5.8) was also selected (Table 1). 
 
3.1.1.2 PREPARATION AND TESTING 
 
In total four MIPs with corresponding NIPs were synthesized by UV-initiated  polymerization 
at 15 °C for 24 hours, followed by curing at 60 °C for 48 hours. (see Table 2 for compositions). 
The template was extracted with soxhlet apparatus and the amount of extracted acetamide was 
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quantified with LC/MS. In total 83% of the template was extracted, which is in accordance with 
previously published literature for bulk polymerizations.214 
 
Table 2 Composition of the acetamide bulk polymers. 
  Monomers Stoichiometry Porogen 
PA1 T/MAA/EDGMA 
1/4/20 MeCN 
PAN1 MAA/EDGMA 
PA2 T/MAAM/EDGMA 
PAN2 MAAM/EDGMA 
PA3 T/MAA/EDGMA 
1/4/20 Toluene 
PAN3 MAA/EDGMA 
PA4 T/MAAM/EDGMA 
PAN4 MAAM/EDGMA 
 
 
In the first step the polymers were evaluated with HPLC analysis. After slurry-packing the 
polymers in columns the retention of acetamide by the MIPs compared to the control polymers 
(NIPs) was tested. Further analysis was performed to determine the selectivity towards 
acetamide over other amides. The amides selected for the selectivity test were; formamide, 
acrylamide, benzamide, methacrylamide and N-tert-butylacrylamide (Figure 32).  
 
 
Figure 32 The template acetamide and the amides used for the selectivity test.  
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The obtained HPLC chromatograms and retention factors are shown in Figure 33 and 
Figure 34 respectively. The polymers PA1 and PA3 containing methacrylic acid as the 
functional monomer, demonstrated a higher retention time of the template acetamide compared 
to the corresponding NIPs, as displayed in Figure 33 and from the calculated k-values. 
 
 
Figure 33 HPLC chromatogram for the polymers PA3 and PAN3 (i) and PA1 and PAN1 (ii). (red curve NIP, blue 
curve MIP). 10 µL 10 mM acetamide solution was injected on the column, monitoring the absorbance at 220 nm 
with a flow rate of 0.5 mL min-1 using MeCN as mobile phase. 
 
 
Figure 34 k’-values for the acetamide selective polymers calculated from the obtained retention times from the 
HPLC chromatograms. 
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To evaluate the selectivity performance of the synthesized MIPs other amides were injected 
onto the column and their retention times were analyzed with HPLC. The resulting 
chromatograms are shown in Figure 35 and Figure 36. Formamide was only tested on PA3 and 
the obtained HPLC chromatograms are shown in Figure 37. From the obtained retention times 
the k-values were calculated for each of the tested amides, the results are displayed in Figure 
38 and Figure 39.  
 
Upon evaluation of the chromatograms and k-values it can be concluded that the imprinting 
step of the two polymers PA1 and PA3 was successful. From the results it is evident that PA1 
and PA3 contain imprinted binding sites complementary to the target genotoxin acetamide. The 
lack of imprinting in polymers PA2 and PA4 containing the amide functional monomer can be 
explained by the prevalence of carboxylic acids to form interactions with amides compared to 
the weak tendency amide- amide interactions. This is evident when comparing the dimerization 
constant of amides and carboxylic acids, where amides display a significant lower constant.215  
 
Although both PA1 and PA3 display imprinting effects, PA3 demonstrates superior 
performance compared to PA1. The better retention of acetamide compared to the other amides 
tested and the characteristic broad and strongly tailing peaks are results of the better imprinting 
of PA3. The broad and strongly tailing peaks are due to the overloading of the low abundance 
high affinity binding sites in the polymer.216  
 
The better imprinting results for PA3 compared to PA1 may best be explained by the use of the 
low polar solvent toluene. Because of the low polarity no competing forces are present that can 
disrupt the formation of the complex between template and functional monomer. Based on the 
results obtained polymer PA3 was considered to be the most suitable polymer and was further 
evaluated for its capability to scavenge acetamide from a model API and acetamide mixture.  
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Figure 35 HPLC chromatograms for selectivity test 1 for PAN1 (i) and PA1 (ii). 10 μL of 10 mM solutions was 
injected on the column, monitoring the absorbance at 220 nm with a flow rate of 0.5 mL min-1  using MeCN as 
mobile phase.11 
 
 
Figure 36 HPLC chromatograms for selectivity test for PAN3 (i) and PA3 (ii). 10 μL of 10 mM solutions was 
injected on the column, monitoring the absorbance at 220 nm with a flow rate of 0.5 mL min-1 using MeCN as 
mobile phase.11  
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Figure 37 HPLC chromatograms for selectivity test of formamide; where the blue is acetamide and red is 
formamide on PAN3. The green is acetamide and pink is formamide on PA3. 10 μL of 10 mM solutions was 
injected on the column, monitoring the absorbance at 220 nm with a flow rate of 0.5 mLmin-1 using ACN as mobile 
phase.  
 
 
 
Figure 38 k’-values from the selectivity tests for PA1 calculated from the obtained retention times from the HPLC 
chromatograms. 
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Figure 39 k’-values from the selectivity tests for PA3 calculated from the obtained retention times from the HPLC 
chromatograms. 
 
3.1.1.3. TEST MODELS FOR ACETAMIDE REMOVAL 
 
Taking into account the aim of this thesis, to examine the possibility to use MIPs as scavangers 
for purification in the pharmaceutical industry, the best candidate has to be tested in mixtures 
in order to mimic the real process conditions. The PA3 polymer was therefore tested in two 
different mixtures made to simulate possible API solutions. Both solid phase extraction (SPE) 
and competitive batch rebinding were used. 
 
The first removal test performed employed a spiked solution with acetamide and the API 
Etodolac as the model system. The SPE cartridges packed with the polymers were loaded with 
a specific amount of the mixture and the collected fractions were analyzed on HPLC. From the 
HPLC results the recovery of acetamide and Etodolac was calculated, and the results are 
displayed in Figure 40. Comparison of the recovery amounts for the MIP and NIP shows that 
in the loading step PA3 binds all the acetamide whereas PAN3 elutes 23 %. In the subsequent 
washing step more acetamide is eluted from PAN3 while the loaded acetamide on PA3 is 
retained on the polymer. In addition to acetamide retention, it is also important to evaluate is 
the API recovery, because for potential application in the pharmaceutical industry of MIPs the 
API losses should not exceed predefined levels. Evaluation of the API recovery shows that 
more than 99 % is recovered in the elution and first washing step. The first removal tests 
indicate that the PA3 polymer successfully removes acetamide from the spiked mixture while 
eluting in principal all API. 
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Figure 40 Recovery diagrams (in percentage) for each fraction (i) and the removal in percentage of API and 
acetamide in the loading step (ii). 0.5 mL of a solution of Etodolac (5 g L-1) and acetamide (250 ppm) in MeCN 
was loaded on 25 mg of PA3 and PAN3, followed with 1 mL washes of MeCN. 
 
The binding capacity of the MIPs is another important feature providing an indication of the 
success of the imprinting. Equilibrium batch rebinding tests are used to study the template 
rebinding properties of the MIP respectively NIP in acetonitrile and ethyl acetate. The amount 
of polymer is kept constant while the template concentration is varied. By quantifying the 
equilibrium free concentration (Cfree) of solute using LC-MS the amount bound template (q) is 
calculated and binding curves of the template acetamide are obtained when q is plotted against 
Cfree. Based on the HPLC and removal tests acetonitrile is the obvious choice of solvent for the 
first rebinding test using the acetamide imprinted bulk polymers. Roughly 50 mg of polymer is 
weighed in HPLC-vials and 1 mL of rebinding solution is added to each vial. After 24 h 
equilibration and sedimentation of the polymer a sample is taken for quantification of the 
amount of bound acetamide using LC-MS. The obtained results are displayed in the plot in 
Figure 41. The rebinding tests show that the MIP in general binds more acetamide than the 
corresponding NIP, thus suggesting selective binding properties of the MIP. However, the 
difference in binding capacities are not as distinguished as expected, and in the end of the 
equilibration the MIP and NIP bind roughly the same amount of acetamide. The q-values for 
both the MIP and NIP reach a plateau, indicating that the binding capacity of the MIP and NIP 
has been reached with a value of approximately 1 and 0.8 mg/g respectively. 
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Figure 41 Rebinding curves of acetamide comparing binding properties of bulk MIP and NIP in acetonitrile. 
 
Following the tests in acetonitrile, rebinding tests in the less polar solvent ethyl acetate was 
performed (dielectric constant 6 versus 37 for ethylacetate and acetonitrile respectively). The 
resulting isotherm binding plot from the batch rebinding tests is displayed in Figure 42. The 
significant difference in the amount acetamide bound between the MIP and NIP strongly 
indicates that selective binding sites are present in the MIP. Furthermore, the binding capacity 
is higher compared to the rebinding test performed in acetonitrile (1.6 and 0.9 mg/g for MIP 
and NIP respectively). 
 
 
Figure 42 Rebinding curves of acetamide comparing binding properties of bulk MIP and NIP in ethyl acetate. 
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Following the equilibration competitive batch rebinding, the time dependence of acetamide 
binding and cross-reactivity of the API and acetamide were investigated for further evaluation. 
These tests were performed at GSK in collaboration with Elin Rundquist.  
 
10mg of polymer is weighed in HPLC-vials and 1mL of a solution with a concentration of 
40 µg/mL acetamide and 6 µg/mL API in acetonitrile was added. The different samples are let 
to equilibrate for five different times before analysis; 0.5 h, 1 h, 2 h, 12 h, and 24 h. The 
experiment was performed in five separate vials and samples were taken from each for analysis 
after the polymer was sedimented. In total three setups were tested; acetamide, API, and a 
mixture of acetamide and API. The results for the rebinding of acetamide are displayed in 
Figure 43.  
 
Initially a difference in binding between the MIP and NIP is observed but over time the 
difference between the two decreases until it is not longer apparent. At the first test point (0.5 h) 
the MIP binds almost four times the amount of NIP, this is followed by a dip in binding at 1 h 
where both the MIP and NIP bound essentially no amount of acteamide. After 2 h a maximum 
is observed where the amount of bound acetamide has increased from 4 µg to close to 7 µg for 
the MIP and the NIP from ca 1 µg to just over 5 µg. At the 12 h measuring point no difference 
between the MIP and NIP can be seen and after 24 h of equilibration time no acetamide is bound 
to the polymers. This behavior indicates that the polymers are overloaded with acetamide. The 
observed behavior can best be explained by the initial higher binding of the template on the 
MIP due to specific binding. With increased equilibration time the impact of non-specific 
binding increases and no difference between MIP and NIP can be observed.  
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Figure 43 Diagram showing the results for the time-dependence rebinding test of acetamide in acetonitrile. 
 
Although the MIP is imprinted with acetamide with the aim to selectively bind acetamide over 
other compounds, other compounds may possibly also interact with the functional monomers 
or the back-bone polymer and bind to the MIP. This is known as cross-selectivity. Therefore 
rebinding tests using only the API were also performed in order to investigate the binding 
behavior of the API on the MIP.  
 
Sampling was performed according to the times used in the previous experiment.  1 mL of a 
solution with a concentration of 6.1 µg/mL API in acetonitrile was applied. The resulting 
diagram is shown in Figure 44. The same behavior as for acetamide is observed, at the first 
sampling points (0.5 h and 1 h) the MIP binds a larger amount of API than the NIP but over 
time (from 2 h to the last point at 24 h) the difference is decreased until both MIP and NIP bind 
the same amount.  
 
Due to the fact that the amount of loaded API is significantly smaller than the amount of 
acetamide used in the previous rebinding test, it can be assumed that the observed binding 
results for the API cannot be explained by overloading but more likely that no significant cross-
reactivity takes place. The polymer does not preferably bind the API which indicates that the 
imprinting step was successful. 
 
0
1
2
3
4
5
6
7
8
0 5 10 15 20 25 30
M
as
s 
b
o
u
n
d
 (
µ
g)
Equilibration time (h)
MIP
NIP
91 
 
 
Figure 44 Diagram displaying the rebinding results of the API on the acetamide imprinted polymers.  
 
Based on these promising results the material was tested in a competitive batch rebinding test. 
In this test an acetonitrile solution with a mixture of acetamide and API is added to the 
polymers. The same concentrations as in the two previous rebinding tests are used, 40 and 
6 µg/mL acetamide and API respectively, and the incubation times are kept the same. The 
results are shown in the diagram below (Figure 45). The results for the competitive rebinding 
test display similar trends as for the acetamide and API when tested separately. Initially the 
MIP bound a larger amount of acetamide than the NIP, after the dip at the 1 h point the bound 
acetamide is increased and after 12 hours the bound acetamide decreases once again. At the last 
data point (24 h) the amount of bound acetamide on the MIP or NIP is close to zero, further 
indicating that the polymers are overloaded. No significant amount of API is bound during the 
competitive rebinding test, hence indicating that the API does not bind selectively to the 
polymer. 
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Figure 45 Result from the competitive rebinding test using a solution containing acetamide and the API. 
 
Because of its structural similarity to acetamide, the nitrogen atom is substituted with a sulfur 
atom, thioacetamide is used for cross-reactivity tests of the acetamide imprinted polymers. SPE 
columns packed with 100 mg of acetamide imprinted polymer are used. These columns are also 
used for the acetamide removal tests (see section 3.2). The polymers are loaded with 80 µg of 
thioacetamide in acetonitrile and washed with pure acetonitrile. The obtained results are shown 
in (Figure 46). No thioacetamide is retained on the polymers; in the loading and wash fractions 
99,6 % and 97,6 % (in total) is eluted for the MIP and NIP respectively. The 2 % difference 
between the MIP and NIP can be explained by dilution errors because the first two fractions 
were diluted 10 times for analysis. Hence no difference in binding of the MIP and NIP is 
observed, indicating that the acetamide MIPs specifically bind acetamide over other compounds 
– even structurally similar compounds.   
 
 
Figure 46 Diagram displaying the mass recovery from the removal test of thioacetamide on acetamide imprinted 
polymers. 
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3.1.2  SUPER-POROUS MIPS 
 
One of the disadvantages with bulk MIPs is the relatively low binding capacity and slow mass 
transfer of the template. In an attempt to improve the binding capacity, a second generation of 
acetamide imprinted polymers are prepared. So called super-porous monolitich MIPs have 
previously been synthesized for capillary electrochromatography. In this technique iso-octane 
is used in varying ratios as a poor solvent for the synthesized polymer chains to decrease the 
polymer density and increase the porosity. However, with increasing porosity of the MIPs they 
also become more fragile.217,218,219 Three different polymers with varying iso-octane amounts 
in respect to the amount of the porogen were prepared for identification of the best composition 
(Table 3).  
 
The recipe for these polymers is based on the one of the bulk acetamide imprinted polymers 
because the monomers used displayed good imprinting (Section 3.1.1). In addition to toluene 
iso-octane is added in different ratios as a solvent, where toluene acts as the good solvent and 
iso-octane as the poor solvent. The imprinting and binding capacities of the polymers are 
evaluated with batch rebinding tests. For facile comparison with the bulk MIP results the 
rebinding tests are performed in the same solvents as used for the bulk polymers, namely 
acetonitrile and ethyl acetate. 
 
Table 3 Displays the composition of the iso-octane precipitation prepared MIPs. 
 Template Monomer Cross-linker Initiator 
Porogen 
(3/4 tot monomer) 
 Acetamide MAA EGDMA ABDV Tol Iso-octane 
   (mmol)  (mmol)  (mmol) (% w/w) (%) (%) 
MIP 25:75 1 4 20 1 25 75 
NIP 25:75 - 4 20 1 25 75 
MIP 50:50 1 4 20 1 50 50 
NIP 50:50 - 4 20 1 50 50 
MIP 75:25 1 4 20 1 75 25 
NIP 75:25 - 4 20 1 75 25 
 
The resulting rebinding test curves in acetonitrile are shown in Figure 47, Figure 48 and Figure 
49. In accordance to the observations for the bulk MIP rebinding tests in acetonitrile there is no 
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significant difference in the binding between the iso-octane precipitated MIPs and NIPs. 
However, the second polymer with 50 % iso-octane and 50 % toluene displays some specific 
binding of acetamide by the MIP, on the other hand the binding capacity is not improved 
compared to the bulk polymers. A better specific binding is also observed for the third iso-
octane polymer with 75 % iso-octane and 25 % toluene, but the obtained binding capacity is 
lower than for the 50:50 polymer. 
 
 
Figure 47 Isotherm binding curves for iso-octane polymer 25:75 in acetonitrile. 
 
Figure 48 Isotherm binding curves for iso-octane polymer 50:50 in acetonitrile. 
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Figure 49 Isotherm binding curves for iso-octane polymer 75:25 in acetonitrile. 
 
The rebinding tests in acetonitrile were followed by ethyl acetate rebinding tests (Figure 
50,Figure 51,Figure 52). All three iso-octane polymers demonstrate higher binding capacity in 
ethyl acetate compared to in acetonitrile. However, the binding capacity overall is not improved 
as expected. The 25:75 and 75:25 polymers both have binding capacities around 1.2 mg/g which 
is lower than 1.6 mg/g obtained for the bulk polymer in ethyl acetate. For the 50:50 polymer 
the observed binding capacity reaches 1.6 mg/g which is comparable to the bulk polymer. 
 
The purpose of the synthesis of the iso-polymer was the improvement of the binding capacity 
in respect to the bulk polymer. Based on the performed experiments it can be concluded that 
the binding capacity is not improved. Nevertheless, the iso-polymers show a slightly stronger 
selectivity compared to the bulk polymers.  
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Figure 50 Displays the isotherm binding curves for iso-octane polymer 25:75 in ethyl acetate. 
 
 
 
Figure 51 Shows the resulting binding curves for iso-octane polymer 50:50 in ethyl acetate. 
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Figure 52 Ethyl acetate rebinding curves for iso-octane polymer 75:25. 
 
3.1.3 PORE-FILLING OF COMPOSITE MATERIALS 
 
A third synthesis approach was investigated since the loading capacity of the precipitation 
polymers did not improve as expected compared to the bulk polymers. In the third generation 
of acetamide imprinted polymers prepared, the pores of spherical composite materials are filled 
with the pre-polymerization mixture and after polymerization the silica is etched leaving a 
spherical polymeric replica. With the resulting defined pore system the hypothesis is that these 
polymers should have a better mass transfer and binding capacity of acetamide.  
 
In total three different sets of pore-filled polymers were synthesized with varying amounts of 
porogen. Because of the promising results obtained upon testing the bulk polymers the PA3 
composition is the basis for the synthesis. 
 
Although the purpose of a porogen in bulk polymers is to introduce pores, in this technique the 
amount of the porogen toluene is decreased and even removed completely. In the pore-filling 
approach the silica itself functions as a mould for pores, and after removal of the silica by 
etching, pores are formed in the polymer. By using an excess amount of solvent in the pre-
polymerization mixture in pore-filling, the risk is that the polymers become less rigid and thus 
possibly collapse. The composition of the three pore-filled polymers is summarized in Table 4.  
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Table 4 Summarizes the composition of the pore-filling polymers. The percent of toluene represents the percent 
of porogen used based on the bulk acetamide polymer recipe. 
 Template Monomer Cross-linker Initiator 
Porogen 
(3/4 tot monomer) 
 Acetamide MAA EGDMA ABDV Tol 
   (mmol)  (mmol)  (mmol) (% w/w) (% of bulk recipe) 
MIP I 1 4 20 1 50 
NIP I - 4 20 1 50 
MIP II 1 4 20 1 10 
NIP II - 4 20 1 10 
MIP III 1 4 20 1 - 
NIP III - 4 20 1 - 
 
Like for the two other formats, the imprinting and binding capacity of the synthesized polymer 
I, II, and II are evaluated with batch rebinding tests in both acetonitrile and ethyl acetate. The 
resulting acetonitrile rebinding plots are shown in Figure 53, Figure 54 and Figure 55. Pore-
filling I polymer has roughly the same binding capacity as the bulk polymer under the same 
conditions, but compared to the iso-octane polymers the binding capacity is increased with 
approximately 60 %. It should also be noted that the binding curve has not reached a proper 
plateau, which is an indication of possible increase of the binding capacity. On the other hand 
the specific binding of acetamide is relatively weak, with MIP I binds around 1.6 mg/g and NIP 
I around 1.2 mg/g.     
 
 
Figure 53 Pore-filling I isotherm plots of acetamide rebinding tests in acetonitrile.  
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The rebinding tests of pore-filling II in acetonitrile show a significant increase in binding 
capacity with a value of approximately 2.5 mg/g, an increase of around 55 % compared to the 
value obtained for the bulk polymer. Once again the plot indicates that the maximum value has 
not been reached, hence an increase in binding capacity may be possible. The difference 
between the MIP and NIP is also more significant approximately 2.5 mg/g for the MIP and 1.4 
mg/g for the NIP, indicating the presence of defined binding sites in the MIP.  
 
 
Figure 54 Displays the plot of acetamide rebinding test in acetonitrile with pore-filling II polymer. 
 
An improvement in rebinding capacity in comparison to the bulk polymer is also displayed by 
the rebinding results for the pore-filling III the last polymer. Although it is slightly lower than 
the binding capacity for pore-filling II, it is approximately 25 % higher than for the bulk 
polymer. Furthermore the MIP III shows specific binding of acetamide compared to the NIP III 
(2.1 mg/g and 0.8 mg/g respectively). 
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Figure 55 Show the rebinding results in acetonitrile for the pore-filling III polymer. 
 
Following the rebinding tests in acetonitrile, tests in ethyl acetate are also performed and the 
results are summarized in Figure 56, Figure 57 and Figure 58. For all three polymers the 
resulting plots in ethyl acetate show similar binding capacity to the rebinding tests in acetonitrile 
and additionally the same trends for the acetamide selectivity are observed.  
To summarize all the rebinding tests performed with the pore-filling polymers, it is apparent 
that the binding capacity is successfully increased in comparison to the bulk polymer with this 
approach. Between the three pore-filling polymers pore-filling I is the least successful polymer 
with the binding capacity more or less equal to the bulk, however the acetamide binding 
specificity is slightly decreased in comparison to the bulk polymer. Both pore-filling II and III 
display increased binding capacity, pore-filling II significantly so with an increase of around 
55 % compared to the bulk. On the other hand with the high binding capacity it is observed that 
the specific acetamide binding of pore-filling II is sacrificed to some extent. Because the NIPs 
bind 56 % and 35 % of what the MIPs do for pore-filling II and III respectively.  
The influence of the amount of solvent was also investigated by synthesizing three different 
polymers with varying amounts of solvents in pre-polymerization. With the silica forming pores 
the risk of using solvents that promote further pore formation is that the polymers become 
fragile and collapse. Thus 50 % of the solvent used for conventional bulk polymerization was 
the maximum used for the pore-filling. Although polymer III with no solvent present in the pre-
polymerization mixture demonstrates an improved binding capacity compared to the bulk 
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polymers, the rebinding results indicate that a small amount of solvent in the pre-polymerization 
mixture promotes both the binding capacity and the specific binding.  
 
 
Figure 56 Porefilling I isotherm plots for acetamide rebinding tests in ethyl acetate. 
 
 
Figure 57  Shows the plot of the rebinding test results in ethyl acetate for the pore-filling II polymers.  
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Figure 58 Displays the rebinding results for pore-filling III in ethyl acetate. 
 
3.2. CHARACTERIZATION OF THE MIP FORMATS 
 
In order to gain further information about the different polymer formats synthesized and in an 
attempt to explain the results from the experiments, the polymers were thoroughly characterized 
by a number of techniques.  
 
3.2.1. MICROSCOPY 
 
Microscopy is used for characterization of the particle shape and size distribution range. In 
Figure 59 microscopy pictures, typical for bulk polymers, of the acetamide imprinted PA3 and 
PAN3 are displayed. The irregular shaped particles have a size distribution range of around 25- 
50 µm as expected from the crushing and sieving procedure. 
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Figure 59 Microscopy pictures of the bulk polymer (left) PA3 and (right) PAN3 after crushing and sieving. 
 
Also the iso-octane polymers were crushed and sieved to the particle size range of 25-50 µm 
during the work-up procedure. The resulting microscopy pictures (Figure 60) show that the 
majority of the particles are within the 25-50 µm range, however smaller particles are also 
observed. During the wet-sieving procedure particles smaller than 25 µm should be filtered out, 
but in this case, even after extensive washing and sieving, some remained. The difficulty to 
remove the smaller particles may be explained by their fragility. When doing the work-up it 
was observed that the iso-octane polymers are softer than the bulk polymers, so much that no 
pistil was needed for crushing. This behavior can be explained by the shape of the polymers, as 
can be seen in the microscopy pictures the larger particles are built up by agglomerated smaller 
almost spherical particles. Hence, making them less rigid than the bulk polymers and thus 
possibly more inclined to break and form smaller particles under physical stress. The iso-
polymers are synthesized via precipitation polymerization meaning that the polymer particles 
formed will precipitate when they reach a certain size and are no longer soluble in the solvent. 
Therefore, smaller particles are formed in comparison to bulk polymers where the synthesis of 
the polymer is not limited by solubility.     
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Figure 60 Microscopy pictures of the iso-octane polymers. Top left down: MIP 25:75, NIP 25:75, MIP 50:50, NIP 
50:50, MIP 75:25, NIP 75:25. 
 
The last polymer format synthesized is the pore-filled composite material. In this approach 
spherical porous silica is filled with pre-polymerization solution and after polymerization the 
silica is removed by etching, leaving polymer replicas. Microscopy pictures (Figure 61) do not 
only give an indication of the particle size range but also whether the silica particles are filled 
properly with pre-polymerization solution. The silica particles filled with polymerization 
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mixture, in the middle, have a solid darker grey shade to them compared to the non-filled silica 
particles, indicating that the pores of the silica have been filled. After etching (right picture) it 
is observed that the formed polymer mirror images of the silica exhibit the same size range as 
the silica composites. In addition, the polymer particles after etching tend to keep the darker 
grey coloring indicating that the etching process to remove the silica is successful. In order to 
confirm that the particles shown on the right hand side consist of polymeric material thermal 
gravimetric analysis before and after etching is performed.   
 
 
Figure 61 Displays pore-filling composite microscopy pictures: (left) bare silica (middle) silica with polymer and 
(right) polymer replica of the etched silica. 
 
3.2.2. THERMAL GRAVIMETRIC ANALYSIS  
 
Thermal gravimetric analysis is used to characterize the decomposition behavior and thermal 
stability of the different acetamide imprinted polymers prepared. By studying the obtained 
decomposition patterns one can obtain information of the chemical composition and the 
polymerization process of the polymer. Weight losses occurring at temperatures lower than 
150 ⁰C are generally attributed to loss of water and decomposition of unreacted monomer, 
cross-linker and monomer-template complex.220,221,222  
 
The TGA curves (Figure 62) for the bulk polymers show that there is no significant difference 
in the decomposition patterns of PA3 and PAN3. Two decomposition steps are observed for 
both polymers, with exothermic peaks around 300 ⁰C and 420 ⁰C. Decomposition starts around 
230 ⁰C which means they are rigid up to this temperature, and beyond that they start to 
disintegrate.  
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 (A) 
 
(B) 
 
Figure 62 TGA curves of bulk polymers PA and PAN3. (A) The weight change in % as function of temperature 
(◦C), and (B) the derivative of the weight change as function of temperature (◦C). 
 
In comparison to the bulk polymers the decomposition patterns of the iso-polymers indicate 
three-step decomposition rather than a two-step (Figure 63). In addition to the exothermic peaks 
around 300 ⁰C and 420 ⁰C, a third one is observed around 250 ⁰C. The observation of the iso-
polymers starting to degrade earlier than the bulk polymer indicates that shorter polymer chains 
are present. Due to the fact that above 150 ⁰C excess water, unreacted monomer, cross-linker 
and monomer-template complex should be degraded, the peak at around 250 ⁰C is most likely 
polymer. As previously mentioned, the iso-polymers are synthesized via precipitation 
polymerization meaning that the polymer particles formed will precipitate when they reach a 
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certain size and thus no longer are soluble in the solvent. The third peak at around 250 ⁰C occurs 
as a result of the decomposition of lower molecularly weight polymer chains, which are not 
observed in the bulk polymers where the polymer chains can grow larger. 
 
(A) 
 
(B) 
 
Figure 63 TGA curves of iso-polymers MIP 25:75, 50:50, 75:25 and NIP 25:75, 50:50, 75:25. (A) The weight 
change in % as function of temperature (◦C), and (B) the derivative of the weight change as function of temperature 
(◦C). 
 
In addition to gaining information about the decomposition behavior and thermal stability, TGA 
analysis is used to follow the progress of the pore-filling procedure for study of the pore-filling 
and removal of the silica by etching. The TGA curves before etching (Figure 64) are analyzed 
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after polymerization in order to observe the ratio of polymer to silica formed. Decomposition 
of the three polymers is not all following the same pattern and after complete combustion all 
but MIP I and NIP I display a total weight loss of approximately 40 %. For the MIP I and NIP 
I the total weight loss is smaller with around 30 %, this is in accordance with the amount of 
solvent used in the pre-polymerization preparation (Table 4 in section 3.1.3). Since the same 
amount of pre-polymerization mixture is used to fill the pores for all three polymers, a smaller 
solvent to monomer and cross-linker ratio means that a larger quantity of polymer is formed. 
The amount of solvent decreases from 50 % to 10 % and the last polymer not containing any 
solvent, polymer I, II and III respectively. It appears that at some level decreasing the solvent 
does not influence the amount of polymer formed, because both polymer II and III display the 
same total weight loss. However, the decomposition patterns of polymer II and III exhibit some 
differences. The onset temperature where polymer II starts to degrade is roughly the same as 
for polymer I and III but the slopes differentiate. In diagram B (Figure 64) it is observed that 
polymer II has a two-step degradation compared to a three-step for polymer I and III. As 
discussed earlier the first peak in the three-step degradation occurs at approximately 125 ⁰C 
indicating un-reacted monomer, cross-linker or template-monomer complex and a second one 
at around 160 ⁰C implying smaller polymer chains present. For polymer II the decomposition 
starts at approximately 220 ⁰C indicating that a smaller amount of shorter polymer chains are 
present than in polymer I and III.  
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(A) 
 
(B) 
 
Figure 64 TGA curves of pore-filling polymers MIP and NIP I, II, III before etching. (A) The weight change in 
% as function of temperature (◦C), and (B) the derivative of the weight change as function of temperature (◦C). 
 
The pore-filled polymers are analyzed with TGA once more after etching in order to control 
that no remaining silica is present. The resulting TGA curves (Figure 65) show that the weight 
loss is close to 100 %, indicating that the silica was removed successfully for the three 
synthesized polymers. The polymers, apart from MIP III, all essentially follow the same 
degradation pattern, with the onset temperature just above 200 ⁰C and full degradation reached 
at approximately 400 ⁰C. MIP III on the other hand has a more distinguished two-peak 
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degradation pattern rather than a broader tailing one-peak pattern observed for the other 
polymers in the derivate weight change diagram. MIP III displays one peak at approximately 
160 ⁰C and the second peak at approximately 380 ⁰C. As discussed earlier in this section the 
peak at 160 ⁰C implies that smaller polymer chains are present. 
 
The result indicating smaller polymer chains in MIP III is contrary to the results observed before 
etching, where polymer II showed indication of smaller polymer chains rather than polymer III. 
This change might be explained by polymer chains being washed out during the etching 
procedure. 
(A) 
 
(B) 
 
Figure 65 TGA curves of pore-filling polymers MIP and NIP I, II, III after etching. (A) The weight change in % 
as function of temperature (◦C), and (B) the derivative of the weight change as function of temperature (◦C). 
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3.2.3. DIFFERENTIAL SCANNING CALORIMETRY ANALYSIS 
 
DSC was used to further study the synthesized MIP format. The thermograms obtained give an 
indication of the crystallization, melting and degradation temperatures for the MIPs.  
 
Table 5 summarizes the results obtained for the different synthesized MIPs. It is observed that, 
apart from porefilling MIP and NIP II, the MIPs and corresponding NIPs have comparable 
temperatures, thus indicating that the template does not affect the polymerization process.  
Furthermore, the bulk and iso-octane polymers display two melting temperatures and the iso-
octane polymers whereas the pore-filling polymers only display one. The melting temperatures 
for the iso-octane and pore-filling polymers are higher compared to the bulk polymers (around 
250 – 300 ⁰C and approximately 220 ⁰C respectively). The value for the bulk polymers are 
corresponding to the on-set temperature for the degradation observed in the TGA analysis 
(Section 3.2.2), however the temperatures for the iso-octane and pore-filling polymers are 
slightly higher. In addition the iso-octane and pore-filling polymers display one characteristic 
peak not observed in the bulk polymers, namely crystallization. The crystallization temperature 
suggests that adjacent polymer chains are stacked to form crystalline structure in the iso-octane 
and pore-filling polymers, thus possibly leading to higher melting temperatures. One possible 
explanation why this is not observed in the bulk polymer is that the polymer chains are not free 
to stack, even though the three MIP formats should have the same degree of cross-linking. As 
discussed in Section 3.2.2 the degradation patterns for the iso-octane and the pore-filling 
polymers suggest that smaller polymer chains might be present. 
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Table 5 Summary of the DSC results. Where Tc is crystallization temperature, Tm the melting temperature and 
Td the degradation temperature. 
  Tc1 (⁰C) Tc2 (⁰C) Tm1(⁰C) Tm2(⁰C) Td(⁰C) 
Bulk PA3 n.f - 149 218 349 
Bulk PAN3 n.f - 151 225 349 
Iso-octane MIP 25:75 145 - 171 277 n.f 
Iso-octane NIP 25:75 148 - 183 304 n.f 
Iso-octane MIP 50:50 151 - 164 263 n.f 
Iso-octane NIP 50:50 150 - 163 260 n.f 
Iso-octane MIP 75:25 n.f - 158 275 n.f 
Iso-octane NIP 75:25 n.f - 164 266 n.f 
MIP I 153 - 252 - n.f 
NIP I n.d n.d n.d n.d n.d 
MIP II 159 223 254 - n.f 
NIP II 128 157 312 - n.f 
MIP III 144 - 269 - n.f 
NIP III 134 159 283 - n.f 
 
3.2.4. POROMETRY USING BET AND DSC ANALYSIS 
 
Porometry analysis of the acetamide imprinted polymer was performed by BET as well as DSC, 
and the results are summarized in (Table 6). The data for the polymers, independent of the 
format, display some significant differences between the dry and swollen state.  The BET 
adsorption-desorption curves obtained indicated type IV hysteresis loop and thus indicating the 
polymers are of mesoporous character. The super-porous iso-octane 25:75 and 50:50 polymers 
have the smallest pore diameter (around 4 nm), and the 75:25 polymer and the bulk polymers 
display double the pore diameter size (approximately 10 nm). The surface area of the iso-octane 
polymers on the other hand are roughly the same for all three polymers, approximately 100 m2/g 
compared to almost 400 m2/g for the bulk polymers. Because of shortage of material no BET 
analysis was performed for NIP I, MIP II and NIP II. However, the results for the rest of the 
pore-filling polymers display larger pore size (approximately 20 nm) compared to the 75:25 
and bulk polymer. It should be noted that the super-porous iso-octane polymers and the pore-
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filling polymers did display indications of the polymer possibly collapsing during analysis, 
because the desorption curve had higher values than adsorption. 
 
Pore analysis with DSC in the swollen state was also performed, although all polymers were 
analyzed three of them did not display the characteristic peak so no pore parameters could be 
calculated. As observed in BET analysis, DSC analysis displays the smallest pore sizes for the 
super-porous iso-octane polymers. Contrary to the BET analysis the bulk polymers have the 
largest pore size, around 25 nm compared to 10 nm in the dry state. This increase in pore size 
may indicate that the bulk polymers swell to some extent in the acetonitrile. The super-porous 
iso-octane polymers do not display any significant change in pore size, thus indicating that they 
might swell less than the bulk polymers. The swelling tests performed in Section 3.2.6 show 
indications of the same trend, although not as distinct as in the DSC results. Interestingly the 
pore size for the pore-filling polymers is smaller in the swollen state compared to the pore size 
observed in the dry state.  
 
The surface area for the bulk polymers by DSC analysis do not change significantly compared 
to in the dry state. The results for the super-porous iso-octane and pore-filling polymers on the 
other hand are significantly different in the swollen state than the results achieved in the dry 
state. The higher surface area (ranging from 440 m2/g to 780 m2/g) observed for the pore-filling 
polymers compared to the bulk polymers are expected when using porous silica as a mould for 
synthesis. The super-porous iso-octane polymers display extremely high surface areas of 
approximately 1700 m2/g. Surface areas with these high values have been observed in 
precipitation polymerization microporous polymer microspheres.223 The ultra-high surface 
areas observed for the super-porous iso-octane polymers probably arise from high micropore 
contents. 
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Table 6 Pore analysis parameters for the acetamide imprinted polymer formats measured by BET and 
thermoporometry. Where n.d is not determined. 
 BET - dry state DSC - swollen state 
  
Pore 
diamater 
(nm) 
Pore 
volume 
(cc/g) 
Surface 
area 
(m2/g) 
Pore 
diamater 
(nm) 
Pore 
volume 
(cc/g) 
Surface 
area 
(m2/g) 
Bulk PA3 10.9 1.01 367 23.3 1.6 270 
Bulk PAN3 10.6 1.03 391 29.3 1.8 257 
Iso-octane MIP 25:75 4.3 0.11 105 4.2 1.9 1812 
Iso-octane NIP 25:75 5.1 0.08 64 - - - 
Iso-octane MIP 50:50 4.3 0.07 64 4.3 1.8 1688 
Iso-octane NIP 50:50 2.4 0.03 51 4.5 1.9 1677 
Iso-octane MIP 75:25 10.0 0.2 88 - - - 
Iso-octane NIP 75:25 9.5 0.3 108 - - - 
MIP I 18.3 0.6 126 10.1 1.5 608 
NIP I n.d n.d n.d n.d n.d n.d 
MIP II n.d n.d n.d 10.1 1.7 696 
NIP II n.d n.d n.d 9.2 1.8 789 
MIP III 15.0 0.7 174 11.0 1.5 540 
NIP III 17.2 - - 10.7 1.2 440 
 
 
3.2.5 SEM CHARACTERIZATION  
 
For further characterization of the three synthesized polymer formats the surface morphology 
was studied with SEM. In addition to the particle shapes information about the pore size can 
also be obtained. The SEM images of the bulk, iso-octane, and pore-filling polymers 
demonstrate a strong change in surface morphology as expected.  
 
The bulk polymers display the characteristic irregular shape caused by the crushing and sieving 
procedure (Figure 66). Randomly distributed mesopores and macropores are observed on the 
surface. 
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Figure 66 SEM pictures of MIP (PA3 top) and NIP (PAN3 bottom) acetamide imprinted bulk polymers. With 
increasing resolution from left to right (100 µm, 9 µm, 600 nm). 
 
In the SEM images of the iso-octane acetamide imprinted polymers typical characteristics of 
super-porous MIPs are observed.217 Like the bulk polymers the iso-octane polymers display 
irregular shaped particles (Figure 67). However, for the 25:75 and 50:50 iso-octane polymers 
at the lowest resolution (100 µm) it can be observed that the particles are composed by smaller 
particles. This may be explained by agglomeration of smaller particles that when crushed and 
sieved form larger particles.  The third polymer, 75:25 iso-octane, displays irregular particles 
like the conventional bulk polymers, but with higher resolution the same agglomeration of small 
particles is observed. The polymer particles are significantly smaller for the 75:25 iso-octane 
polymer than for the 25:75 and 50:50 iso-octane polymers. Agglomeration of smaller particles 
is further supported when studying the highest resolution images.  
 
Contrary to the bulk polymers, smaller pores are not observed in the iso-octane polymers. 
Instead µm-sized round components of macro-porous MIPs with so called super-pores 
connecting them are observed. The polymers with the largest amount of iso-octane, polymer 
75:25, display significantly smaller round components. An explanation for the smaller formed 
polymer components are that when using an excess of the bad solvent iso-octane the polymer 
precipitates more rapidly than when using an excess of toluene. The smaller agglomerates 
observed in the 75:25 polymers also explain the fragility noticed during the crushing and sieving 
procedure.  
116 
 
The SEM images of the pore-filled MIPs display uniformly shaped circular particles 
complementary to the porous silica moulds, indicating that the pore-filling polymerization was 
successful (Figure 68). Pore-filling of porous silica moulds results in MIP particles with a size 
range and morphology reflecting the characteristics of the original silica mould. Spherical 
polymer particles are observed for all three polymer pairs, thus indicating that the amount of 
solvent used in the pre-polymerization mixture probably does not influence the pore-filling 
polymerization. 
 
Further magnification show a more homogenous pore size distribution than for the conventional 
bulk polymers. The pores observed for the polymers, especially pairs I and II, appear to be 
larger than the conventional bulk polymers. The apparent more homogenous pore size 
distribution may be attributed to the pre-defined pores in the silica moulds. MIP III displays 
smaller pore size compared to the other pre-filled polymers, this could be due to the fact that 
some of the silica is not entirely removed during the etching procedure. 
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Figure 67 SEM pictures of iso-octane acetamide imprinted bulk polymers. With increasing resolution from left to 
right. 
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Figure 68 SEM images of the acetamide imprinted pore-filling polymers I, II, and III, and the corresponding NIPs 
after etching for removal of the silica. Increasing resolution from left to right. 
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3.2.6 SWELLING TESTS 
 
The polymers swelling behavior was evaluated by swelling tests in both MeCN and ethyl 
acetate (Figure 69). No swelling tests were performed for the pore-filling polymers due to 
limited amount of polymer available. The MIPs synthesized in this thesis are all highly cross-
linked polymers, therefore high swelling ratios are not expected. No significant difference in 
swelling ratios between the two different polymer formats is observed. 
 
 
Figure 69 Swelling ratios for bulk and iso-octane polymers in MeCN and ethyl acetate. 
 
3.2.7 CONCLUSION ACETAMIDE IMPRINTED POLYMERS 
 
Novel molecularly imprinted polymers have been designed and synthesized, which can 
recognize the pharmaceutical impurities acetamide. Thorough testing and evaluation of these 
MIPs have demonstrated potentials to purify APIs as selective adsorbents because of their high 
affinity binding sites. Rebinding tests indicates that high affinity interactions are present 
between the binding sites of the MIP and the target impurity acetamide, which results in high 
efficiency purification. The new MIPs developed answer to the industrial call for systems that 
provide a high binding specificity between acetamide and MIPs. 
 
For the aim of synthesizing polymers with a high capacity for pharmaceutical applications 
different formats were compared for optimization. The first generation bulk polymers were 
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synthesized for optimization of the monomer composition and proof of concept. The strategy 
was to use common commercially available monomers and cross-linkers for facilitating future 
scale-up processes. HPLC analysis, batch rebinding test and SPE experiments demonstrated 
strong imprinting and high specific binding of acetamide. However, for successful industrial 
application an improved loading capacity would be beneficial. 
 
Two further formats were synthesized with the aim to improve the binding capacity and with 
the same or stronger specific binding. The two formats chosen were super-porous MIPs and 
pore-filling of porous silica particles, where the idea was that the inherent defined porous 
characteristics would improve the desired features. In general the binding capacity in ethyl 
acetate is slightly higher than in acetonitrile across all the formats tested. This is probably 
because of the difference in polarity of the two solvents, where the more polar acetonitrile 
disrupt the binding of acetamide. The super-porous polymers do not display an increase in 
binding capacity as expected, they do however demonstrate an increase in the specific binding 
compared to the bulk polymers. An explanation for this observation may be that with the 
additional iso-octane in the pre-polymerization mixture acting as a bad solvent the self-
assembly of acetamide and MAA is promoted, and thus creating stronger binding sites. A 
successful increase in binding capacity was observed in pore-filling polymer II and III. Pore-
filling polymer II being the better of the two with an increase of approximately 60 % compared 
to the bulk polymers. The increased binding capacity can be attributed to the more defined pores 
present in the pore-filling polymers after removal of the silica mold. In the bulk polymers the 
pore system is more heterogeneous and the higher binding capacity in the pore-filling polymers 
may be attributed to the more homogeneous pore system. This is supported by the SEM images 
displaying the pores in the polymers and by the porometry analysis performed where increased 
surface area is observed for the pore-filling polymers. In general the rebinding tests demonstrate 
stronger specific binding for the super-porous polymers and the pore-filling polymers compared 
to the bulk polymers. 
 
The degradation patterns and swelling properties of the polymer formats are rather similar, as 
can be expected since they are all highly cross-linked polymers with the same monomer and 
cross-linker composition. 
 
It can be concluded that the binding capacity for acetamide could successful be increased, 
without sacrificing the specific binding via pore-filling polymerization.  
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3.3 THIOACETAMIDE IMPRINTED POLYMERS 
 
One aim of this work is to investigate the feasibility to use MIPs for purification of active 
pharmaceutical ingredients of different sizes. It is thus interesting to investigate the possible 
removal of other genotoxins. Following the positive results obtained from the acetamide 
imprinted polymers the same monomer recipe was used for imprinting of the structural similar 
thioacetamide as proof of concept.   
3.3.1 REBINDING EVALUATION 
 
The static rebinding tests were performed in both acetonitrile and ethyl acetate, the same 
solvents as the experiments performed for the acetamide imprinted polymers. In addition to 
facilitate a comparison of the performance with the acetamide imprinted polymers, the use of 
acetonitrile and ethyl acetate also represent possible real circumstances for thioacetamide 
removal.  
 
The first rebinding test was carried out in acetonitrile and the results are shown in Figure 70. 
Binding capacities are similar to the ones observed for the acetamide imprinted polymers. 
However, no significant difference between the binding capacities of the MIP and NIP is 
observed, indicating poor thioacetamide imprinting. Rebinding in acetonitrile indicate that 
unspecific binding is present in the MIPs. 
  
 
Figure 70 Rebinding isotherms of thioacetamide polymers in MeCN. 
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Following the rebinding in acetonitrile further rebinding test were performed in ethyl acetate 
(Figure 71). In contrast to the rebinding experiment in acetonitrile a significant difference in 
binding of thioacetamide between the MIP and NIP is observed. Furthermore, the binding 
capacity in ethyl acetate of the MIP is improved compared to in acetonitrile, with an increase 
from approximately 1.4 mg/g to 2.1 mg/g. The results indicate that specific binding of 
thioacetamide is taking place rather than unspecific binding. 
 
The difference in the results for rebinding in acetonitrile and ethyl acetate observed might be 
explained by the different characteristics of the solvents. Acetonitrile is a more polar solvent 
with a polar term of 18 whereas ethyl acetate has a polar term of 5.3. This difference in polarity 
implies that acetonitrile might interfere with the specific binding of thioacetamide in the 
imprinted binding sites. 
 
 
Figure 71 Thioacetamide imprinted polymer rebinding isotherms in ethyl acetate. 
 
The thioacetamide imprinted polymers were further tested by SPE removal of thioacetamide in 
ethyl acetate (Figure 72). A solution with 25 ppm thioacetamide in ethyl acetate was added to 
a SPE column with 100 mg of polymer followed by addition of pure ethyl acetate washes, the 
elution fractions were collected and analyzed. The results display that the MIP bind roughly 
20 % more than the NIP in the loading fractions, thus indicating specific binding of the 
thioacetamide. After wash 1 nearly all the loaded thioacetamide has been eluted from both the 
MIP and NIP and in the rest of the washes trace amounts are eluted. 
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Figure 72 Recovery diagram of SPE removal of thioacetamide in ethyl acetate. 
 
3.3.2 CHARACTERIZATION OF THIOACETAMIDE IMPRINTED POLYMERS 
 
For an indication of the crystallization, melting and degradation temperatures of the 
thioacetamide polymers DSC analysis was performed.  The heat flow behavior displayed is the 
same as for the acetamide imprinted bulk polymers in Section 3.2.3. DSC analysis of the MIP 
and NIP displays two melting peaks and a degradation peak (Figure 73). Like for the acetamide 
imprinted bulk polymers, no crystallization peak is observed, the first melting peak appears at 
152 ⁰C and the second at 227 ⁰C, and a degradation peak is observed at 346 ⁰C. The melting 
and degradation temperatures are in accordance to the temperatures observed for the acetamide 
imprinted polymers. 
 
DSC analysis was also used for thermoporometry to determine the pore area, size and volume. 
However, the pore area, size and volume could not be determined with this characterization 
technique because no peak was detected (See Appendix).  
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Figure 73 DSC thermogram of the thioacetamide imprinted polymers. 
 
BET was used for pore analysis of the thioacetamide polymers and the results are summarized 
in Table 7. The pore analysis corresponds well to the data obtained for the acetamide imprinted 
polymers. The pore diameter and volumes are slightly smaller for the thioacetamide polymers 
than for the acetamide polymers, but they are still in the same range as may be expected since 
the same polymerization mixture and porogen were used. 
 
Table 7 BET pore analysis parameters for the thioacetamide MIP and NIP polymers.  
 BET - dry state 
  
Pore diamater 
(nm) 
Pore volume 
(cc/g) 
Surface area 
(m2/g) 
MIP 8.1 0.74 368 
NIP 7.5 0.76 406 
 
Swelling tests in acetonitrile and ethyl acetate display swelling ratios of approximately 1.4 in 
both solvents for MIP and NIP (Figure 74). This corresponds to the values observed for the 
acetamide bulk polymers and are expected from highly cross-linked polymers. 
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Figure 74 Swelling ratios for thioacetamide imprinted polymers in MeCN and ethyl acetate. 
 
3.3.3 CONCLUSION THIOACETAMIDE IMPRINTED POLYMERS 
 
The aim of this experiment was to further investigate the feasibility to use MIPs for purification 
of active pharmaceutical ingredients. After the first positive results of acetamide imprinting and 
the subsequent removal thereof, it is of great interest to investigate the imprinting and specific 
removal of other possible genotoxins.  Therefore, the same monomer composition was used to 
imprint thioacetamide.  
 
Thioacetamide imprinted bulk polymers were successfully synthesized and evaluation of the 
MIP indicate the polymer contains specific binding sites for thioacetamide. Although, the static 
rebinding tests display that no specific binding takes place in the MIP when tested in 
acetonitrile, the results in ethyl acetate display a strong specific binding in the MIP. This 
observation may be explained by the difference in polarity of the two solvents, with acetonitrile 
being more polar than ethyl acetate. Furthermore, sulfur is slightly less electronegative than 
nitrogen thus probably less inclined to form strong hydrogen bonds with methacrylic acid. This 
may explain why the formation of thioacetamide specific binding sites is not as good as 
observed for the acetamide imprinted bulk polymers. 
 
The thioacetamide bulk polymers display an increased binding capacity in ethyl acetate 
compared to the acetamide bulk polymers. The SPE experiment performed in ethyl acetate 
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further indicate that specific binding sites for thioacetamide are present in the MIP even if the 
difference between the MIP and the NIP is not so large. However, with further optimization of 
the polymer composition, such as another functional monomer or choice of porogen, more 
specific binding and higher binding capacities may be achieved. For the purpose of proof of 
concept in this thesis the results obtained are satisfactory. 
 
3.4 2-AMINOPYRIMIDINE IMPRINTED POLYMERS 
  
The feasibility of applying MIPs as scavengers for purification of APIs was further examined 
by synthesizing bulk imprinted 2-aminopyrimidine polymers (Figure 75). As described in 
section 1.4.3 aminopyridine derivatives can be used as starting materials and catalysts in API 
synthesis. These derivatives are considered to be compounds of concern, thus efficient removal 
of residue amounts is of interest. In this case study 2-aminopyrimidine was chosen because it 
and its derivatives are also considered compounds of concern due to the structural similarity to 
aminopyridine. 
 
 
Figure 75 Structure of 2-aminopyrimidine. 
 
A total of four polymers were synthesized and the composition of the polymers is summarized 
in Table 8. In addition to the polymer composition used for both the acetamide and 
thioacetamide imprinted polymers a second functional monomer and sovent was used, namely 
4-vinylpyridine (4-VP) and dimethylformamide (DMF) respectively. 4-VP was selected as an 
alternative because of its capability to form non-covalent bonds and DMF was chosen because 
of future possible combination with synthesis of imprinted OSN membranes. 
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Table 8 Composition of the 2-aminopyrimidine imprinted bulk polymers. 
  Monomers Stoichiometry Porogen 
M I T/MAA/EDGMA 
1/4/20 Tol 
N I MAA/EDGMA 
M II T/4-VP/EDGMA 
N II 4-VP/EDGMA 
M III T/MAA/EDGMA 
1/4/20 DMF 
N III MAA/EDGMA 
M IV T/4-VP/EDGMA 
N IV 4-VP/EDGMA 
 
3.4.1 REBINDING EVALUATION OF 2-AMINOPYRIMIDINE IMPRINTED 
POLYMERS 
 
Initial batch rebinding tests in acetonitrile were performed in order to evaluate the imprinting 
effect of the synthesized polymers. 50 mg of polymer was weight in HPLC-vials and two 
concentrations 0.3 and 0.6 mg/mL were added. After equilibration over night the samples were 
analyzed with HPLC.  
 
The obtained results indicate that polymers with MAA as the functional monomer resulted in 
successful imprinting of 2-aminopyrimidine, whereas the polymers using 4-VP as the 
functional monomer were not successful. This can be observed when studying the imprinting 
factors for the four synthesized polymers (Table 9), where values above 1 indicate specific 
binding sites in the MIP. 
 
Table 9 Imprinting factors for the 2-aminopyrimidine imprinted polymers. 
  Imprinting factor 
PI 1,5 
PII 0,9 
PIII 1,6 
PIV 0,6 
Imprinting factor (IF) was calculated from the maximum bound amount for MIP and NIP. 
 IF = mbound,MIP /mbound,MIP 
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It is observed that both M I and M III bind more than their respective NIPs, thus indicating that 
specific binding sites are present in both polymers and that successful imprinting is achieved in 
both toluene and DMF (Figure 76). However, the binding capacity for M I is slightly higher 
than for M III, this can probably be explained by the difference in polarity of toluene and DMF. 
DMF is more polar than toluene and can thus disturb the interactions between the template and 
functional monomer, where DMF has a polar term of 13.7 and toluene 1.4 (Section 1.4.7). 
 
 
Figure 76 Rebinding test results for polymer I and III imprinted with MAA as the functional monomer in MeCN. 
M I and N I using toluene as the porogen , M III and N III using DMF as the porogen. 
 
For the rebinding results for the polymers using 4-VP as the functional monomer no specific 
binding by the MIPs can be observed (Figure 77). In both cases the NIPs bind more than the 
MIPs. For polymer IV the difference between the MIP and NIP is more pronounced than in 
polymer II, indicating that the more polar porogen DMF promotes more unspecific binding sites 
in the polymers.  
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Figure 77 Rebinding test results for polymer II and IV imprinted with 4-VP as the functional monomer in MeCN. 
M II and N II using toluene as the porogen , M IV and N IV using DMF as the porogen. 
 
3.4.2 CONCLUSION 2-AMINOPYRIMIDINE IMPRINTED POLYMERS 
 
The aim of this experiment was to further investigate the feasibility to use MIPs for purification 
of active pharmaceutical ingredients. Specific binding of two small impurities using 
commercial available monomers has already been demonstrated in this thesis, and to investigate 
how versatile the monomer composition used for acetamide and thioacetamide is for 
pharmaceutical applications 2-aminopyrimidine was imprinted. A second commonly used 
monomer, 4-VP, was used in addition to MAA. For the purpose of potentially transfer the MIPs 
to synthesis of imprinted OSN membranes, imprinting in DMF besides in toluene was 
performed.   
 
Four different 2-aminopyrimidine bulk polymers were successfully synthesized, however the 
evaluation of the polymers indicate that specific binding sites for the template is only present 
in the MAA-based polymers. In the polymers using 4-VP as the functional monomer unspecific 
binding seems to be more prominent. The preliminary rebinding tests display that polymers 
synthesized with MAA as the functional monomer in both toluene and DMF result in 
successfully imprinted polymers. When using the more polar solvent DMF it is observed that 
the binding capacity decreases slightly, indicating that the interaction between the template-
monomer may be disrupted to some extent.  
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It can be concluded from the first preliminary binding tests that specific binding of 2-
aminopyrimidine could be achieved using the same monomer composition as for acetamide and 
thioacetamide. The observation that specific bind sites are present also in the polymer 
synthesized in DMF indicates that the MIP composition may be used in the synthesis of 
imprinted OSN membranes. However, with further testing and optimization of the polymer 
composition more efficient MIPs may be achieved. For the purpose of proof of concept in this 
thesis the results obtained are satisfactory. 
 
3.5 HYBRID APPROACH – A CASE STUDY OF APPLICATION FOR THE 
COMBINATION OF MIP AND OSN  
 
As extremely low contamination levels are required for APIs, efficient impurity removal and 
high accuracy low level analysis is crucial. For this purpose OSN and MIPs are viable solutions, 
as they are two emerging separation techniques, indicating promising performance in lab-scale 
studies. OSN separates solutes primarily based on steric factors and as many genotoxins are 
small (commonly 50-150 Da) compared to drug substances (commonly 250-1000 Da) a large 
separation potential is often present.  
 
MIPs can be designed to selectively bind to specific impurities hence enabling specific removal 
of a selected genotoxin. Both techniques are described in detail in the introduction part. 
Although both MIPs and OSN display a high potential for efficient purification applications in 
the pharmaceutical industry, they also have their own disadvantages. For MIPs the loading 
capacity, the sometimes tedious screening procedures needed and the use of (large amounts of) 
templates for the imprinting process are factors limiting the industrial implementation. The 
process of screening solvents is a reoccurring issue in OSN membrane field too. Furthermore, 
the lack of literature on performance and applicability in comparison to the traditional processes 
used, unsatisfactory separation performance leading to intolerable API loss or purity level, and 
high solvent consumption all have an influence on the slow pharmaceutical industrial 
implementation. In an attempt to address these issues, especially the separation performance 
and solvent use by the OSN membranes and the loading capacity of the MIPs, the two 
techniques were tested in a so called hybrid approach. 
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In collaboration with Elin Rundquist, the PhD student within the project based in 
GlaxoSmithKlein, the two techniques were tested and compared in a process mimicking real 
application processes. However, it should be noted that the system used was made up to fit the 
testing parameters and the drug candidate used has no acetamide impurities in the real 
purification processs. The test was designed to comply with the strict regulations 
pharmaceutical companies have. It employed a range of approaches including re-design of 
processes to avoid generation of genotoxins, alteration of process parameters to reduce 
impurities to acceptable levels, increased process understanding to prove that genotoxin cannot 
be formed or is effectively removed and toxicity studies to demonstrate that genotoxins are not 
harmful at the low levels envisaged.224,225  
 
In our case study we assumed that the genotoxin, namely acteamide, was formed during the 
work-up despite the introduced controls and that the drug substance may still be viable for use 
after removal of the harmful material. The case study aims can be summarized as: 
 Investigate the feasibility for removal of genotoxic impurity acetamide through 
individual use of OSN and MIP respectively 
 Investigate the feasibility of using a combined approach of OSN and MIP, i.e. a hybrid 
approach, to improve potential acetamide removal from the individual techniques 
 Provide a process comparison of OSN and MIP to evaluate strengths and weaknesses 
of the individual methods 
 
3.5.1 PROCESS PARAMETERS 
 
The process stream set up in this experiment was based on a, at the time, recently published 
project from UCB Pharma (Belgium)226. In this work aqueous washes are used to eliminate 
acetamide during the work-up steps and the final concentration of acetamide obtained was 
lower than the limit of quantification and in many cases even lower than 0.1 ppm (the limit of 
detection). Therefore the aim of the hybrid experiment was to reach the same concentration in 
order to be able to compare the different approaches.  
 
As the API test molecule a GSK drug candidate that was under development was used. The 
selected GSK API has a molecular weight of approximately 480 g mol-1 and it was identified 
as a suitable test molecule, because one process step deals with the removal of thioactetamide. 
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However, it should be noted that no real problem to remove thioacetamide exists and the API 
was only chosen on the basis that thioacteamide is structurally similar to acetamide, so that the 
conditions are as close to reality as possible. As a result the acetamide imprinted MIPs and 
acetamide as the impurity are used in this case study, but as a test the cross-selectivity to 
thioacetamide will be examined. For the purpose of recreating the conditions in the UCB paper 
ethyl acetate was used as the solvent, in addition a second experiment with acetonitrile was 
performed based on the HPLC results (Section 3.1.1.2). Selected process stream conditions are 
summarized in Table 10. 
 
Table 10 Summary of selected process stream for OSN and MIP collaboration 
Process parameters 
API GSK API under development 
API molecular weight 480 g mol-1 
Impurity Acetamide 
Impurity molecular weight 59.07 g mol-1 
Solvent Acetonitrile and ethyl acetate 
API concentration 1 % wt 
Impurity concentration 1000 ppm 
Target impurity concentration  0.1 ppm 
 
 
The choice of membranes was based on the matching of the molecular weights of the 
compounds with the reported cut-off curves for commercial OSN membranes. For processing 
in ethyl acetate Starmem™122 and Duramem™200 were selected as the most suitable 
membrane candidates and membranes were used for screening. For processing in acetonitrile 
Duramem™150 was selected as the most suitable membrane candidate and used for all 
processing. No membrane screening was carried out as all other commercially available 
membranes were deemed too loose for the suggested application. 
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3.5.2 METHODS FOR GENOTOXIC REMOVAL 
 
Three different scenarios were selected for testing of genotoxin removal: 
1. OSN operated in a continuous diafiltration mode 
2. MIP packed columns 
3. OSN and MIP operated in a combined approach with OSN used for removal of the 
majority of the genotoxic impurity and MIP used as a final polishing phase 
 
For operation in ethyl acetate a membrane screening was carried out to investigate the 
separation potential of the GSK API and the selected genotoxin acetamide. Screening was 
carried out in a cross-flow system at 30 bar and ambient pressure. The feed solution was re-
circulated for 4.0 h to reach close to maximum membrane compaction before the permeate was 
sampled for rejection testing. Screening was limited to study in ethyl acetate where two 
membranes are screened simultaneously. 
 
Diafiltration was carried out in a MET dead-end cell to minimize the feed volume requirement. 
For operation in ethyl acetate a total of 200 mL feed solution was used for the diafiltration. To 
minimize the overall solvent requirement and processing time the feed solution was reduced to 
100 mL for testing in acetonitrile. All processing was carried out at 30 bar and ambient 
temperature. MIP polymer (100 mg) was packed in a SPE column and sealed with a frit. Prior 
to operation the MIPs and NIPs columns were washed with methanol in order to remove any 
remaining acetamide and then equilibrated in ethyl acetate using a SPE vacuum manifold 
(Figure 78). NIPs were used as a control to verify that a potential separation is based on a 
successful imprinting step. 
 
For removal test 1 MIPs were compared with OSN for removal of the complete selected 
concentration of 1000 ppm. During initial test 800 µL of the feed solution was loaded on the 
MIP and NIP columns, and pulled through using the SPE vacuum manifold. The loading elutant 
was collected in HPLC vials and analyzed as the initial sample. The columns were further 
washed with 3 x 800 µL ethyl acetate, followed by 2 x 800 µL methanol containing 0.1% formic 
acid. All washing fractions were collected separately and analyzed for API and acetamide 
content. 
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                                 a                                                                      b    
Figure 78 Illustration of the columns used to pack the polymers (a) and the SPE vacuum manifold used to 
perform the removal tests (b). 
 
For removal test 2 the MIPs were tested as a polishing phase after membrane filtration. 
Retentate from diafiltration in ethyl acetate after 3.0 and 3.6 diafiltration volumes (containing 
40 and 25 ppm respectively) was used as the feed solution. Multiple samples were tested to 
investigate MIP performance at different concentration levels of acetamide. Removal test 2 was 
carried out according to the protocol detailed for removal test 1. However, the final two washes 
with methanol and formic acid were exchanged for pure ethyl acetate as methanol disturbs the 
acetamide analysis as it is eluting simultanously as the acetamide, thus making it more difficult 
to detect low concentrations of acetamide. 
 
3.5.3 RESULTS HYBRID APPROACH 
3.5.3.1 OSN ANALYSIS 
 
A membrane screening was carried out to investigate the separation potential of the API and 
acetamide in ethyl acetate. Screening data is summarized in Table 11. 
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Table 11 Summary of screening data for API and acetamide in ethyl acetate. 
Membrane Batch Equipment 
API R  
(%) 
Acetamide R 
(%) 
Flux 
(Lm-2h-1) 
DuramemTM200 M128 Cross-flow 93.9 6.9 12.7 
StarmemTM122 (1) 255.1 Cross-flow 81.9 0.9 100.4 
StarmemTM122 (2) 255.1 Dead-end 85.2 1.0 111.5 
StarmemTM122 (3) 9104.1 Dead-end 96.8 1.5 83.7 
StarmemTM122 (4) 9104.1 Dead-end 97.9 1.4 86.1 
 
 
Screening data indicates significantly varying API rejection data for Starmem™122. The 
differences could be a result of membrane damage, membrane not sealing properly or a result 
of minor batch variations. To ensure that the performance of the membrane disc is accurate a 
leak test was carried out for Starmem™122 (4). 
 
An ideal membrane for the given separation has a high API rejection close to 100%, while 
maintaining a significantly lower acetamide rejection. The screening data indicates that the 
highest API rejection was observed for Starmem™122 at 97.9% compared to 93.9% for 
Duramem™200. Additionally the acetamide rejection was lower for Starmem™122 indicating 
a larger overall separating potential. Starmem™122 was hence selected as the most suitable 
membrane for processing in ethyl acetate. 
 
For operation in acetonitrile Duramem™150 was identified as the only potential membrane for 
use. Therefore no membrane screening was carried out but a rejection test was performed after 
2.0 h re-circulation to investigate the API rejection prior to diafiltration processing. Rejection 
data for Duramem™150 in acetonitrile is summarized in Table 12. 
 
Table 12 Summary of rejection data for Duramem™150 in acetonitrile. 
Membrane Batch Equipment 
API R  
(%) 
Acetamide R 
(%) 
Flux 
(Lm-2h-1) 
DuramemTM150 M087 Dead-end 99.8 5.2 14.9 
 
Data in Table 12 indicate that in acetonitrile Duramem™150 has an API rejection of 99.8% 
while still maintaining a low acetamide rejection of 5.2%. This is close to the ideal membrane 
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performance and in combination with the intermediate flux of 14.9 Lm-2h-1 Duramem™150 is 
deemed a highly suitable membrane for acetamide removal. 
 
Because of the data obtained in the membrane screening suggest a potential leak for 
Starmem™122, a leak test was performed. To ensure accurate measurement of membrane 
performance a leak test was carried out using a large API molecule (~600 g mol-1) which has 
previously measured > 99% rejection in ethyl acetate. Rejection and flux data for the marker 
molecule is summarized in the table below. 
 
Table 13 Rejection and flux data for marker test. 
Membrane Batch Equipment 
Marker R  
(%) 
Flux 
(Lm-2h-1) 
DuramemTM150 9104.1 Dead-end 99.4 126.7 
 
The data displayed in Table 13 indicates that the rejection of the marker molecule is above 99 % 
which is consistent with previously observed data. The consistent and high rejection indicates 
that the membrane disc is sufficiently sealed and the recorded rejection in the membrane 
screening is an accurate measurement of the membrane performance. 
 
Diafiltration was carried out in ethyl acetate and acetonitrile respectively. For each test the 
permeate was collected in 100 mL fractions and the feed concentration of the API and 
acetamide was calculated based on a mass-balance. Additionally retentate samples was taken 
after 1, 2 and 3 diafiltration volumes for the ethyl acetate test and after 3 and 6 diafiltration 
volumes passed for the acetonitrile test. In addition to the measured concentrations for the API 
and acetamide estimated levels based on a rejection mass-balance are included as a comparison. 
Diafiltration data for ethyl acetate and acetonitrile is summarized in Figure 79 and Figure 80 
respectively. 
 
137 
 
 
Figure 79 Estimated and measured concentration levels of API and acetamide in the feed vessel during diafiltration 
in ethyl acetate. 
 
Data in Figure 79 indicate that there is a significant decrease in the acetamide concentration 
with increasing volumes of solvent passed. This is consistent with expected behavior as 
acetamide has a low rejection of 1.4% and is likely to wash out. The decrease in acetamide 
concentration is further consistent with the estimated mass-balance concentration based 
rejection values. Some deviations between the measured and estimated values can be observed 
around 1.0 and 1.5 diafiltration volumes of solvent passed. The deviation is believed to be a 
direct result of the permeate removed after 1.0 diafiltration volumes being slightly lower than 
100 mL making the retentate volume larger and hence indicating a lower concentration than the 
accurate value. The volume was adjusted over the next diafiltration volume passed after which 
the measured and estimated concentrations again correlated well. 
 
The rejection of the API was measured to 97.9 %, which is close to the ideal value of 100 %. 
However, the small deviation from full rejection will result in some API losses over time and 
the API concentration was observed to decrease throughout the test. Data in Figure 79 further 
indicate that the measured and estimated API concentrations are similar. Smaller deviations 
observed for the measured API concentration in the feed samples are likely to be a result of 
2 mL retentate samples being removed from the filtration to be used as feed in MIP processing. 
 
Diafiltration was continued until 3.6 diafiltration volumes of solvent had passed after which the 
acetamide concentration had been reduced to 25 ppm and the API concentration to 6.9 g L-1 
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(based on permeate samples to avoid introducing error from retentate sampling). The decrease 
in API concentration is equivalent to an overall API loss of 7.6 % to reach an acetamide level 
of 25 ppm. To reach the target level of 0.1 ppm mass-balance estimations indicate that a total 
of 8.75 diafiltration volumes solvents must be passed, which would result in an overall API loss 
of 16.8 %. Losses are deemed too significant for processing and the test in ethyl acetate was 
aborted. 
 
For testing in acetonitrile the feed volume was reduced to 100 mL to reduce the overall 
processing time and solvent requirement. Data for diafiltration in acetonitrile is summarized in 
Figure 80. 
 
 
Figure 80 Estimated and measured concentration levels of API and acetamide in the feed vessel during diafiltration 
in acetonitrile. 
 
Similar to Figure 79  the data in Figure 80 indicates a significant decrease in the acetamide 
concentration during the diafiltration. Based on the measured acetamide concentration in the 
permeate samples data in Figure 80 further indicate that the decrease in acetamide concentration 
is similar to the expected behavior based on mass-balance estimations. Important to note is that 
the retentate samples indicate that the acetamide concentration is slightly higher than the 
expected value based on both the permeate samples and the mass-balance estimation. This could 
be a result of the acetamide rejection being higher than the originally measured value. Mass-
balance calculations indicate that to obtain the measured acetamide levels, after 3 and 6 
diafiltration volumes respectively, the acetamide rejection would have to be 20 %, which is 4 
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times higher than the measured value of 5.2 %. For such a large difference in the measured 
rejection to be possible a significant error must have been made during the screening test. 
However as the API rejection, which is based on the same sample, appears consistent with the 
diafiltration data such a significant error is deemed unlikely and the small difference seen is 
more likely to be a result of small errors in the removed permeate volume. 
 
The API rejection remains > 99% throughout the experiment and the losses of API can be 
considered rather small. The measured API concentration based on the permeate samples are 
consistent with the expected performance based on the calculated mass-balance. Smaller 
deviations can be observed between the measured API concentrations in the retentate samples 
and the permeate samples. This is likely to be a direct result of 2 mL retentate samples being 
removed from the filtration to be used as feed in a MIP phase. 
 
The experimental data for the diafiltration in ethyl acetate and acetonitrile is summarized in 
Table 14. In addition mass-balance estimations of the overall API loss and solvent requirement 
to reach the desired acetamide concentration of 0.1 ppm are included for comparison. Finally 
an estimation of the solvent requirement for a potential acetamide rejection of 20 % is included 
to investigate the impact on the diafiltration for a higher retention of the impurity. 
 
Table 14 Summary of experimental and calculated diafiltration data. 
Sample 
Acetamide 
(ppm) 
API losses 
(%) 
Solvent usage 
(DV) 
Ethyl acetate, experimental data 24.9 7.6 3.6 
Ethyl acetate, estimation 0.1 16.8 8.8 
Acetonitrile, experimental data (feed) 1.7 1.3 6.0 
Acetonitrile, experimental data (permeate) 5.4 1.3 6.0 
Acetonitrile, estimation 5.2% rejection 0.1 1.7 8.7 
Acetonitrile, estimation 20% rejection 0.1 2.1 10.5 
 
 
Data in Table 5 indicate that the lack of 100 % API rejection for Starmem™122 operated in 
ethyl acetate will result in significant losses of API over time. Large API losses in combination 
with the reasonably high solvent requirement indicate that OSN is not suitable for removal of 
acetamide from the given ethyl acetate solutions. OSN might however still be useful as an initial 
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rough clean to reduce the acetamide concentration sufficiently for MIP purification to be viable. 
Additionally if the API was slightly larger hence resulting in a larger rejection OSN could be a 
viable option for the separation. 
 
For acetonitrile the API rejection of Duramem™150 is close to the desired value of 100 % and 
only minor losses of API are seen throughout the test. The overall solvent requirements for the 
full diafiltration to reach 0.1 ppm acetamide are still very large however and suitability for OSN 
purification will have to be evaluated based on the process in question. 
 
3.5.3.2 MIP ANALYSIS 
 
Removal test 1 uses the complete concentration 1000 ppm sample for testing and aims to 
investigate the MIP separation capability compared to OSN. Acetamide and API concentrations 
are measured for each samples and concentration and mass-recovery is summarized in Table 
15 and Figure 81 for acetamide and in Table 16 and Figure 82 for the API.  
 
Table 15 Acetamide concentration and mass-recovery in MIP and NIP samples from removal test 1. 
  
Loading 
elutant 
Wash 1 Wash 2 Wash 3 Wash 4 Wash 5 Total 
  Concentration in ppm 
MIP 0.5 946.2 22.0 3.2 2.9 1.2 - 
NIP 57.5 843.6 6.1 0.3 1.0 0.6 - 
  Mass-recovery in µg 
MIP 0.4 757 17 4 2 1 781 
NIP 46 675 5 0.2 0.8 0.5 727 
  Mass-recovery in % 
MIP 0.05 94.6 2.2 0.3 0.3 0.1 97.6 
NIP 5.7 84.4 0.6 0.03 0.1 0.6 90.9 
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Figure 81 Percentage mass-recovery for acetamide in removal test 1. 
 
Table 16 API concentration and mass-recovery in MIP and NIP samples from removal test 1. 
  
Loading 
elutant 
Wash 1 Wash 2 Wash 3 Wash 4 Wash 5 Total 
  Concentration in ppm 
MIP 7.1 2.8 0.04 0 0 0 - 
NIP 6.1 2.7 0.02 0 0 0 - 
  Mass-recovery in mg 
MIP 5.7 2.3 0.04 0 0 0 8.0 
NIP 4.9 2.2 0.02 0 0 0 7.1 
  Mass-recovery in % 
MIP 78.0 31.1 0.5 0 0 0 109.5 
NIP 67.2 30.2 0.2 0 0 0 97.6 
 
 
Figure 82 Percentage mass-recovery for API in removal test 1. 
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The data from removal test 1 indicates that the MIPs are retaining acetamide better than the 
NIPs. This is illustrated in Table 15 where only 0.05 % of the acetamide is eluted in the loading 
fraction on the MIP column compared to 5.7 % on the NIP column. Important to note is that 
the acetamide concentration used (1000 ppm) is very high and might be above the loading 
capacity of the MIPs. One indication that this might be the case is illustrated in the 1st washing 
fraction where the majority of the acetamide (94.6 %) is washed out. The early elution of 
acetamide indicates that only a limited amount of acetamide was bound to the MIP and the 
majority of the separation effect observed might be a result of the packed column rather than 
the imprinting. Some acetamide was however bound to the MIP as indicated by the difference 
between the MIP and NIP columns. 
 
Data in Table 16 indicate that the API is not retained by the polymers and all of the loaded API 
appears to elute in the loading elute and wash fraction 1. However, data in Figure 81 indicates 
that the majority of the acetamide is eluting in wash fraction 1 hence making the 30 % of API 
eluting in this fraction unusable. The significant loss of API indicates that though some degree 
of separation is possible, MIPs operated in a single stage are not suitable as a means of 
separation at the concentration levels used for removal test 1. 
 
Table 17 Acetamide concentration and mass-recovery in MIP and NIP samples from removal test 2.1 (sample 
3.6 diafiltration volumes retentate). 
  
Loading 
elutant 
Wash 1 Wash 2 Wash 3 Wash 4 Wash 5 Total 
  Concentration in ppm 
MIP 0 < 0.2 7.9 11.0 14.2 1.1 - 
NIP < 0.2 18.6 4.8 0.05 3.7 0.7 - 
  Mass-recovery in µg 
MIP 0 0 6 9 11 0.9 27 
NIP 0 15 4 0.01 3 0.5 22 
  Mass-recovery in % 
MIP 0 0 36.1 49.9 64.4 5.1 155.5 
NIP 0 84.5 21.8 0.2 16.6 3.0 126.2 
 
In removal test 2 the viability using MIPs in the hybrid approach as a polishing phase is 
evaluated. The samples removed during the membrane diafiltration are tested on the MIP 
columns. Removal test 2 was repeated for OSN retentate samples taken after 3.0 and 3.6 
diafiltration volumes had passed and the acetamide concentration is 40 and 25 ppm in the 
respective samples. Data from removal test 2.1 using the lowest concentration acetamide 
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sample (3.6 diafiltration volumes retentate) is summarized in Table 17 and Figure 83 for 
acetamide and Table 18 and Figure 84 for the API. 
 
 
 
Figure 83 Percentage mass-recovery for acetamide in removal test 2.1 (sample 3.6 diafiltration volumes retentate) 
 
Table 18 API concentration and mass-recovery in MIP and NIP samples from removal test 2.1 (sample 3.6 
diafiltration volumes retentate). 
  
Loading 
elutant 
Wash 1 Wash 2 Wash 3 Wash 4 Wash 5 Total 
  Concentration in ppm 
MIP 5.3 2.6 0.05 0 0 0 - 
NIP 5.2 2.6 0.04 0 0 0 - 
  Mass-recovery in mg 
MIP 4.26 2.06 0.04 0 0 0 6.35 
NIP 4.17 2.11 0.04 0 0 0 6.31 
  Mass-recovery in % 
MIP 82.6 40.0 0.7 0 0 0 123.3 
NIP 80.9 40.9 0.7 0 0 0 122.4 
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Figure 84 Percentage mass-recovery for API in removal test 2.1 (sample 3.6 diafiltration volumes retentate). 
 
The data for acetamide in removal test 2.1 indicates that the lower concentration acetamide is 
clearly retained by the MIP, as the recovery is close to zero in the load elutant and wash fraction 
1 compared to the NIP where 84.5 % of the acetamide is eluted in the 1st wash. Furthermore the 
API data display the same behavior as previously seen in removal test 1; that the majority of 
the API is eluted in the load elutant and the 1st wash fraction. The data obtained for both 
acetamide and API clearly indicate that for a low acetamide concentration of 25 ppm MIPs are 
an efficient polishing phase. Acetamide is successfully removed down to the specified levels 
while the overall API losses are estimated to be less than 1 %. 
 
Table 19 Acetamide concentration and mass-recovery in MIP and NIP samples from removal test 2.2 (sample 
3.0 diafiltration volumes retentate) 
  
Loading 
elutant 
Wash 1 Wash 2 Wash 3 Wash 4 Wash 5 Total 
  Concentration in ppm 
MIP 0 2.7 1.7 8.8 3.2 1.0 - 
NIP < 0.2 29.5 3.9 <0.2 <0.2 <0.2 - 
  Mass-recovery in µg 
MIP 0 2 1 7 3 0.8 14 
NIP 0 24 3 0 0 0 22 
  Mass-recovery in % 
MIP 0 6.9 4.3 22.3 7.8 2.6 44 
NIP 0 74.6 9.9 0 0 0 84 
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Figure 85 Percentage mass-recovery for acetamide in removal test 2.2 (sample 3.0 diafiltration volumes retentate). 
 
Following removal test 2.1, a second test was performed for the investigation of the loading 
capacity limit. Removal test 2.2 has a higher concentration acetamide sample, 3.0 diafiltration 
volumes retentate containing 40 ppm acetamide. The data obtained will give an indication on 
the minimum diafiltration volumes needed for the amount of MIPs used in this test to function 
satisfactory as a polishing phase. Data from removal test 2.2 using the 3.0 diafiltration volumes 
retentate sample is summarized in Table 19 and Figure 85 for acetamide and Table 20 and 
Figure 86 for the API. 
 
Table 20 API concentration and mass-recovery in MIP and NIP samples from removal test 2.2 (sample 3.0 
diafiltration volumes retentate). 
  
Loading 
elutant 
Wash 1 Wash 2 Wash 3 Wash 4 Wash 5 Total 
  Concentration in ppm 
MIP 5.7 2.7 0.1 0 0 0 - 
NIP 5.6 2.8 0.1 0 0 0 - 
  Mass-recovery in mg 
MIP 4.6 2.2 <0.1 0 0 0 6.8 
NIP 4.5 2.3 <0.1 0 0 0 6.8 
  Mass-recovery in % 
MIP 84 40 0.9 0 0 0 124 
NIP 83 41 0.8 0 0 0 124 
0
6,9
4,3
22,3
7,8
2,6
0
74,6
9,9
0 0 0
0
10
20
30
40
50
60
70
80
Loading
elutant
Wash 1 Wash 2 Wash 3 Wash 4 Wash 5
R
e
co
ve
ry
 (
%
)
MIP
NIP
146 
 
 
Figure 86 Percentage mass-recovery for API in removal test 2.2 (sample 3.0 diafiltration volumes retentate). 
 
The acetamide data indicate that acetamide is retained better on the MIP compared to the NIP 
and after wash 1 6.9 % acetamide is eluted from the MIP compared to 74.6% eluted from the 
NIP. The mass recovery data is also a good indication that the separation of acetamide on the 
MIP can be attributed to imprinting and not just the column effect. The MIP mass-recovery 
from the loading and washes 1-5 only adds up to 43.9 % indicating that significant amounts of 
acetamide remain on the MIP column, whereas the same number for the NIP is 84.4 %. For a 
conventional MIP test the column would be washed with methanol and 0.1 % formic acid 
directly after 100 % of the desired solute has eluted. However for this test methanol is disturbing 
the acetamide LC-MS analysis with overlapping peaks and to ensure accurate analysis the 
process solvent is used for all washes. The washing of the column is hence less effective 
resulting in some acetamide remaining in the column. 
 
The data obtained for the API shows that the entire amount of API is eluting in the loading 
fraction and in wash fraction 1.  Because some acetamide is eluting already in the wash fraction 
1 the API eluting in wash 1 is therefore lost. The early elution of acetamide in wash fraction 1 
indicates that the loading capacity of the MIPs are somewhere between 40 and 25 ppm (retentate 
concentrations after 3.0 and 3.6 diafiltration volumes passed). To ensure API purification 
without significant losses of API the MIP loading capacity must not be exceeded. 
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3.5.4 CONCLUSION HYBRID APPROACH 
 
This case study aims to investigate the combination of MIPs and OSN for application in the 
pharmaceutical industry. In order to demonstrate the viability of this hybrid approach the two 
techniques were tested separately and finally combined, so that a good comparison as well as 
eventual shortcomings of the techniques can be identified. 
 
The OSN experiments demonstrate feasibility for acetamide removal in both ethyl acetate and 
acetonitrile. In the case of removal in ethyl acetate the screening tests indicated that 
StarmemTM122 is the most suitable membrane for the specified experiment parameters, with a 
measured API rejection of 97.9 % and acetamide rejection of 1.4 %. Mass-balance calculations 
demonstrate that in order to reach the desired acetamide concentration of 0.1 ppm a total of 8.8 
diafiltration volumes are required. This would result in an estimated overall API loss of 16.8 % 
for the full process. Diafiltration results show that the overall loss of API after the second and 
last sample taken for the MIP testing, 3.6 diafiltration volumes, is 7.6 %. These results clearly 
demonstrate the feasibility of separation of the API and acetamide using OSN, however the 
large API losses in combination with high solvent requirements application in similar processes 
is not recommended. 
 
For the specified separation in acetonitrile, DuramemTM150 is deemed the most suitable 
membrane based on the obtained results. The measured rejection of API and acteamide was 
99.8 % and 5.2 % respectively. Mass-balance calculations indicate that a total of 8.7 diafiltration 
volumes are required to reach the desired acetamide concentration of 0.1 ppm. this results in an 
overall API loss for the full process of 1.7 %. Once again the solvent requirement for the 
diafiltration process is large, but the high rejection in acetonitrile results in a low overall loss 
of API. For this application in acetonitrile OSN might be a suitable alternative for acetamide 
removal nonetheless solvent usage must be evaluated compared to alternative techniques. 
 
The OSN experiments show that the acetamide rejections are generally low resulting in a rapid 
decrease in concentration over the initial diafiltration volume. After a limited volume of one 
diafiltration volume the API losses are still limited and OSN might be a suitable alternative for 
“rough” cleaning process. This is where the hybrid approach using OSN for initial “rough” 
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separation and MIPs as a polishing phase for removal of impurities to very low concentrations 
potentially could exhibit a benefit. 
 
The removal tests for the MIPs were limited to testing in ethylacetate. For removal test 1 where 
the starting concentration was loaded on the MIP column an imprinting effect could be 
distinguished, although no effective removal of acetamide was observed in the overall process. 
The results obtained indicate a clear over-loading of the column, reflected in amount of 
acetamide retained on the column after the loading. The main part of acetamide is eluted in 
wash fraction 1 and hence has a concentration close to the feed. This elution in the first wash 
fraction is therefore not suited for further processing and the API eluted in this fraction is 
unusable. The overall API loss hence adds up to a significant value of approximately 30 % 
indicating that it is not feasible to use MIPs for high concentration removal of acetamide.  
 
The full feed concentration removal test was followed by two removal tests using samples taken 
from the OSN retentate after different diafiltration volumes. For removal test 2.1 where the 
lowest concentration acetamide of 25 ppm was loaded on the MIP column, a clear separation 
of acetamide and the API can be observed. In comparison to the NIP the MIP effectively 
removes acetamide and thereby decreasing the concentration from 25 ppm to < 0.2 ppm. In 
addition more or less no API is retained on the column and after wash 1 everything is eluted, 
indicating that there is no cross-selectivity or binding site competition of the API on the MIP 
column. Hence the MIPs can effectively remove acetamide to the specified concentration with 
on overall API loss of less than 1 %. In removal test 2 a higher concentration of acetamide in 
the loading step was used. The small amount acetamide that is eluting in wash fraction 1 
indicates that the loading capacity of the MIPs is reached and must hence be between 25 and 
40 ppm for this experiment. So depending on the purity specifications of the API the amount 
of MIPs used can be adjusted accordingly.  
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3.6 HIGH-THROUGHPUT SYNTHESIS FOR MIPS VIA GRAFTING ON MEMBRANES 
 
There is a rather large number of parameters that can be varied during the optimization process 
of MIPs, hence conventional polymerization, processing and evaluation techniques are not 
suitable for optimizations where time is of the essence. This limits industrial applications of 
MIPs where time is often constrained, therefore new robust time-efficient screening techniques 
is of great importance for the future of MIPs in industry. The screening techniques available in 
literature today are based on combinatorial design and high-throughput synthesis and analysis 
to synthesis so called miniMIPs, basically monolithic MIPs scaled down. Automation of the 
process can easily be achieved by using liquid handling robots and 96-well microtiter and filter 
plates. The miniMIPs are synthesized in the 96-well microtiter plate followed by transfer of the 
miniMIPs to a 96-well filterplate, where the template removal and the template rebinding step 
is performed. With this method it is possible to synthezise and evaluate a library of miniMIPs 
in a couple of weeks. 227,228,229,230,231 
 
However, the time needed for synthesis and analysis of a library is still rather substantial and 
the critical step contributing to a large part of the time is template removal. Because of the small 
amounts of solvents used for washing and the inherent slow diffusion kinetics of the template, 
as many as 20-30 washing steps can be required. In order to reduce the time needed for library 
synthesis and analysis, Hovarth et. al. introduced thin polymer layers/films on the surface of 
porous membrane 96-well filter plates.232 The considerably decreased diffusion path length 
improves the template release and the washing can be performed in a flow-through mode. The 
grafting of thin MIP films on porous membrane surfaces has already been prepared for affinity 
purposes.233,234,235,236 This combination of thin film grafted membranes and filtration 
microplates offers a new system for high-throughput synthesis and testing of MIPs. It offers 
some advantages over the conventional miniMIP approach, for example less time-consuming 
template removal, flow-through mode instead of a large number of consecutive steps of batch 
washing, evaluation of imprinting effect can be performed in situ and that the material can be 
analyzed directly under SPE conditions.232 
 
The aim of this work is to develop this screening method further by combining the approach of 
Hovarth et al. 232 with the work published by Belfort et al. 237. A new high throughput system 
was developed using 96-well membrane filter plates by grafting directly from the membrane 
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by UV-initiation.  Belfort et al. has shown that a thin layer of monomers can be grafted on the 
surface of polyether sulfone (PES) membranes by immersion in a monomer mixture. The 
special feature of these membranes is that no initiator is needed because radicals are formed on 
the surface upon UV-radiation (Figure 87). During the development of the HTS using PES 
membranes two different types with pore sizes of 300 kDa and 0.45 µm were used. After the 
development of a working grafting procedure the template chosen for screening and imprinting 
was somatostatin. The reason for this is that in the following section the application of MIPs as 
catalysts, in this particular case the enhancement of cyclisation of the peptide somatostatin, will 
be investigated. 
 
 
Figure 87 Cleavage of PES from illumination by UV.237 
 
3.6.1 PREPARATION OF GRAFTED MEMBRANES 
 
The grafting on PES membranes follows a very simple procedure, where the membrane is first 
washed with methanol and deionized water to remove surfactants before use. Then the 
membrane is soaked in the monomer solution and subsequently illuminated with UV for 
grafting from the surface. Since the permeability of the membranes is a key attribute for the 
improved screening system it is important to be examined. For this purpose a stock solution 
with the ratio 1:3 of monomer to solvent was prepared.238,239 The mother solutions containing 
the template somatostatin, functional monomer acrylamide and MAA, cross-linker ethylene 
bisacrylmamide (EBA) were prepared from dilution of the stock solution. After soaking in the 
monomer solution the plate or loose membranes are placed in a special built glass box with 
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quartz lid, designed to create an oxygen free environment, in an incubator (Figure 88). After 
UV polymerization the template is removed by washing the membranes with warm 40 ⁰C 
methanol containing 1% formic acid. Template removal of somatostatin can be followed by 
measuring the fluorescence after each wash. Residual acid is washed away with extensive 
methanol. 
 
 
Figure 88 System setup for UV polymerization of the MIPs supported in microfiltration plates: (A) vacuum 
manifold, (B) nitrogen gas, (C) filterplate, (D) cling film, and (E) UVC lamp. Modified from reference 232. 
  
3.6.2 GRAFTING OPTIMIZATION AND METHOD FOR INITIAL TESTING  
 
In the first step the different pore sizes of the membrane were examined in order to find the 
most suitable one to avoid blockage of the pores. The two 96-well plates with the pore sizes 
300 kDa and 0.45µm were treated the same and polymerizations were carried out under the 
same conditions. For the first grafting test two different parameters were varied in order to find 
the optimal polymerization conditions, namely monomer dilution and polymerization time 
(Figure 89). An aqueous polymerization system was used, with acrylamide and MAA as the 
functional monomers, ethylene bisacrylamide (EBA) as the crosslinker, and somatostatin as the 
template. The cross-linking level was 50 %.  
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Figure 89 Schematic representation of the varying monomer dilution and polymerization time optimization. 
 
Independent of the monomer dilution and polymerization time, the 300kDa pore size 96-well 
filter plate does not seem suited for polymer grafting experiments.  During template removal it 
is observed that the 300 kDa filter plate is blocked and no washing solution passes through the 
membrane. The 45 µm pore size filter plate on the other hand is not blocked and the template 
is successfully removed. Hence, only the 45 µm pore size filter plate is used for further 
experiments. The template was removed with repeated washes of MeOH (40 ºC) containing 
1 % formic acid and the procedure was followed by fluorescence measurements at 375 nm. 
Template removal followed the same trend independently of monomer dilution and 
polymerization time, and two representative removal diagrams are shown in Figure 90. The 
template removal diagrams indicate that the template somatostatin is successfully removed after 
10 washes. The majority of somatostatin is washed out during the first five washes.  
 
 
Figure 90 Example of template removal for 20 minutes (left) and 50 minutes (right) polymerization time with 
1:20 monomer dilution. 
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Following template removal, a first preliminary rebinding test was performed. A solution of 
0.025 mM somatostatin in HEPES buffer was added to each well and equilibrated for 5 hours. 
The amount of bound somatostatin in percentage was calculated from the fluorescence 
measurements and summarized in Figure 91. Although the amount of bound somatostatin 
observed is rather low (roughly 20%), the obtained results indicate a difference in binding 
between the MIPs and NIPs for the grafted membranes with monomer dilutions of 1:5 and 1:20. 
When studying the binding percentages for these monomer dilutions over time, indication of a 
larger difference in binding between the MIPs and NIPs is observed for longer polymerization 
times. 
 
 
Figure 91 Rebinding test result, comparison of bound somatostatin between MIP and NIP. The values shown are 
in percentage (%). 
 
Following the first grafting optimization experiment further tests were performed to determine 
the optimal polymerization time. Since the first optimization test indicated that a longer 
polymerization time might be beneficial UV exposure times of up to 180 minutes were 
investigated (Table 21). In this test the polymerization mixture composition (monomer: solvent 
ratio 2:1) was kept constant in order to observe the exposure time influence in detail. Because 
of limited amounts of somatostatin the grafting optimization experiment was carried out with 
the cyclic peptide desmopressin as an analog.  
 
 
 
 
 
 
 
50 min 20 min 10 min 5 min 2 min 1 min
Ratio 1:3 NIP 11 8 5 11 13 4
MIP 26 22 15 17 19 23
Ratio 1:5 NIP 0 0 1 13 10 3
MIP 21 21 19 23 26 24
Ratio 1:20 NIP 0 3 1 6 5 3
MIP 24 19 23 21 35 12
Ratio 1:50 NIP 33 39 35 35 33 87
MIP 4 10 13 13 21 10
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Table 21 Summary of polymerization time optimization test. The monomer:solvent ratio is 2:1. A control non-
imprinted grafted membrane was also prepared. 
Composition of the polymerization mixture 
Compound Ratio 
Template Desmopressin 0.2 mmol 
Functional monomer Acrylamide 3 mmol 
Functional monomer Methacrylic acid 1 mmol 
Cross-linker Ethylene bisacrylamide 4 mmol 
Solvent HEPES buffer 0.48 ml 
Polymerization times 
min 
1, 5, 10, 30, 60, 90, 180 
 
After polymerization according to the specified times the membranes were cut out from the 
filter plate and analyzed with TGA. The thermal stability of the blank membrane was 
investigates by TGA for comparison of grafted membranes (Figure 92). The TGA curve of the 
blank PES membrane demonstrates one-step degradation with an onset temperature at 
approximately 500 ⁰C. This is slightly higher than observed for bulk polymers.  
 
 
Figure 92 TGA curve of the blank membrane. 
 
After polymerization and washing of the membranes TGA was performed in order to see if the 
grafting procedure may be monitored with this analysis. The curves for the NIP grafted 
membranes with polymerization times 5, 10, 30, 60, and 90 minutes are summarized in Figure 
93. It is observed that with increasing polymerization time the plateau between 200 ⁰C and 
400 ⁰C is higher, hence indicating a smaller weight loss. This may be explained by formation 
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of highly cross-linked polymer grafted to the membrane surface, indicating that a higher 
polymerization time is more beneficial. When comparing the TGA curves obtained for the 
polymerization times 90 and 180 minutes no difference in mass loss is observed, indicating that 
polymerization is completed (Figure 94). Thus, polymerization times longer than 90 minutes 
do not improve the grafting of the membranes. 
 
 
Figure 93 TGA curves of the grafted NIP membranes with different polymerization times; 5, 10, 30, 60, and 90 
minutes.  
 
 
Figure 94 TGA curves of the grafted NIP membranes comparing the two different polymerization times 90 and 
180 minutes.  
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The grafted NIP membrane with the polymerization time of 90 minutes was also analyzed with 
SEM to study the surface compared to a non-grafted blank PES membrane (Figure 95). A clear 
difference between the grafted and non-grafted surfaces can be observed. The surface of the 
non-grafted blank membrane is smooth and the pores are distinct, whereas the grafted 
membrane surface displays a rougher surface and blocked pores indicating that polymer is 
successfully grafted on the membrane surface. Both membrane surfaces were additionally 
analyzed with EDX to obtain information on the elemental composition (Table 22). The grafted 
NIP and MIP membranes display an increased amount of nitrogen compared to the non-grafted 
membrane, indicating that polymer is successfully grafted on the surface. As a result of nitrogen 
containing monomers being present on the surface. The slightly higher level of nitrogen present 
on the MIP membrane compared to the NIP membrane can be explained by the template 
desmopressin. 
 
 
Figure 95 SEM images of grafted PES membrane, 90 minutes exposure time (top) and non-grafted blank PES 
membrane (down). 
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Table 22 Elemental composition of non-grafted blank membrane, NIP membrane, MIP membrane determined 
by EDX analysis. 
 Elemental composition 
Sample name 
C 
(%) 
N 
(%) 
O 
(%) 
S 
(%) 
Blank membrane 63.46 0.41* 30.11 5 
NIP membrane 57.77 4.9* 32.01 4.66 
MIP Membrane 54.29 7.23* 34.65 2.91 
  *>2 Sigma   
 
The SEM images displayed partially blocked pores by grafted polymer. Hence, following the 
polymerization time optimization the amount of grafted polymer on the surface is investigated. 
For proper function of the membranes it is crucial that the grafting of polymers do not block 
the pore and thus decrease the permeability to the extent where a solution can pass through the 
membrane anymore. For the grafting optimization loose membranes were soaked in the pre-
polymerization mixture and subsequently polymerized under UV for 90 minutes. In order to 
calculate the grafting amount the membranes were weighed before and after polymerization. In 
this experiment two different cross-linking levels are used to investigate the influence of cross-
linker amount of pore blockage (namely 20 % and 40 %), in addition one NIP pre-
polymerization was prepared for each cross-linking level. The composition of the pre-
polymerization mixtures is summarized in Table 23. 
 
After polymerization, washing in methanol, and drying the membranes were weighed and the 
amount of grafted polymer was calculated for the MIP membranes. Furthermore, the 
permeability of the MIP and NIP membranes was compared to a blank membrane, in order to 
gain information about blockage of the pores. The results for the grafting and permeability are 
shown in Table 24. It is observed that the amount of grafted polymer increases slightly with 
40 % cross-linking level compared to the membrane grafted with 20 % cross-linking level. This 
observation may be expected with the larger amount of cross-linker. However, with the 
increased amount of grafted polymer the permeability of the membrane subsequently decreases, 
thus indicating that the pores of the membrane are getting blocked. 
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Table 23 Composition of the polymerization mixtures used in the grafting optimization experiment. The NIP 
pre-polymerization mixtures were prepared according to the same compositions but without the template. 
Composition of the polymerization mixtures 
MIP 20% CL 
Template Somatostatin 4 µmol 
Functional monomer Methacrylamide 40 µmol 
Functional monomer Methacrylic acid 280 µmol 
Cross-linker Methylene bisacrylamide 80 µmol 
Solvent Phosphate buffer, 50 mM pH 7 500 µL 
MIP 40%CL 
Template Somatostatin 4 µmol 
Functional monomer Methacrylamide 40 µmol 
Functional monomer Methacrylic acid 200 µmol 
Cross-linker Methylene bisacrylamide 160 µmol 
Solvent Phosphate buffer, 50 mM pH 7 500 µL 
 
The SEM images further support the blockage of the pores with increasing cross-linking level 
(Figure 96). It can be observed that with the 40 % cross-linking level a larger amount of polymer 
is formed at the surface and that the pores are more blocked. Although the permeability of the 
membrane grafted with 20 % cross-linking level also displays a decrease, it is not as large as 
for the 40 % cross-linking level and can thus be considered acceptable for the purpose of this 
thesis. Grafting of polymer on the surface will subsequently increase the polymer density on 
the surface and consequently block the pores, so a balance between the amount of polymer 
grafted and the permeability of the membrane needs to be found. 
 
Table 24 Amount of grafted polymer and permeability of the MIP membranes with 20 % and 40 % cross-linking 
and blank membrane for comparison. 
 
Grafted polymer 
amount 
Permeability 
  mg ml/min 
MIP 20 % CL 5.2 218 
MIP 40% CL 7.9 152 
Blank membrane - 333 
 
 
159 
 
 
Figure 96 SEM images of the MIP grafted PES membranes with 20 % cross-linking (top) and 40 % cross-linking 
(bottom). 
 
Following the grafting optimization where the 20 % cross-linking level grafted membrane was 
established as the most suitable membrane composition for HTS grafting of membrane filter 
plates, a rebinding test over time was performed to investigate the imprinting effect. The 20 % 
cross-linking level MIP membrane and the corresponding NIP membrane were soaked and 
equilibrated in 1 mg/ml somatostatin phosphate buffer. Sampling was done at different times 
and analyzed by HPLC to determine any difference between the MIP and NIP membranes. The 
resulting rebinding curves demonstrate a saturation of somatostatin binding over time for both 
the MIP and NIP membranes (Figure 97). After the full 24 h equilibration it is observed that 
saturation for the MIP and NIP has been reached and no difference in binding amount can be 
detected. Although the MIP membrane bind marginally more than the NIP membrane, the 
saturation effect is observed at 7 h equilibration as well. However, even though the binding 
results indicate that there is no difference in binding between the MIP and NIP membrane after 
saturation, a difference is displayed for the first three data points where the MIP membrane 
binds more somatostatin than the NIP membrane. This can probably be explained by imprinting 
sites being present in the MIP membrane and not only non-specific binding sites as for the NIP 
membrane. Overloading of the binding capacity is a possible explanation why the MIP and NIP 
160 
 
display the same saturation level after longer equilibration time. Since the purpose of the HTS 
imprinted membrane plates is to be tested by directly passing the template solution over the 
membrane without any significant equilibration time, the difference observed in the first data 
points thus indicate that the imprinted membranes may be a suitable screening technique. 
   
 
Figure 97 Rebinding test results over time for the MIP and NIP grafted membrane with 20 % cross-linking level. 
Sampling at; 1 h, 3 h, 5 h, 7 h, and 24 h. 
 
3.6.3 CONCLUSION HIGH-THROUGHPUT SYNTHESIS FOR MIPS VIA GRAFTED 
MEMBRANES 
 
In this experiment a novel and more effective HTS screening method for MIP libraries was 
developed. General mini-libraries are time-consuming with several steps including moving the 
polymers from the polymerization tray to a filter plate for template extraction. With MIP grafted 
membrane surfaces the screening process is more straightforward. The grafting polymerization 
process, with radicals forming at the surface because of cleavage of PES by UV illumination 
(Figure 87), support polymer chain growth at the pore surfaces.  
 
Successful grafting of both membrane filter plates and loose membrane discs is supported by 
calculations of the grafting amount and permeability. Furthermore TGA, SEM and EDX 
analysis also strongly indicate that polymer is successfully grafted on the membrane surface. 
The results display that there is a delicate line between the amount of polymer grafted and 
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blockage of the pores. Since permeability of the membranes after grafting of the MIP is an 
important characteristics for successful screening of MIPs. Thus it is imperative to find the 
optimal polymerization conditions for the grafting amount so that a difference in binding 
behavior can be observed without sacrificing permeability of the membrane.  
 
The rebinding tests performed on both the grafted membranes filter plates and grafted loose 
membrane discs display that a difference in binding between the MIP and NIP can be observed. 
This is a good indication that grafted membrane filter plates can be used for efficient screening 
of MIP libraries.  
 
3.7 SOMATOSTATIN IMPRINTED POLYMERS FOR CATALYTICALLY 
APPLICATIONS 
 
One interesting application of MIPs is as catalysts. As mentioned in the introduction examples 
of MIPs used as catalysts have been published in literature. In this chapter the feasibility to use 
MIPs as catalysts for cyclic peptide synthesis in pharmaceutical industry is examined. 
Therapeutic peptides offer a great potential of new and powerful targets and applications for 
the pharmaceutical industry (for more details see section 1.7). However the inherent challenges 
handling and synthesizing peptides calls for new and innovative solutions.  
 
A common method for the synthesis of peptides is the so called solid phase peptide synthesis 
(SPPS).240 This technique is based on the growing peptide chain being immobilized on a solid 
porous support enabling a facile wash step in order to remove e.g. unreacted reagents or side-
products. SPPS is performed by repeated cycles commencing with a coupling reaction of a 
protected amino acid to the support, followed by a wash and then deprotection and finishing 
with an additional wash step. When synthesizing a cyclic peptide connected via a sulfur bridge 
there is always a risk of dimerization and oligomerization, i.e. two or more peptide chains are 
bound together instead of an intra reacted sulfur bridge. Here MIPs could possibly offer a 
solution to this problem by functioning as catalysts, where the binding pockets imprinted with 
the cyclic peptide somatostatin could possibly promote the cyclization over dimerization and 
oligomerization (Figure 98). 
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Figure 98 Schematic drawing of how somatostatin imprinted polymers in theory could promote cyclisation of the 
peptide and thus minimize dimerization. 
 
3.7.1 SOMATOSTATIN IMPRINTED BULK POLYMERS  
 
The first generation imprinted somatostatin polymers for applications as catalysts were 
synthesized in bulk format using organic solvents as porogens. Although peptides can be 
difficult to dissolve in organic solvents they are suitable for imprinting purposes because they 
are less polar than aqueous solutions, and thus do not compete with the template - monomer 
interactions. Solubility test showed that methanol and acetonitrile containing 1% trifluoretic 
acid (TFA) were the most suitable solvents to use for the imprinting of somatostatin. In order 
to investigate whether the somatostatin is degraded or structurally affected, the polymerization 
was initiated with both UV and 50 ⁰C. Composition of the pre-polymerization mixture used for 
the synthesis is summarized in Table 25. 
 
Table 25 Composition of the pre-polymerization mixture of the somatostatin imprinted polymers. 
Name Composition Stoichiometry Porogen Polymerization 
Som MIP 1 T/MAA/EDGMA 
0.2/4/20 MeCN with 1% TFA UV 
Som NIP 1 MAA/EDGMA 
Som MIP 2 T/MAA/EDGMA 
0.2/4/20 MeCN with 1% TFA 50 ⁰C 
Som NIP 2 MAA/EDGMA 
Som MIP3 T/MAA/EDGMA 
0.2/4/20 MeOH 50 ⁰C 
Som NIP3 MAA/EDGMA 
 
After template removal by extraction, crushing and sieving the polymers were slurry packed in 
HPLC-columns for analysis. A 1 mM somatostatin in 10 % acetic acid solution was injected to 
S-S 
-SH 
-SH 
Oxidation 
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study whether a difference in the retention of somatostatin is present in the polymers. The only 
polymer that displayed retention of the injected somatostatin was Som MIP 1 and the resulting 
chromatograms of cross-reactivity testing between somatostatin and desmopressin are 
displayed in Figure 99. The results show that the somatostatin imprinted polymer retains 
somatostatin better than the corresponding NIP, retention time of 26 min and 11 min 
respectively. The broad and tailing somatostatin retention peak observed is typical of imprinted 
polymers, indicating that specific binding sites are present in the polymer. Desmopressin on the 
other hand has roughly the same retention time, approximately 5 minutes, on both the MIP and 
NIP, suggesting that specific binding sites are present in the somatostatin imprinted polymer.  
 
Figure 99 Retention of somatostatin (red) and desmopressin (blue) on Som MIP 1 and Som NIP 1 in HPLC 
analysis. 1 mM somatostatin in 10 % acetic acid (HAc) solution. Mobile phase 95% ACN 5% H2O 0.1% HAc. 
 
Since one of the objectives for the application of MIPs as catalysts is peptide synthesis, the 
synthesized MIPs need to demonstrate functionality in aqueous solutions. Thus further HPLC-
analysis was performed to investigate the binding behavior in different mobile phases. With the 
95 % MeCN 5 % H20 0.1 % HAc mobile phase as a starting point a number of different MeCN 
mixtures were tested for the Som MIP 1 (Figure 100). The results display that for three of the 
mobile phases, no elution of somatostatin is detected, represented by columns with 120 minute 
elution time. This behavior is consistently observed for the mobile phases not containing any 
acid. Although elution is observed for the 50 % MeCN 50 % H2O mobile phase, the retention 
times are very long at around 1 hour. The acid containing mobile phases on the other hand do 
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display elution of somatostatin. However, the results indicate that TFA is too strong an acid 
because the TFA containing mobile phases do not retain the peptide at all.  
 
The results where somatostatin is completely retained on the column can possibly be explained 
by precipitation of somatostatin in MeCN and MeCN/ H2O mobile phases. The precipitation 
seems to be hindered by addition of an acid in the mobile phase.  However, addition of a strong 
acid indicates that the acid compete with the non-covalent interactions between the template 
and the functional groups in the binding site, thus somatostatin is not retained in the column. 
Using the less strong acetic acid seems to be a good choice for a balance between avoiding 
precipitation and still observing specific binding of somatostatin.  
 
 
Figure 100 Evaluation of retention of somatostatin in different mobile phases. 
 
The somatostatin imprinted bulk polymer showed that the template was successfully retained 
on the column during HPLC-analysis, thus indicating selective binding sites. However, with 
limited solubility and precipitation problems the somatostatin imprinted polymers do not 
demonstrate any binding in aqueous solutions. For application of MIPs as catalysts in peptide 
synthesis in aqueous solution, new somatostatin imprinted polymers using water compatible 
monomers and cross-linkers have to be synthesized. 
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3.7.2 SOMATOSTATIN IMPRINTED MINIMIP LIBRARY 
  
The first generation imprinted somatostatin bulk polymers showed good imprinting effect in 
organic solvents but they failed to perform in aqueous solutions. In an attempt to find the 
optimal composition for somatostatin MIPs exhibiting imprinting in aqueous solutions a 
miniMIP library was prepared for screening. The parameters investigated were cross-linking 
level and functional monomer composition (Figure 101). Phosphate buffer was used as the 
porogen and two comonomers N-isopropylacrylamide (NIPAM) and methacrylamide (MAAm) 
were used. The molar ratio between the template somatostatin and total monomer was kept 
constant for the library (1:100). An automated robot system was used to prepare the library in 
a 96-well plate and polymerization was initiated thermally. A control NIP plate was prepared 
in the same way but without template. After polymerization was completed the miniMIPs were 
transferred to a filter plate for template removal by extensive washing. The template extraction 
was followed by fluorescent measurements. Rebinding tests were performed to find the most 
promising compositions. 
 
    Comonomer NIPAM Comonomer MAAm 
Funtional 
monomer   None HEMA DMAEMA MAA 4-VP MAA+4-VP None HEMA DMAEMA MAA 4-VP MAA+4-VP 
   1 2 3 4 5 6 7 8 9 10 11 12 
A  10% CL  5% 5% 5% 5% 5%  5% 5% 5% 5% 5% 
B 10% CL  10% 10% 10% 10% 10%  10% 10% 10% 10% 10% 
C 20%CL  5% 5% 5% 5% 5%  5% 5% 5% 5% 5% 
D 20%CL  10% 10% 10% 10% 10%  10% 10% 10% 10% 10% 
E 30%CL  5% 5% 5% 5% 5%  5% 5% 5% 5% 5% 
F 30%CL  10% 10% 10% 10% 10%  10% 10% 10% 10% 10% 
G 40% CL  5% 5% 5% 5% 5%  5% 5% 5% 5% 5% 
H 40% CL   10% 10% 10% 10% 10%   10% 10% 10% 10% 10% 
Figure 101 Overview of the library prepared with different cross-linking levels and monomer compositions. 
Porogen 50 mM phosphate buffer pH=7. The molar ratio template to total monomer was 1:100. Where N,N'-
Methylenebisacrylamide (MBA) is the cross-linker; methacrylic acid (MAA), 2-Hydroxyethyl methacrylate 
(HEMA), 4-vinylpyridine (4-VP), 2-(dimethylamino)ethyl methacrylate (DMAEMA) are functional monomers; 
methacrylamide (MAAm), N-isopropylacrylamide (NIPAM) are co-monomers. 
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Rebinding test was performed to screen the MIP and NIP filter plates. The amount of 
somatostatin bound was determined by bicinchoninic acid (BCA) assay and for facilitating the 
evaluation the results are color coded according to the amount bound (Figure 102). The 
rebinding results demonstrate some imprinted polymer compositions that selectively bind more 
somatostatin over the corresponding NIPs. Based on the binding capacity data and the 
imprinting factors of the library as shown in Figure 103 monomer compositions that tend to 
form successfully imprinted polymers can be distinguished and thus give an indication of 
composition to scale up.   
 
  Concentration (µg bound/mg polymer)    
  1 2 3 4 5 6 7 8 9 10 11 12    
A 
MIP 
    
3,1 1,7             3,2      0-1 µg/mg 
NIP 1,6 1,6             1,9      1-2 µg/mg 
B 
MIP 
    
2,9 3,3   2,3     2,1     2,4    2-3 µg/mg 
NIP 2,9 3,3   2,1     0,6     0,1    3< µg/mg 
C 
MIP 
    
2,4 2,6   3,9                
NIP 1,9 2,4   1,9                
D 
MIP 
      
        2,3   2,2        
NIP         1,6   1,4        
E 
MIP 
      
        0,4     2,4 2,8    
NIP         0,4     1,4 0,2    
F 
MIP 
    
  3,7   1,7     0,7   0,3 1,1    
NIP   2,0   0,8     0,0   0,0 0,1    
G 
MIP 1,9 
  
1,9 2,1     0,0 3,2 1,6 3,0 1,8 1,9    
NIP 0,2 1,6 2,1     0,0 0,0 1,0 1,0 1,1 1,0    
H 
MIP 
    
1,8     1,9         0,7 1,1    
NIP 1,7     1,2         0,4 0,5    
Figure 102 Rebinding test results of the MIP library. 0.4 mg somatostatin in 500 µl phosphate buffer was added 
to each polymer and equilibrated for 24 h. For numbers marked red the MIP and NIP bind an equal amount of 
somatostatin. 
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  Imprinting factor mass bound MIP/mass bound NIP    
  1 2 3 4 5 6 7 8 9 10 11 12    
A 
MIP 
<1 <1 1,9 1,1 <1 <1 <1 <1 <1 <1 1,6 <1 
   
NIP    
B 
MIP 
<1 <1 1,0 1,0 <1 1,1 <1 <1 3,5 <1 <1 25,7 
   1 IF 
NIP    1 - 2 IF 
C 
MIP 
<1 <1 1,3 1,1 <1 2,1 <1 <1 <1 <1 <1 <1 
   2-5 IF 
NIP    5> IF 
D 
MIP 
<1 <1 <1 <1 <1 <1 <1 1,4 <1 1,6 <1 <1 
   
NIP    
E 
MIP 
<1 <1 <1 <1 <1 <1 <1 1,0 <1 <1 1,7 12,8 
   
NIP    
F 
MIP 
<1 <1 <1 1,9 <1 2,1 <1 <1 0,7/0 <1 0,3/0 8,1 
   
NIP    
G 
MIP 
11,2 <1 1,2 1,0 <1 <1 3,2 3,2/0 1,5 3,1 1,6 1,9 
   
NIP    
H 
MIP 
<1 <1 1,1 <1 <1 1,7 <1 <1 <1 <1 1,9 2,2 
   
NIP    
Figure 103 Calculated imprinting factors for the MIP library. For the rebinding test 0.4 mg somatostatin in 500 µl 
phosphate buffer was added to each polymer and equilibrated for 24 h. For numbers marked red the imprinting 
factor is equal to 1. 
 
When comparing the results depending on the co-monomer used with varying functional 
monomers it can be observed that the co-monomer MAAm display more imprinted polymer 
compositions than NIPAM, 18 and 13 respectively (Figure 104). Furthermore, the rebinding 
data also indicate that DMAEMA, MAA, 4-VP, and a combination of MAA and 4-VP are 
suitable functional monomers for successful imprinting of somatostatin. The results also 
indicate that the higher cross-linker content 30 % and 40 % might be beneficial for successful 
imprinting. This can probably be explained by that with the lower cross-linker levels the formed 
polymers are gel-like and can thus swell in solution. A certain amount of cross-linking is 
necessary to form rigid specific binding sites able to recognize the imprinted template, with too 
much swelling the binding site may no longer structurally correspond to the template. 
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Figure 104 Number of polymers with imprinting for the two co-monomers with varying functional monomers. 
 
The screening of the miniMIP library displayed some hit polymer compositions and with this 
in mind different polymer compositions were scaled up for further testing. Based on the 
rebinding results from the miniMIP library it was decided to use different combinations of 
MAA and 4-VP as functional monomers, MAAm as the co-monomer and MBA as the cross-
linker, the exact composition is summarized in Table 26. Two different cross-linking levels 
were used, whereas the molar ratio of the functional monomer was kept constant in the 
experiment. An example of the prepared polymers is shown in Figure 105 displaying a slight 
discoloration of the MIP compared to the NIP after polymerization. This might be explained by 
possible degradation of somatostatin during the polymerization process. 
 
Table 26 Composition of the scaled up somatostatin imprinted polymers from the miniMIP library. 
  Somatostatin MAA 4-VPy MAAm MBA Mol ratio 
PM1 4.0 20 20 280 80 4:40:280:80 
PM2 4.0 40 - 280 80 4:40:280:80 
PM3 4.0 - 40 280 80 4:40:280:80 
PM4 4.0 20 20 200 160 4:40:200:160 
PM 5 4.0 40 - 200 160 4:40:200:160 
PM6 4.0 - 40 200 160 4:40:200:160 
PN1 - 20 20 280 80 40:280:80 
PN2 - 40 - 280 80 40:280:80 
PN3 - - 40 280 80 40:280:80 
PN4 - 20 20 200 160 40:200:160 
PN5 - 40 - 200 160 40:200:160 
PN6 - - 40 200 160 40:200:160 
1 1
4
3
0
4
1
2
3
2
5 5
NIPAM
MAAm
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Figure 105 Prepared PN1 (left) and PM1 (right) after polymerization. 
 
After polymerization the template somatostatin was removed with repeated washes of H2O: 
MeOH: FA (60:20:20) and the fractions were analyzed with HPLC. The chromatograms from 
the HPLC analysis are summarized in Figure 106 where the first and last washes are displayed. 
It can be observed that somatostatin is successfully removed from the polymers, this is further 
supported by the calculated recovery of the template (Figure 107). The low recovery percentage 
for PM2 can be explained by loss of the first washing fraction. 
 
  
  
Figure 106 HPLC chromatogram of: A) The first washing fraction of MIP, B) last washing fraction of MIP, C) 
The first washing fraction of NIP, D) The last washing fraction of NIP. 
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Figure 107 Calculated recovery of template from template extraction. The first washing fraction of PM2 was 
lost hence the low recovery percentage.  
 
In order to determine the polymer amount needed for the rebinding test, a sample of PM2 was 
first dried by filtration and subsequently analyzed with TGA. Based on the results observed in 
Figure 108 it is predicted that 15% of the weight is polymer. Hence 100 mg of wet polymer was 
used for the rebinding tests with a theoretical dry weight of 15 mg.    
 
 
Figure 108 Determination of dry weight of PM2 by TGA. 
 
For the rebinding tests 100 mg of wet polymers was incubated with two different somatostatin 
concentrations (10 µM and 100 µM) for 24 hours and analyzed with HPLC.  For the resulting 
rebinding test results for the somatostatin imprinted polymers it is observed that PM2 and PM5 
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bind more somatostatin than their corresponding NIPs (Figure 109), indicating that the polymer 
composition with only MAA a the functional monomer form specific binding sites for both 
cross-linking levels used. The binding capacity displayed for PM2 is slightly higher than for 
PM5, this can probably be explained by the lower cross-linking level allowing the polymer to 
swell more and thus making the binding sites accessible for binding of somatostatin. Evaluation 
of the imprinting factors for the polymers shows that the highest imprinting factor is obtained 
for PM2 at the lower rebinding concentration, however for the higher concentration the 
imprinting factor is significantly decreased from 21 to 1.5 (Figure 110). This observation might 
be explained by overloading of the polymer and thus non-specific binding behavior becomes 
more significant.   
 
  
  
  
Figure 109 Rebinding test for polymer P1-P6: Somatostatin (10 µM and 100 µM), phosphate buffer pH 7, 24 h. 
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The up-scaling experiments showed that somatostatin imprinted polymers for rebinding in 
aqueous solutions were successfully synthesized. In addition the results obtained from the 
screening of the miniMIP library gave a good indication of suitable polymer compositions for 
larger scale imprinted polymers. 
 
Figure 110 Imprinting factors for PM1 to PM6. 
 
3.7.3 CATALYTIC TESTING OF SOMATOSTATIN IMPRINTED POLYMERS   
 
With the successful development of somatostatin imprinted polymers in section 3.6.2 
demonstrating specific binding of somatostatin in aqueous solutions, the possibility to use these 
MIPs as catalysts for cyclisation of linear somatostatin is investigated. A first preliminary 
concept experiment is performed with the somatostatin imorinted polymer PM2 that 
demonstrated a good selective binding of somatostatin in section 3.6.2. 
 
As a result of only the cyclic somatostatin product being available, the first step of the 
experiment is to open the cyclic somatostatin to form linear peptides. A reduction protocol that 
opens the thiol ring was adapted from one used by colleagues in the group. Dithiothreitol (DTT) 
(50 mM) was prepared in phosphate buffer and added to the peptide solution. Following shaking 
over night, the samples were analyzed with LC-MS and compared with a sample containing the 
non-reduced cyclic somatostatin. LC-MS analysis showed that with the reduction protocol the 
linear form of somatostatin could be detected. 
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Following the reduction test an oxidation protocol was tested for ring closing. The oxidation 
protocol promotes intramolecular disulfide formation by potassium ferricyanide. Efficient rates 
of oxidation have been reported, and has proved to be especially efficeient for the somatostatin 
family, when using the relatively mild inorganic oxidizing reagent potassium ferricyanide 
(K3Fe(CN)6) .241  
 
After reduction of the somatostatin samples 0.01 M K3Fe(CN)6 solution in phosphate buffer 
was added in 20 % excess of the theoretical peptide amount and after oxidation over 4.5 hours 
the samples were analyzed with LC-MS. In this first experiment the concentration of the linear 
and cyclic amount of somatostatin could not be determined, thus the ratio between linear and 
cyclic somatostatin was compared in oxidized somatostatin sample without polymer, and 
oxidized somatostatin in the presence of PM2 and PN2 (Table 27). In addition an experiment 
with desmopressin was performed in the same manner to investigate the selectivity of any 
possible catalytic cyclisation of the somatostatin imprinted polymers. 
 
Table 27 Ratio linear:cyclic peptide after oxidation with K3Fe(CN)6 solution.  
Ratio linear: cyclic peptide 
  Somatostatin Desmopressin 
Oxidation no polymer 105 475 
Oxidation PN2 44 390 
Oxidation PM2 35 363 
 
Although the results obtained are not quantitative the differences in ratios between linear to 
cyclic can be observed. The results display that for every cyclic peptide detected there are 105 
linear somatostatin peptides and 475 linear desmopressin tested in absence of polymer. When 
comparing the corresponding values for oxidation in the presence of PN2 and PM2 the ratios 
for somatostatin are smaller than in the free solution. It is also observed that the ratio for PM2 
is smaller compared to the PN2 ratio, thus indicating that as possible promotion of cyclisation 
is occurring in the PM2 sample. The fact that the ratios for both PM2 and PN2 are smaller 
compared to free solution might be explained by peptide being retained on the polymer, as the 
solutions were measured directly from the samples and no washing of the polymers was 
performed before analysis. This can also be seen when studying the peak areas (Appendix). 
Furthermore, the results observed for oxidation of desmopressin, indicate that desmopressin is 
not retained to the same extent as somatostatin on the polymers since the ratios of free solution 
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and polymer differentiate less compared to somatostatin. The desmopressin results might be an 
indication of the somatostatin imprinted polymers selectively promoting cyclisation of linear 
somatostatin. 
 
3.7.4 CONCLUSION SOMATOSTATIN IMPRINTED POLYMERS FOR 
CATALYTICALLY APPLICATIONS   
 
Therapeutic peptides offer a great potential of new and powerful targets and applications for 
the pharmaceutical industry (Section 1.7). However the inherent challenges handling and 
synthesizing peptides calls for new and innovative solutions. The objective for this chapter was 
to investigate the application of MIPs as catalysts for cyclic peptide synthesis in pharmaceutical 
industry. In this work the cyclic peptide somatostatin is used for feasibility testing and a second 
cyclic peptide, desmopressin, is used as a control for selectivity of the imprinted polymers.  
 
The first approach was to use bulk polymerization in organic for imprinting of somatostatin. 
The successfully synthesized polymer showed that the template was successfully retained on 
the column during HPLC-analysis, thus indicating selective binding sites. Furthermore, the 
cross-reactivity test of injecting desmopressin, a peptide very similar in shape and size, did not 
display retention like for somatostatin, thus supporting the observation of somatistatin selective 
binding sites.  As a result of problems with precipitation and limited solubility no retention of 
somatostatin was observed in aqueous solutions. For application of MIPs as catalysts in peptide 
synthesis in aqueous solution, new somatostatin imprinted polymers using water compatible 
monomers and cross-linkers are evaluated. 
 
For the second approach a miniMIP library was used for screening of monomer compositions 
forming good imprinted binding sites for somatostatin. Two 96-well plates, one MIP and one 
NIP, with varying functional monomers, co-monomers and cross-linking levels, were 
successfully prepared and analyzed. The results obtained from the rebinding test display that 
the co-monomer MAAm exhibit more successfully imprinted polymer compositions than 
NIPAM. Furthermore, the rebinding data also indicate that DMAEMA, MAA, 4-VP, and a 
combination of MAA and 4-VP are suitable functional monomers for successful imprinting of 
somatostatin. The results also indicate that the higher cross-linker content 30 % and 40 % might 
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be beneficial for successful imprinting. This might be explained by that with the lower cross-
linker levels the formed polymers do not exhibit rigid binding sites because of their gel-like 
appearance and inherent swelling behavior. Therefore the swelling might lead to decreased 
recognition of the imprinted template. 
 
Based on the screening of the miniMIP libraries a total of six polymer compositions were scaled 
up with three different functional monomers composition and two cross-linking levels. The up-
scaling experiments showed that somatostatin imprinted polymers for rebinding in aqueous 
solutions were successfully synthesized. In addition the results obtained from the screening of 
the miniMIP library gave a good indication of suitable polymer compositions for larger scale 
imprinted polymers. 
 
With the objective of the chapter in mind, application of MIPs as catalysts, the polymer with 
the most promising selectivity for somatostatin was used to test the catalytically properties. The 
first preliminary tests showed that by using reduction and oxidation protocols for peptides, 
somatostatin and desmopressin could be opened and re-closed and followed by LC-MS 
analysis. By studying the linear to cyclic peptides ratios obtained by LC-MS, it can be observed 
that the ratio of linear to cyclic peptide decreases, meaning that the cyclic form increases and 
thus indicating that the presence of polymer promotes the cyclisation of somatostatin. 
Furthermore, the preliminary results suggest that the imprinted polymer promotes the 
cyclisation better than the corresponding NIP and the promotion also exhibits selectivity for the 
imprinted somatostatin as the desmopressin does not display any significant change in ratio 
compared to the free solution control sample. 
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4 CONCLUSION AND OUTLOOK 
 
In this work new molecularly imprinted polymer based scavangers for purification of small and 
large APIs are developed, analyzed and evaluated for application in pharmaceutical industry. 
The work can be broken down into three projects focusing on removal of small genotoxic 
impurities, new efficent screening method for MIPs, and MIPs as catalysts in peptide synthesis. 
 
Novel molecularly imprinted polymers have been designed and synthesized which can 
recognize pharmaceutical impurities such as acetamide, thioacteamide and aminopyrimidine. 
Thorough testing and evaluation have demonstrated the feasibilty to use MIPs as selective 
sorbents for purification of APIs. Rebinding tests indicate that high affinity interactions are 
present between the binding sites of the MIP and the target impurities, resulting in a high 
efficient purification. The new MIPs developed present a new and inventive purification 
technique for the pharmaceutical industry, and offer an efficeint and selective sorbent. 
 
With industrial applications in mind, where scalability, costs and efficiency are important 
factors to consider, different MIP formats were compared for optimization of a high capacity 
sorbent for pharmaceutical applications. The imputity chosen for imprinting was acetamide, as 
it was decided within the consortium that it is a good represenattion of small impurities in the 
pharmaceutical industry. The first generation bulk polymers were synthesized for optimization 
of the monomer composition and proof of concept. The strategy was to use common 
commercially available monomers and cross-linkers for facilitating future scale-up processes. 
HPLC analysis, batch rebinding test and SPE experiments demonstrated strong imprinting and 
high specific binding of acetamide. Thus highly specific MIPs could be synthesiszed using 
common commercial chemicals. However, for successful industrial application an improved 
loading capacity would be beneficial. 
 
Two further formats were synthesized with the aim to improve the binding capacity and with 
the same or better binding properties. The two formats chosen were super-porous MIPs and 
pore-filling of porous silica particles, where the idea was that the inherent defined porous 
characteristics would improve the desired features. For the synthesis the same monomer 
composition as for the bulk polymers was used, and with only the porogen amount and 
composition was altered for optimization. Both super-porous and pore-filled MIPs were 
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succesfully synthesized, they did however display some different characteristics. For the two 
different polymer formats the binding capacity in ethyl acetate is in general slightly higher than 
in acetonitrile. This observation might be explained by the difference in polarity of the two 
solvents, where the more polar acetonitrile disrupt the binding of acetamide. The super-porous 
polymers do not display an increase in binding capacity as expected, they do however exhibit 
an increased specific binding compared to the bulk polymers. An explanation for this 
observation may be that with the additional iso-octane in the pre-polymerization mixture acting 
as a bad solvent the self-assembly of acetamide and MAA is promoted, and thus creating 
stronger binding sites. Pore-filling polymer II and III on the other hand exhibit an increased 
binding capacity, with pore-filling polymer II being the better of the two with an increase of 
approximately 60 % compared to the bulk polymers. The increased binding capacity might be 
attributed to the more defined pores present in the pore-filling polymers after removal of the 
silica mold. In the bulk polymers the pore system is more heterogeneous and the higher binding 
capacity in the pore-filling polymers may be attributed to the more homogeneous pore system. 
This is supported by the SEM images displaying the pores in the polymers and by the porometry 
analysis performed where increased surface area is observed for the pore-filling polymers.  
 
In conclusion the rebinding tests in general demonstrate stronger specific binding for the super-
porous polymers and the pore-filling polymers compared to the bulk polymers. Furthermore the 
binding capacity for acetamide could successful be increased without sacrificing the specific 
binding via the pore-filling approach.  
 
With the imprinting of acetamide demonstrating that highly specific MIP based sorbents could 
be synthesiszed using commerical monomers, it is of great interest to investigate the imprinting 
and specific removal of other possible genotoxins. For MIP sorbents to become implemented 
as an alternative purification technique in industry the facile production and braod range of 
target compounds need to be demonstrated.  In order to further investigate the feasibility to use 
MIPs for purification of small active pharmaceutical ingredients the same monomer 
composition was used to imprint thioacetamide.  
 
Thioacetamide imprinted bulk polymers were successfully synthesized and evaluation of the 
MIP indicate the polymer contains specific binding sites for thioacetamide. Although the static 
rebinding tests display that no specific binding takes place in the MIP when tested in 
acetonitrile, the results in ethyl acetate display a strong specific binding in the MIP. This 
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observation may be explained by the difference in polarity of the two solvents, with acetonitrile 
being more polar than ethyl acetate. Furthermore, sulfur is slightly less electronegative than 
nitrogen thus probably less inclined to form strong hydrogen bonds with the functional 
monomer methacrylic acid. This may explain why the formation of thioacetamide specific 
binding sites is not as good as observed for the acetamide imprinted bulk polymers. The 
thioacetamide bulk polymers display an increased binding capacity in ethyl acetate compared 
to the acetamide bulk polymers. The SPE experiment performed in ethyl acetate further indicate 
that specific binding sites for thioacetamide are present in the MIP even if the difference 
between the MIP and the NIP is not so large. However, with further optimization of the polymer 
composition, such as another functional monomer or choice of porogen, more specific binding 
and higher binding capacities may be achieved. For the purpose of proof of concept in this 
thesis the results obtained are satisfactory. 
 
A third small impuruty was imprinted in order to further investigate the application of MIP 
based sorbents in pharmaceutical purification. Since specific binding of two small impurities 
using commercial available monomers has already been demonstrated in this work, this 
experiment study how versatile the monomer composition used for acetamide and 
thioacetamide is for pharmaceutical applications. The impurity imprinted in this experiment 
was 2-aminopyrimidine. In addition to MAA, a second commonly used monomer, 4-VP, was 
used. For the purpose of potentially transfer the MIPs to synthesis of imprinted OSN 
membranes, imprinting in DMF besides in toluene was performed.   
 
In total four 2-aminopyrimidine imprinted bulk polymers were successfully synthesized, 
however the evaluation of the polymers demonstrate that specific binding of the template is 
only present in the MIPs synthesized using MAA as the functional monomer. The polymers 
with 4-VP as the functional monomer unspecific binding seems to be more prominent. The 
preliminary rebinding tests display that polymers synthesized with MAA as the functional 
monomer in both toluene and DMF result in successfully imprinted polymers. When using the 
more polar solvent DMF it is observed that the binding capacity decreases slightly, indicating 
that the interaction between the template-monomer may be disrupted to some extent.  
 
It can be concluded from the first preliminary binding tests that specific binding of 2-
aminopyrimidine could be achieved using the same monomer composition as for acetamide and 
thioacetamide. Hence suggesting that MAA can be used over a broad range of impurities to 
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achive specific MIP sorbents. With the results in DMF displayingt specific binding of 2-
aminopyrimidine suggests that the MIP composition can be used in the synthesis of imprinted 
OSN membranes. However, with further testing and optimization of the polymer composition 
more efficient MIPs may be achieved. For the purpose of proof of concept in this thesis the 
results obtained are satisfactory. 
 
Within the framework of the NEMOPUR project two purification techniques were investigated, 
namely MIPs and OSN. Apart from studying MIPs and OSN separately it is also of interest to 
study the impact of combining the two. This case study aims to investigate the combination of 
MIPs and OSN for application in the pharmaceutical industry. In order to demonstrate the 
viability of this hybrid approach the two techniques were tested separately and finally 
combined, so that a good comparison as well as eventual shortcomings of the techniques can 
be identified. The benchmark for the study is a paper describing acetamide removal where a 
final concentration of 0.1 ppm acetamide is reached.226 
 
A membrane screening in acetaonitrile and ethyl acetate was performed for the OSN 
experiments in order to demonstrate feasibility for acetamide removal in both ethyl acetate and 
acetonitrile. These results clearly demonstrate the feasibility of separation of the API and 
acetamide using OSN, however the overall large API losses in combination with high solvent 
requirements means that the application for API purification might be limited. 
 
The OSN experiments show that the acetamide rejections are generally low resulting in a rapid 
decrease in concentration over the initial diafiltration volume. After a limited volume of one 
diafiltration volume the API losses are still limited and OSN might be a suitable alternative for 
“rough” cleaning process. This is where the hybrid approach using OSN for initial “rough” 
separation and MIPs as a polishing phase for removal of impurities to very low concentrations 
potentially could exhibit a benefit. 
 
The removal tests for the MIPs were limited to testing in ethylacetate. For removal test 1 where 
the starting concentration was loaded on the MIP column an imprinting effect could be 
distinguished, although no effective removal of acetamide was observed in the overall process. 
The results obtained indicate a clear over-loading of the column, reflected in the amount of 
acetamide retained on the column after the loading. The main part of acetamide is eluted in 
wash fraction 1 and hence has a concentration similar to the feed. This elution in the first wash 
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fraction is therefore not suited for further processing and the API eluted in this fraction is 
unusable. The overall API loss hence adds up to a significant value of approximately 30 % 
indicating that it is not feasible to use MIPs for high concentration removal of acetamide.  
 
The full feed concentration removal test was followed by two removal tests using samples taken 
from the OSN retentate after different diafiltration volumes. For the first removal test with a 
concentration of 25 ppm acetamide was loaded on the MIP column, a clear separation of 
acetamide from the API can be observed. In comparison to the NIP the MIP effectively removes 
acetamide and thereby decreasing the concentration from 25 ppm to < 0.2 ppm. In addition 
more or less no API is retained on the column and after wash 1 everything is eluted, suggesting 
that the API does not bind to the MIP. Hence the MIPs can effectively remove acetamide to the 
specified concentration with on overall API loss of less than 1 %. In the second removal test a 
higher concentration of acetamide in the loading step was used in order to examine the loading 
capacity of the MIP. However the results suggest that the loading capacity of the MIPs is 
reached because acetamide is eluting in already in the first washing step. Thus the loading 
capacity for the MIP is most likely between 25 and 40, hence depending on the purity 
specifications of the API the amount of MIPs used can be adjusted accordingly.  
 
The case study of the hybrid approach suggests that depending on the specified purification 
requirements, a combination of MIPs and OSN can be beneficial. The OSN membranes work 
as a first rough spearation with their high rejection values, and the MIPs function as a polishing 
phase with their high specific binding properties. However, before the hybrid approach can be 
imlemented on a large scale application in the pharmaceutical industry a number of process 
parameters need to be evaluated. Currently OSN and MIP are operated on different volume 
scales therefore scale-up should preferably be addressed as a future objective. For a better 
comparison of the two technologies with one and other, and with other conventional purification 
techniques further studies needs to be conducted. Where suggested parameters for process 
comparison include but are not limited to; obtainable impurity levels, API yield losses, solvent 
requirements, scale-up opportunities, maintenance and operational cost, equipment investment 
cost, and energy requirements. 
 
One of the drawbacks with MIPs is the time-consuming screening process for monomer 
compositions forming efficent imprinted polymers. For en implementation of MIP based 
sorbents in the pharmaceutical industry, functioning MIPs need to be developed in a timely 
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manner. The screening processes are precently based on miniMIPs, although this screening 
process is fairly fast, a couple of weeks is still quite some time. Therefore a novel and more 
effective HTS screening method based on grafting of membranes for MIP libraries was 
developed in this work. General mini-libraries are time-consuming with several steps including 
moving the polymers from the polymerization tray to a filter plate for template extraction. With 
MIP grafted membrane surfaces the screening process is more straightforward.  
 
It was shown that successful grafting of both membrane filter plates and loose membrane discs 
is supported by calculations of the grafting amount and permeability. Furthermore TGA, SEM 
and EDX analysis also strongly indicate that polymer is successfully grafted on the membrane 
surface. The results display that there is a delicate line between the amount of polymer grafted 
and blockage of the pores. Since permeability of the membranes after grafting of the MIP is an 
important characteristics for successful screening of MIPs. Thus it is imperative to find the 
optimal polymerization conditions for the grafting amount so that a difference in binding 
behavior can be observed without sacrificing permeability of the membrane.  
 
The rebinding tests performed on both the grafted membranes filter plates and grafted loose 
membrane discs display that a difference in binding between the MIP and NIP can be observed. 
This is a good indication that grafted membrane filter plates can be used for efficient screening 
of MIP libraries. It is suggested that future work should include screning of different templates 
in order to show that the screening process works over a broad range of compounds – from 
small to large. Furthermore, the screnning outcome should be directly compared to a 
conventional miniMIP library in order to evaluate if the screening can be transferred smoothly 
without any impact on the imprinting results.  
 
One interesting and growing part in pharmaceutical industry is peptide therapeutics. 
Therapeutic peptides offer a great potential of new and powerful targets and applications for 
the pharmaceutical industry. However, the inherent challenges handling and synthesizing 
peptides calls for new and innovative solutions, hence opening up an opportunity to implement 
MIPs. The objective for this chapter was to investigate the application of MIPs as catalysts for 
cyclic peptide synthesis in pharmaceutical industry. In this work the cyclic peptide somatostatin 
is used for feasibility testing and a second cyclic peptide, desmopressin, is used as a control for 
selectivity of the imprinted polymers.  
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The first approach was to use bulk polymerization in organic for imprinting of somatostatin. 
The successfully synthesized polymer showed that the template was successfully retained on 
the column during HPLC-analysis, thus indicating selective binding sites. Furthermore, the 
cross-reactivity test of injecting desmopressin, a peptide very similar in shape and size, did not 
display retention like for somatostatin, thus supporting the observation of somatistatin selective 
binding sites.  As a result of problems with precipitation and limited solubility no retention of 
somatostatin was observed in aqueous solutions. For application of MIPs as catalysts in peptide 
synthesis in aqueous solution, new somatostatin imprinted polymers using water compatible 
monomers and cross-linkers are evaluated. 
 
For the second approach a miniMIP library was used for screening of monomer compositions 
forming good imprinted binding sites for somatostatin. Two 96-well plates, one MIP and one 
NIP, with varying compositions, were successfully prepared and analyzed. The results obtained 
from the rebinding test display that the co-monomer MAAm exhibit more successfully 
imprinted polymer compositions than NIPAM. Furthermore, the rebinding data also indicate 
that DMAEMA, MAA, 4-VP, and a combination of MAA and 4-VP are suitable functional 
monomers for successful imprinting of somatostatin. The results also indicate that the higher 
cross-linker content 30 % and 40 % might be beneficial for successful imprinting. This might 
be explained by that with the lower cross-linker levels the formed polymers do not exhibit rigid 
binding sites because of their gel-like appearance and inherent swelling behavior. Therefore the 
swelling might lead to decreased recognition of the imprinted template. 
 
Based on the screening of the miniMIP libraries a total of six polymer compositions were scaled 
up with three different functional monomers composition and two cross-linking levels. The up-
scaling experiments showed that somatostatin imprinted polymers for rebinding in aqueous 
solutions were successfully synthesized. In addition the results obtained from the screening of 
the miniMIP library gave a good indication of suitable polymer compositions for larger scale 
imprinted polymers. 
 
In order to evaluate a possible application of MIPs catalysts, the up-scaled polymer with the 
most promising selectivity for somatostatin was used to test the catalytically properties. The 
first preliminary tests showed that by using reduction and oxidation protocols for peptides, 
somatostatin and desmopressin could be opened and re-closed and followed by LC-MS 
analysis. By studying the linear to cyclic peptides ratios obtained by LC-MS, it can be observed 
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that the ratio of linear to cyclic peptide decreases, meaning that the cyclic form increases and 
thus indicating that the presence of polymer promotes the cyclisation of somatostatin. 
Furthermore, the preliminary results suggest that the imprinted polymer promotes the 
cyclisation better than the corresponding NIP and the promotion also exhibits selectivity for the 
imprinted somatostatin as the desmopressin does not display any significant change in ratio 
compared to the free solution control sample. 
 
Although the results suggest that MIPs can function as catalysts and promote cyclisation of 
somatostatin, the results obtained are only preliminary. For future work a method where 
quantitative and not only qualitative determination of linear and cyclic somatostatin needs to 
be developed. One possibility is to use the so called Ellman analysis to determine the thiol group 
concentration in a sample. Furthermore, optimization of the sampling method should be 
performed, e.g. SPE format with washing of the MIPs to ensure that no peptide is bound to the 
polymer when analysing the samples. 
 
In conclusion the work described in this thesis suggests that MIPs may be an attractive new 
alternative purification method. It is also suggested that before succesful implementation of 
MIPs on a large scale, further work concerning scale-up, reproducibilty, good manufaturing 
practice, and process optimization should be performed.  
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5 EXPERIMENTAL 
5.1 MATERIALS 
 
Acetamide (AA) was obtained from Fluka (Buchs, Switzerland); Methacrylic acid (MAA), 
methacrylamide (MAAM), Ethylene glycol dimethacrylate (EGDMA) from Sigma Aldrich 
(Germany), Toluene, Acetonitrile (MeCN) and Trifluoroacetic acid (TFA) from Acros (Geel, 
Belgium) and Methanol (MeOH) from AppliChem GmbH (Germany); 2,2'-Azobis(2,4-
dimethylvaleronitrile) (ABDV) from Wako Pure Chemical Ind. Ltd. (Japan). Formic acid from 
AppliChem GmbH (Darmstadt, Germany. The amides used for the selectivity tests were the 
following; acrylamide from Sigma Aldrich (Germany), formamide from AppliChem GmbH 
(Darmstadt, Germany), benzamide from Fluka (Buchs, Switzerland), MAAM from Sigma 
Aldrich (Germany) and N-tert butylacrylamide from Sigma Aldrich (Germany). For the AA 
removal tests Etodolac was used and kindly provided by Lonza (Switzerland). Silicaparticles 
for the porefilling polymers (Si500, 0.16 cm3/g, 5 µm, 35 m2/g) were received from Silicycle. 
 
Before use EGDMA was purified according to the following procedure: EGDMA was washed 
with 10% aqueous NaOH, water, brine and water once more in this order. The EGDMA was 
subsequently dried over MgSO4 and then distilled under vacuum. The other chemicals were 
used as received. Anhydrous solvents, toluene and acetonitrile, were stored over molecular 
sieves. All other chemicals were of reagent grade or higher. For analysis HPLC grade 
acetonitrile and LC-MS grade acetonitrile was used. 
 
For synthesis of the thioacetamide imprinted polymers, thioacetamide was purchased from 
Sigma Aldrich (Germany). The monomers and solvents used for synthesis and analysis were 
the same as for the acetamide imprinted polymers. 
 
2-aminopyrimidine was obtained from Sigma Aldrich (Germany) for the synthesis of the 2-
aminopyrimidine imprinted polymers. MAA and EGDMA are the same as for the other 
synthesized polymers and the monomer 4-vinyl pyridine (4-VP) was obtain from Sigma Aldrich 
(Germany). Anhydrous solvents, toluene and dimethylformamide (DMF) from Acros (Geel, 
Belgium), were stored over molecular sieves. For rebinding tests and analysis HPLC-grade 
acetonitrile was used. 
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For the hybrid approach acetamide and thioacetamide were obtained from Sigma Aldrich 
(Germany). MS-grade MeCN and ethyl acetate were used for rebinding tests and analysis. 
 
For the high-throughput synthesis for MIPs via grafting on membranes, 96-well filterplates 
(Seahorse Labware, Chicopee, MA, USA) with PES membrane (pore sizes 0.45 µm and 
300 kDa) mounted and sealed by the manufacturer (Seahorse Bioscience, North Billerica, MA, 
USA) were used. Loose membrane discs (pore sizes 0.45 µm) were obtained from Satorius 
Stedim Biotech (France). Acrylamide, methacrylamide, methacrylic acid, ethylene-bis-
acrylamide (EBA), N,N-methylenebisacrylamide (MBA), phosphate buffer (Na2HPO4 and 
NaH2PO4) and 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) were purchased 
from Sigma-Aldrich. The templates desmopressin and somatostatin were kindly provided by 
Lonza (Switzerland). 
 
The somatostatin imprinted miniMIP library and the scaled up bulk polymers were synthesized 
using a variety of different monomers, co-monomers and crosslinkers including; MAA, MBA, 
N-isopropylacrylamide (NIPAM), hydroxyethyl methacrylate (2- HEMA), 4-VP, 2-
(Dimethylamino)ethyl methacrylate (DMAEMA) and MAAM. The inititators ammonium 
persulfate (APS) and Tetramethylethylenediamine (TMEDA) were purchased from Sigma-
Aldrich. For the cyclisation tests dithithreitol (DTT) and potassium ferricyanide (K3Fe(CN)6) 
in phosphate buffer were used for reduction and oxidation of somatostatin and desmopressin 
respectively. 
 
5.2 APPARATUS AND METHODS 
 
ELEMENTAL ANALYSIS 
Elemental Analysis was performed at the Department of Organic Chemistry, Johannes 
Guttenberg Universität Mainz using a Heraeus CHN-rapid analyzer (Hanau, Germany). Before 
analysis the polymers were dried under vaccum and 50°C over night and afterwards the 
Eppendorf tubes were sealed before shipment. 
 
HPLC 
HPLC measurements were carried out on Hewlett-Packard HP 1050 or 1100 instruments 
(Agilent Technology, Waldbronn, Germany) equipped with a diode array UV detector and a 
workstation. Depending on the analyte analyized the method was adjusted accordingly. 
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MASS SPECTROMETRY  
LC-MS analysis was performed on a Thermo Scietific LTQ Orbitrap mass spectrometer with a 
resolution of 60000 at m/z 400. Depending on the method mass range of 50 to 1800 u was 
analyzed. 
 
MICROSCOPY 
Optical microscopy was performed using a LEICA DMR fluorescence microscope HC (Leica, 
Bensheim, Germany). The polymer particles were placed on a glass slide and covered with a 
glass slide before analysis. 
 
THERMAL GRAVIMETRIC ANALYSIS 
Thermal gravimetric analysis (TGA) was carried out using a TGAQ50 (TA instruments, 
Eschborn, Germany). The sample (~ 10-15 mg) was placed in a platinum pan, which is 
suspended in a sensitive balance together with the reference pan. The sample was then heated, 
in a furnace, with at a rate of 10 or 20°C/min, under N2 atmosphere. 
 
DIFFERENTIAL SCANNING CALORIMETRY ANALYSIS 
DSC analysis was performed on a DSC Q200 TA instrument (TA instruments, Eschborn, 
Germany). Approximately 5 mg of polymer sample was placed into an aluminum pan. The pan 
was then sealed and crimped with an aluminum lid. The pan was placed into the calorimeter 
and a reference pan was placed beside it. The atmosphere was then made inert by purging with 
nitrogen gas. A nitrogen flow rate of 50 mL/min was sustained in order to avoid interference 
by oxygen during isothermal scanning mode. The DSC scans were started at 30 °C and 
increased to 120 °C at a rate of 10 °C/min. 
 
For thermoporometry analysis a sample of approximately 1-2 mg is immersed in 2-5 µL solvent 
in a hermetic aluminum pans. The samples are quenched at -60 °C at a scanning rate of 5 °C/min 
and the melting behavior of the solvent is analyzed. For the analysis in this work MeCN was 
used with a melting point of -46 ±0.3 °C. 
 
POROMETRY ANALYSIS  
BET nitrogen adsorption analysis was carried out on a Quantachrome Nova 4000e 
(Quantachrome Corporation, USA) automatic adsorption instrument. Before analysis sample 
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was prepared by placing approximately 50 mg of polymer in a glass cell and degassing under 
vaccum over night at 50 °C. 
 
SCANNING ELECTRON MICROSCOPY 
SEM images were taken on a Hitachi H-S4500 FEG in secondary mode with an acceleration 
voltage of 1 kV. Before analysis the sample was placed on special SEM holders with carbon 
foil. Different resolutions were recorded depending on the sample. 
 
SWELLING TESTS 
For the swelling tests NMR tubes were filled with dry polymer until 1 cm was reached and then 
1 mLof the intended solvent was added. After equilibration of the particles in the solvent for 24 
h the volume of the swollen particles was measured. To calculate the volume swelling ratio can 
be calculated by dividing the wet bed volume with the dry bed volume. 
 
5.3 ACETAMIDE IMPRINTED POLYMERS  
5.3.1 POLYMER PREPARATIONS 
 
For the bulk polymers a total of four different imprinted polymers (PA1 - 4) were prepared for 
the acetamide with two different functional monomers and the same cross-linker polymerized 
in two different porogens. The imprinted polymers were prepared in the following manner. The 
acetamide template (1 mmol), functional monomer (4 mmol) and the cross-linker EGDMA (20 
mmol) were dissolved in toluene or acetonitrile (13.8 ml). The initiator ABDV (1% w/w of total 
monomers) was added to the solution. The solution was transferred to a glass ampoule, cooled 
to 0 °C and purged with a flow of dry nitrogen for 10 min. The tubes were then flame-sealed 
while still under cooling and the polymerization initiated by placing the tubes in an incubator 
pre-set at 15 °C and illuminated with UV-light. After 24 h the tubes were broken and the 
polymers lightly crushed. They were thereafter extracted in a Soxhlet-apparatus with a solution 
of 80 % MeOH, 15 % formic acid and 5 % water for 48 h. The remaining acid in the polymers 
was then washed away with methanol using a Soxhlet-apparatus with methanol for 24 h. This 
was followed with further crushing and sieving. The desired particle size fractions (25-50 μm) 
were repeatedly sedimented (80:20 = methanol:water) to remove fine particles and then slurry-
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packed into HPLC columns (125 mm x 4.0 mm i.d.) using the same solvent mixture as pushing 
solvent. Non-imprinted polymers (PAN1 - 4) were prepared in the same way as imprinted 
polymers, but with no template molecule in the pre-polymerization solution.  
 
For the preparation of the super-porous iso-polymers a total of three different polymers were 
prepared with varying total amounts of iso-octane as the porogen (25 %, 50 % and 75 % iso-
octane of the total porogen volume). The acetamide template (1 mmol), functional monomer (4 
mmol) and the cross-linker EGDMA (20 mmol) were dissolved in toluene and iso-octane 
mixture (total volume of 13.8 ml). The initiator ABDV (1% w/w of total monomers) was added 
to the solution. The solution was transferred to a glass ampoule, cooled to 0 °C and purged with 
a flow of dry nitrogen for 10 min. Samples were polymerized under UV at 15 °C for 24h and 
then incubated in the fridge (8 °C) over night. The formed polymers were crushed in particle 
size fractions (25-50 μm) after Soxhlet removal of the template. Non-imprinted control 
polymers were prepared in the same manner without the template. 
  
A total of three different porefilling imprinted polymers were prepared with the same ratio as 
for the bulk polymers but with varying amounts of porogen. The acetamide template (1 mmol), 
functional monomer (4 mmol) and the cross-linker EGDMA (20 mmol) were dissolved in 
toluene (6.9 mL and 1.4 mL) and for polymer III no porogen was used. The initiator ABDV 
(1% w/w of total monomers) was added to the solution. The pre-polymerization mixture was 
purged with nitrogen before added in smaller portions to the silica (300 µL per 500 mg silica) 
and carefully stirred. Polymerization was perfermoed at 50 °C for 24 hours. Following 
polymerization the particles were suspended in 15 mL aqueous solution of NH4HF2 (3 M) in 
polyethylene flasks to etch the silica. The resulting polymers were washed with destilled water 
to ensure the removal of SiF4 and [NH4]F. Complete removal of silica from the matrix of the 
polymers was followed with TGA.  
 
The success of the bulk polymer synthesis was evaluated with elemental analysis: 
Anal. calc. for PA1 in percent: C=60.21, H=7.11. Found: C=59.02, H=7.20, N=0.15 
Anal. calc. for PAN1 in percent: C=60.21, H=7.11. Found: C=58.64, H=7.23, N=0.13 
Anal. calc. for PA2 in percent: C=60.26, H=7.21, N=1.30. Found: C=59.31, H=7.64, N=1.18 
Anal. calc. for PAN2 in percent: C=60.26, H=7.21, N=1.30. Found: C=59.29, H=7.67, N=1.33 
Anal. calc. for PA3 in percent: C=60.21, H=7.11. Found: C=59.53, H=7.47, N=0.13 
Anal. calc. for PAN3 in percent: C=60.21, H=7.11. Found: C=59.56, H=7.43, N=0.13 
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Anal. calc. for PA4 in percent: C=60.26, H=7.21, N=1.30. Found: C=59.48, H=7.52, N=1.24 
Anal. calc. for PAN4 in percent: C=60.26, H=7.21, N=1.30. Found: C=59.38, H=7.58, N=1.30 
 
5.3.2 HPLC TESTING OF ACETAMIDE MIP PERFORMANCE 
 
The evaluation of the extraction procedures was carried out by HPLC using an Agilent HP1050 
or HP 1100 system (Agilent Technologies, Wilmington, DE) equipped with a diode array-UV 
detector and a workstation. HPLC columns (125 x 4.0 mm i.d.) slurry packed with the MIPs 
were evaluated. The instrument was operated in an isocratic mode using a mobile phase 
consisting of MeCN at 0.5 mL/min flow rate. Chromatograms were obtained by injecting a 
fixed volume (10 μL) of spiked solutions of the compounds and subsequently monitoring the 
absorbance at 230, 220 and 205 nm depending on the analyte. The retention factor (k) was 
calculated as k=(t-t0/t0), where t is the retention time of the analyte and t0 is the retention time 
of the void marker (acetone). 
 
5.3.3 TEST MODEL FOR ACETAMIDE REMOVAL 
 
Scavenging experiments were performed using cartridges from Isolute SPE Accessories, 
Biotage (Sweden), that were packed with 25 mg of the PA3 polymer or the corresponding non 
imprinted polymer PAN3. The cartridges were washed extensively with methanol and then 
equilibrated with acetonitrile. 0.5 mL of a solution of Etodolac (5 g/L) and acetamide (250 ppm) 
in acetonitrile was loaded on the cartridges. A SPE-cartridge manifold was used to pull the 
sample through the packed polymers to be collected in a 1 vial. The SPE cartridges were then 
washed with 1 mL of acetonitrile and the washing elutants were collected in separate vials. The 
loading eluent and washing eluents were analyzed by HPLC, using a Hewlett-Packard HP 1050 
or 1100 instruments (Agilent Technology, Waldbronn, Germany) equipped with a C-18 column 
(250 x 4.60 mm, 5 micron, 48790-52) using a gradient. The gradient used was 100% H2O the 
first five min followed by a mixture of MeCN and H2O, 95% and 5% respectively (6-16 min), 
and then the mobile phase was switched back to 100% H2O (17-20min). Acetamide was 
monitored at 220 nm and Etodolac at 300 nm. 
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5.3.4 EQUILIBRIUM REBINDING TESTS 
 
Rebinding tests were performed for the three different formats of acetamide imprinted polymers 
in order to compare the rebinding properties of the polymers. The tests were done in HPLC 
vials or Eppendorf tubes depending on the amount of polymer used. Solutions with a range of 
specified template concentrations are added to a known amount of polymer (50 mg for bulk and 
isopolymer and 10 mg for porefilling polymer) and let to equilibrate under constant mixing. 
After equilibrium is reached (24 hours) the polymers are sedimented and a sample is withdrawn 
from the vial or tube for LC-MS analysis for determination of the free concentration. For LC-
MS analysis a gradient was applied to Gemini-NX C18 column (length 150x2 mm, particle size 
3 µm, Phenomenex Inc) with solvent A (H2O 0.1 % FA) and solvent B (MeOH 0.1 % FA) (0-
1 min 100 % A, 10-11 min 0 % A, 11,5 min 100 %, 15 min 100 % A). UV was monitored at 
250 nm over a mass range of 50 to 550 m/z. 
5.4 THIOACETAMICE IMPRINTED POLYMERS 
5.4.1 POLYMER PREPARATION 
 
The thioacetamide imprinted bulk polymers were prepared according to the recipe for PA3 
polymer (Section 5.3.1) but with thioacetamide as the template instead of acetamide. The 
imprinted polymers were prepared in the following manner. The thioacetamide template (1 
mmol), functional monomer (4 mmol) and the cross-linker EGDMA (20 mmol) were dissolved 
in toluene (13.8 ml). The initiator ABDV (1 % w/w of total monomers) was added to the 
solution. Non-imprinted control polymers were also synthesized. Polymerization and sample 
preparation was otherwise conducted as described in section 5.3.1.  
 
5.4.2 EQUILIBRIUM REBINDING TESTS 
 
Evaluation rebinding tests of the thioacetamide imprinted polymers was conducted in the same 
manners as for the acetamide MIPs (Section 5.3.4). 
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5.5 2-AMINOPYRIMIDINE IMPRINTED POLYMERS 
5.5.1 POLYMER PREPARATION 
 
A total of four different 2-aminopyrimidine imprinted polymers were synthesized, with two 
different functional monomers in two different solvents. The first two MIPs were based on the 
successful acetamide recipe for PA3 with MAA as the functional momomer. The second 
functional monomer used was 4-VP. The template 2-aminopyrimidine (1 mmol), functional 
monomer (4 mmol) and the cross-linker EGDMA (20 mmol) were dissolved in toluene or DMF 
(13.8 ml). The initiator ABDV (1% w/w of total monomers) was added to the solution. Non-
imprinted control polymers were also synthesized. Polymerization and sample preparation was 
otherwise conducted as described in section 5.3.1.  
 
5.5.2 EQUILIBRIUM REBINDING TESTS 
 
Evaluation rebinding tests of the 2-aminopyrimidine imprinted polymers was conducted in the 
same manners as for the acetamide MIPs (Section 5.3.4). The rebinding tests were analyzed by 
HPLC, using a Hewlett-Packard HP 1100 instruments (Agilent Technology, Waldbronn, 
Germany) equipped with a C-18 column (250 x 4.60 mm, 5 micron, 48790-52) using isocratic 
mode. Mobile phase 40 mM ammonium acetate, pH 4.4/MeCN (1:1) with a flow rate of 
1 mL/min and UV detection at 220 nm. 
 
5.6 HYBRID APPROACH – MIPS AND OSN 
5.6.1 MATERIALS  
 
Acetamide and thioacetamide was purchased from SigmaAldrich. The inhouse API was kindly 
provided by GlaxoSmithKline. The MIPs used was 1st generation bulk polymers synthesized at 
TU Dortmund. For processing in ethyl acetate Starmem™122 (batch 255.1 and 9104.1) and 
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Duramem™200 (M128) were used (MET Evonik).  For processing in MeCN Duramem™150 
(M087) (MET Evonik) was used. All solvents were of LC-MS grade. 
 
5.6.2 ANALYSIS 
 
Acetamide was analyzed using LC/MS with single ion detection set at MH+ = 60. Level of 
quantification was determined to 0.2 ppm and level of detection is slightly lower ranging 
between 0.1-0.2 ppm. API was detected and quantified using a project specific HPLC method. 
 
5.7 HIGH-THROUGHPUT SYNTHESIS FOR MIPS VIA GRAFTING ON MEMBRANES 
5.7.1 MATERIALS 
 
The 96-well filter plates with pore sizes 300 kDa and 0.45 µm were purchased from Seahorse 
Bioscience, US. Ninety-six well 2 mL Seahorse Bioscience membrane filter plate, polyether 
sulfone (PES) membrane. Functional monomer acrylamide, crosslinking monomer ethylene 
bisacrylamide (EBA), 10mM HEPES buffer pH=7 as porogen. Template was somatostatin 
(provided by Lonza, Switzerland). 
 
 
5.7.2 PREPARATION OF GRAFTED MEMBRANES 
 
The grafting on PES membranes follows a very simple procedure where the membrane is first 
washed with methanol and deionized water to remove surfactants before use. Then the 
membrane is soaked in the monomer solution and subsequently illuminated with UV for 
grafting from the surface. For this purpose a stock solution with the ratio 1:3 of monomer to 
solvent was prepared. The mother solutions containing the template somatostatin, functional 
monomer acrylamide and MAA, cross-linker EBA were prepared from dilution of the stock 
solution. Solutions for the non-imprinted control membranes were also prepared in the same 
way but without the template. The solutions were purged with nitrogen gas for approximately 
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10 minutes before 50 µL was pipetted to each well and for the loose membranes incubation in 
the solution for 10 minutes. After soaking in the monomer solution the plate or loose 
membranes are placed in a special built glass box with quartz lid, designed to create an oxygen 
free environment, in an incubator. Before addition of the membrane the glass box is purged 
with nitrogen for 20 minutes. For the membrane to stay wet and not dry out circa 1 cm of 
Millipore water is filled at the bottom of the box. After addition of the membranes the oxygen 
free environment is re-equilibrated for 10 minutes before the UV-lamp is turned on and during 
the polymerization the temperature in the incubator chamber is kept constant at 15 ⁰C. For 
template removal warm 40 ⁰C methanol containing 1 % formic acid is used for washing the 
membranes. Template removal of somatostatin can be followed by measuring the fluorescence 
after each wash. Residual acid is washed away with extensive methanol. 
 
5.7.3 GRAFTING OPTIMIZATION AND METHOD FOR INITIAL TESTING 
 
Both types of the membrane filter plates were used (300 kDa and 0.45 μm pore size). The 
crosslinking level used was 50 %. Polymer composition in molar ratio was 
Som/MAA/Acrylamide/EBA 0.2/1/3/4 with 10mM HEPES buffer pH=7 as porogen. Solutions 
for the nonimprinted wells were also prepared in the same way but without the template. The 
solutions were purged with nitrogen gas for approximately 10 minutes before 50 μl was pipetted 
to each well. The plate was place in a special built glass box with quartz lid, designed to create 
an oxygen free environment, in the incubator. In order to try not to dry the membranes out a 
collecting plate was placed at the bottom of the box, with every second well filled with millipore 
water. The plate was purged with nitrogen for 20 minutes before the UV-light was turned on. 
The temperature in the incubator chamber was kept constant at 15 ˚C. The plate was exposed 
to the UV light for varying times. The template was then removed by adding varm (40 ˚C) 
MeOH containing 1 % formic acid fifteen times. The fluorescence was measured after each 
wash to record the extraction of somatostatin. The acid was then removed with extensive 
washing with MeOH. For the first rebinding test 400 μL of 0.025 mM Somatostatin in 10mM 
HEPES pH= 7 was added to the each well and equilibrated for 5 hours. Fluorescense was 
measured between 300 and 500 nm for the samples. 
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5.8 SOMATOSTATIN IMPRINTED POLYMERS FOR CATALYTICAL APPLICATIONS 
5.8.1 PREPARATION SOMATOSTATIN IMPRINTED BULK POLYMERS 
 
A total of three different somatostatin imprinted polymers were synthesized. The template 
somatostatin (0.2 mmol), functional monomer (4 mmol) and the cross-linker EGDMA (20 
mmol) were dissolved in 1 % TFA in MeCN and MeOH. (4/3 of total volume). The initiator 
ABDV (1% w/w of total monomers) was added to the solution. Non-imprinted control polymers 
were also synthesized. Polymers prepared in 1 % TFA in MeCN were polymerized using both 
UV and thermal initiation. Polymers prepared in 1 % TFA in MeCN and MeOH were initiated 
by UV at 15 °C for 24 h and cured at 60 °C for 48 h. The thermally initiated polymer prepared 
in 1 % TFA in MeCN was initiated at 50 °C for 24 h and cured at 60 °C for 48 H. Polymerization 
and sample preparation was otherwise conducted as described in section 5.3.1.  
 
HPLC analysis was carried out on slurry packed columns (50 x 4.6 mm) using an isocratic mode 
(mobile phase 0.1 % HAc in MeCN/ H2O 95/5). UV was recorded at 220 nm. 
 
5.8.2 SOMATOSTATIN IMPRINTED MINIMIP LIBRARY 
 
MiniMIP library was synthesized using 96-well PTFE microtiter plate and PTFE coated 
closures (Radleys) and for pipetting of the polymer solutions a LISSY sample handler with four 
ports was used (Zinsser Analytic). Two plates were prepared one with and one without template 
in phosphate buffer (50 mM, pH= 7). Stock solutions of the functional monomers (0.2 M and 
1 M) were prepared in the same porogen except for 4-VP that was prepared in a 9:1 mixture of 
phosphate buffer and DMF. Stock solutions of the initiators APS and TEMEDA was prepared 
(90 mg/mL and 46 mg/mL respectively). For the MIP plate somatostatin was added in a 1:100 
molar ration template to total monomer to one initiator solution. Prior to pipetting the monomer 
stock solutions were purged with nitrogen. The solutions were then pipetted into the 96-well 
PTFE microtiter plate (Figure 111). Before polymerization the plate was sealed with a PTFE-
coated silicone lid and then polymerization took place at 50 °C for 24 h. 
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      Comonomer NIPAM Comonomer MAAm 
  (µL) None HEMA DMAEMA MAA 4-VP MAA+4-VP None HEMA DMAEMA MAA 4-VP MAA+4-VP 
  X-linker Co-monomer 1 2 3 4 5 6 7 8 9 10 11 12 
A  470 25  2.5 2.5 2.5 2.5 2.5  2.5 2.5 2.5 2.5 2.5 
B 425 25  12.5 12.5 12.5 12.5 12.5  12.5 12.5 12.5 12.5 12.5 
C 445 50  2.5 2.5 2.5 2.5 2.5  2.5 2.5 2.5 2.5 2.5 
D 400 50  12.5 12.5 12.5 12.5 12.5  12.5 12.5 12.5 12.5 12.5 
E 395 100  2.5 2.5 2.5 2.5 2.5  2.5 2.5 2.5 2.5 2.5 
F 350 100  12.5 12.5 12.5 12.5 12.5  12.5 12.5 12.5 12.5 12.5 
G 345 150  2.5 2.5 2.5 2.5 2.5  2.5 2.5 2.5 2.5 2.5 
H 300 150   12.5 12.5 12.5 12.5 12.5   12.5 12.5 12.5 12.5 12.5 
Figure 111 Amount of stock solution added to each well. To each well APS (10 µL) and TEMEDA (10 µL) was 
added. Two plates were prepared, with and without somatostatin template (template was added to one initiator 
solution). Cross-linker was MBA. 
 
After polymerization the polymers were transferred to a 96-well filter plate. The template was 
extracted by repeating washing steps with 1 % FA in MeOH (500 µL) until no absorbance of 
somatostatin was detected using a plate reader SAFIRE (Tecan Deutschland GmbH). Before 
rebinding experiments, the plates were washed with the same solvent as in the rebinding test 
for reconditioning. Rebinding tests were performed by addition of 500 µL somatostatin solution 
in phosphate buffer (50 mM, pH= 7) and the filter plates were sealed and equilibrated under 
shakingfor 24 hours. The rebinding tests were analyzed with HPLC Luna 5u C18 column, 
Phenomenex and the elution was performed at a flow rate of 1 mL/min and 5 µL injections for 
a duration of 10 minutes in isocratic mode 0.1 % FA in H2O/MeCN (95/5 % w/w). Absorbance 
at 220 nm was monitored. The rebinding tests were also analyzed using BCA protein assay 
reagent kit (Sigma Aldrich) according to accompanying protocol.  
 
For the upscaling of the miniMIP library hit polymers a total of six different polymers were 
synthesized based on the hit polymers from the miniMIP library. A detailed overview of the 
polymer composition is summarized in Table 26. Three polymers were prepared as followed, 
template somatostatin (4 µmol), functional monomer (40 µmol), co-monomer MAAm (280 
µmol) and cross-linker MBA (80 mmol) were dissolved in phosphate buffer (50 mM, pH= 7, 
500 µL). The other three polymers were prepared as followed, template somatostatin (4 µmol), 
functional monomer (40 µmol), co-monomer MAAm (200 µmol) and cross-linker MBA 
(160 mmol) were dissolved in phosphate buffer (50 mM, pH= 7, 500 µL). The initiators APS 
and TEMEDA (2% w/w of total monomers) was added to the solution. Non-imprinted control 
polymers were also synthesized. Polymerization took place at 50 °C for 24 hours. For template 
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removal the polymer (2 g, wet) was washed with 3 x 10 mL of H2O: MeOH: FA (60:20:20). 
The fraction was collected and measured by HPLC for calculations of the recovery. For 
calculations of the somatostatin recovery a standard solution in 50 mM phosphate buffer was 
prepared based on the amount used in the pre-polymerization mixture (13 mg/ml). 
 
Gradient for HPLC method used for analysis; 0 min 21 % mobile phase B, 15 min 40 % mobile 
phase B, 17 min 21 % B, 20 min 21 % B. Where mobile phase  A is prepared by  diluting 11 
ml of phosphoric acid with water, adjusting to pH 2.3 with triethylamine and diluting to 1000 
ml with water. Mobile phase B is acetonitrile 100 %. Flow rate 1.0 mL/min and UV detection 
at 215 nm. Injection volume of 100 μL. Column used is Luna C18 (155 mm× 4.6 mm I.D., 
5µm) HPLC column protected by an RP18 guard column (4.0 mm×3.0 mm I.D., 5 µm), both 
from Phenomenex (Torrance, CA, USA). 
 
For the rebinding tests 100 mg of wet polymers was incubated with 100 µL of 10 µM and 100 
µM of standard Somatostatin in 50 mM phosphate buffer, pH 7, for 24 hours. 
  
5.8.3 CATALYTIC TESTING OF SOMATOSTATIN IMPRINTED POLYMERS   
 
10 mg of PM2 and PN2 was weighed in Eppendorf tubes. 1 mM Somatostatin and 
Desmopressin phosphate solutions were prepared (16.38 mg in 10 mL). For reduction of the 
peptides 50 mM dithiothreitol (DTT) was prepared in phosphate buffer pH 4 (77.4 mg in 
10 mL). 5 mL of DTT solution was added to 5 mL peptide solution. The solutions were shaken 
over night for the reduction of the peptides to take place. 500 µl of reduced peptide solution 
was added to the eppendorfs with the polymer and two control eppendorf without polymer. For 
oxidation a 20 % excess of K3Fe(CN)6 solution prepared in phosphate buffer was added to 
the eppendorfs. The samples were shaken and oxidized for 4.5 hours and then 100 µl of solution 
was taken for LC-MS analysis after the polymer was sedimented. 
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7 APPENDIX 
 
 
Figure 6. 1 DSC thermogram for the bulk polymers. 
 
Figure 6. 2 DSC thermograms of the MIP iso-polymers. 
 
Figure 6. 3 DSC thermograms of the NIP iso-polymer. 
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Figure 6. 4 DSC thermograms of the porefilling MIPs. 
 
Figure 6. 5 DSC thermograms of the porefilling NIP. 
 
Figure 6. 6 DSC thermograms for porometry calculations for the bulk polymers. 
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Figure 6. 7 DSC thermograms for porometry calculations for the 25:75 iso-octane polymers. 
 
Figure 6. 8 DSC thermograms for porometry calculations for the 50:50 iso-octane polymers. 
 
Figure 6. 9 DSC thermograms for porometry calculations for the 75:25 iso-octane polymers. 
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Figure 6. 10 DSC thermograms for porometry calculations for MIP I pore-filling polymer. 
 
Figure 6. 11 DSC thermograms for porometry calculations for pore-filling polymer II. 
 
 
Figure 6. 12 DSC thermograms for porometry calculations for pore-filling polymer III. 
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Figure 6. 13 DSC thermograms for porometry calculations for thioacetamide bulk polymers. 
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